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1 Abbreviations 
AAV     adeno-associated virus 
Ad    adenovirus 
Akt (PKB)   protein kinase B 
ALS    amyotrophic lateral sclerosis 
Amp    ampicillin 
AMPK    5' AMP-activated protein kinase 
Anxa1    annexin A1 
Anxa6    annexin A6 
Arg-1    arginase 1 
ATF2    activating transcription factor 2 
ATP    adenosine triphosphate 
AV    average 
BAT    brown adipose tissue 
bFGF (FGF2)   basic fibroblast growth factor 
BSA    bovine serum albumin 
CaMKIV   calcium/calmodulin-dependent protein kinase type IV 
CBP    CREB-binding protein 
CD133    prominin-1 
CEE    chicken embryo extract 
ChIP-Seq   chromatin immunoprecipitation- sequencing 
CK    creatine kinase 
c-Met (HGFR)   hepatocyte growth factor receptor  
CMV    cytomegalovirus 
CnA    calcineurin A 
Cox5b    cytochrome c oxidase subunit 5B, mitochondrial 
CREB    cAMP response element-binding protein 
CT    X-ray computed tomography 
CTX    cardiotoxin 
CycS    cytochrome c, somatic 
d    day(s)  
D2R    dopamine type 2 receptor 
DAPI    4',6-diamidino-2-phenylindole 
db    diabetic 
DHR    downhill running 
DMD    Duchenne muscular dystrophy 
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DMEM    Dulbecco's modified Eagle's medium 
DTT    dithiothreitol 
Dysf    dysferlin 
EBD    Evans blue dye 
ECM    extracellular matrix 
EDL    extensor digitorum longus muscle 
EDTA    ethylene diamine tetraacetic acid 
EGTA     ethylene glycol tetraacetic acid   
e    embryonic 
ER    estrogen receptor 
ERR    estrogen-related receptor 
FACS    fluorescence-activated cell sorting 
FAO    fatty acid oxidation 
FAP    fibro/adipogenic progenitor 
FBS    fetal bovine serum 
FDG    2-deoxy-2-[18F]-fluoro-D-glucose  
FGF-2 (bFGF)   fibroblast growth factor 2 
FGFR1    fibroblast growth factor receptor 1 
FI    fusion index 
FMISO    [18F]-fluoroiminidasole  
FN    fibronectin 
FoxO    forkhead box protein O 
Fzd7    frizzled-7 
G0    resting phase 
GABP (NRF2)   GA-binding protein 
GAlert    alerted state of resting phase 
Gastro    gastrocnemius muscle 
GCN5    histone acetyltransferase GCN5 
GFP    green fluorescent protein 
Glut4    glucose transporter type 4 
GOI    gene of interest 
h    hour(s) or human 
H&E    hematoxylin and eosin stain 
HA    influenza hemagglutinin 
HEPES    2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HFD    high-fat diet 
HGF    hepatocyte growth factor 
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hMPCs    human muscle precursor cells 
HNF4α    hepatocyte nuclear factor 4 alpha 
HS    horse serum 
HSA    human α-skeletal actin 
HSC    hematopoietic stem cell 
Hz    hertz 
Ig     immunoglobulin     
IGF-1    insulin-like growth factor 1 
IHC    immunohistochemistry 
IL-1    interleukin 1 
IL-10    interleukin 10 
IL-4Rα    interleukin 4 receptor alpha 
IL-6    interleukin 6 
im    intramuscular 
inj    injection 
ip    intraperitoneal 
Itga7    integrin 7alpha 
KD    knock-down 
KifC3    kinesin family member C3 
LA    Luria-Bertani Agar 
LARGE    like-acetylglucosaminyltransferase 
LB    Luria-Bertani broth 
LDH    lactate dehydrogenase 
LGMD 2B   limb-girdle muscular dystrophy type 2B 
LKB1    liver kinase B1 
M    macrophage 
MAPK    mitogen-activated protein kinase 
MB    myoblast 
MCK    muscle creatine kinase 
MCOLN1   mucolipin-1 
MCP-1 (CCL2)   monocyte chemotactic protein 1 
Mdx    mouse model of DMD 
MEF2    myocyte enhancer factor 2 
MG53 (TRIM72)   mitsugumin 53  
min    minute(s) 
MIP-1α (CCL3)   macrophage inflammatory protein 1alpha 
MIP-1β (CCL4)   macrophage inflammatory protein 1beta 
Abbreviations 
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mKO    muscle-specific knock-out 
MMP    matrix metalloproteinase 
MOI    multiplicity of infection 
MRF-4 (Myf6)   myogenic regulatory factor 4, herculin 
mRFP    monomer red fluorescent protein 
MRFs    myogenic regulatory factors 
ms    millisecond(s) 
Mstn (GDF-8)   myostatin 
MT    myotube 
mTG    muscle-specific transgenic 
mTORC1   mammalian target of rapamycin complex 1 
Myc    avian myelocytomatosis viral oncogene homolog 
Myd    myodystrophy 
Myf5    myogenic factor 5 
MyHC    myosin heavy chain 
Na3VO4   sodium orthovanadate 
Na4P2O7x10H2O  sodium pyrophosphate decahydrate 
NADH     nicotinamide adenine dinucleotide (reduced) 
NaF    sodium fluoride 
NFκB    nuclear factor kappa B 
NMJ    neuromuscular junction 
NO    nitrogen monoxide 
NRF1    nuclear respiratory factor 1 
ob    obese 
OCT    optimal cutting temperature compound 
OE    overexpression 
OXPHOS   oxidative phosphorylation 
p16 (CDKN2A)   cyclin-dependent kinase inhibitor 2A 
p300     E1A binding protein p300 
PAGE    polyacrylamide gel electrophoresis 
Pax7    paired box 7 
PBS    phosphate buffered saline 
PET    positron emission tomography 
PFA    paraformaldehyde 
PGC-1    peroxisome proliferator-activated receptor γ coactivator 1 
PI3K    phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP3    phosphatidylinositol (3,4,5)-trisphosphate 
Abbreviations 
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PKA    cAMP-dependent protein kinase 
PML    promyelocytic leukemia protein 
PPAR    peroxisome proliferator-activated receptor 
PRC    PGC-1-related coactivator  
pS6    phospho-S6 ribosomal protein 
PVDF    polyvinylidene difluoride 
QU    quadriceps muscle 
Rab27b    Ras-related protein Rab-27B 
Rab3a    Ras-related protein Rab-3A 
RER    respiratory exchange ratio 
RFP    red fluorescent protein 
ROS    reactive oxygen species 
RT    room temperature 
s    second(s) 
SC    satellite cell 
sc    subcutaneous 
Sdc4    syndecan-4 
SDM    site-directed mutagenesis 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM    standard error of the mean 
Sirt1    NAD-dependent deacetylase sirtuin-1 
SNAP    soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein 
SNARE    SNAP receptor 
SOL    soleus muscle 
Spry1    sprouty 1 
SRC-1    steroid receptor coactivator 1 
Syt7    synaptotagmin VII 
Sytl2     synaptotagmin-like 2 
T0    time point zero 
T3    time point 3 days 
TA    tibialis anterior muscle 
TBP    TATA box binding protein 
TFAM    mitochondrial transcription factor A 
TGF-β    transforming growth factor beta 
TNC    tenascin-C 
TNF-α    tumor necrosis factor alpha, cachexin 
TR    thyroid hormone receptor 
Abbreviations 
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TrisHCl    2-Amino-2-hydroxymethyl-propane-1,3-diol hydrochloride 
Vamp1    vesicle-associated membrane protein 1 
VEGF    vascular endothelial growth factor 
Vis    visceral 
WAT    white adipose tissue 
Wnt7a    wingless-type MMTV integration site family, member 7A 
WT    wild type 
YFP    yellow fluorescent protein 
α-SMA (ACTA2)  alpha smooth muscle actin 
 
Summary 
10 
2 Summary 
The benefits of exercise on wellbeing have been known to mankind for thousands of 
years, yet the underlying mechanisms of exercise have been explained only relatively recently. 
Today we know that lack of exercise is associated with many chronic pathologies, and that 
regular moderate exercise, on the other hand, can improve human health. Signaling pathways 
activated by endurance exercise lead to skeletal muscle adaptations, and at the core of these 
adaptations lies peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α). These 
modulations brought about by PGC-1α enhance muscle endurance, and protect against several 
atrophic conditions. In addition, endurance exercise has been shown to increase the number of 
satellite cells and regenerative potential of skeletal muscle. However, in some pathologies, 
exercise is not an option for improvement of systemic and muscle phenotype.  
Interestingly, experiments in mice have revealed that overexpressing PGC-1α mimics the 
effects of exercise, and that this is associated with a fiber type switch towards a more oxidative 
phenotype. Although PGC-1α was shown to palliate dystrophic condition by protecting muscles 
from damaging effects of contractions, PGC-1α’s effects on satellite cells and regeneration have 
not been investigated. In addition, the causes of the protective role of PGC-1α in muscle have not 
been elucidated. 
Using mouse models with overexpression and deletion of PGC-1α specifically in skeletal 
muscle, in combination with cardiotoxin injury, we have investigated the contribution of PGC-1α 
to skeletal muscle regeneration. Our results indicate that PGC-1α improves muscle’s initial 
response to injury resulting in a faster removal of necrotic tissue. Additionally, PGC-1α reduces 
fibrosis development in a model of chronic damage. Considering the PGC-1α levels in 
regenerating muscles, these differences were probably driven by the preexisting milieu of muscle 
residing inflammatory cells dependent on PGC-1α expression in myofibers, and were associated 
with myostatin and insulin-like growth factor 1 (IGF-1) levels prior and after injury, 
respectively. However, overall regeneration was neither impaired nor improved with PGC-1α 
deletion or overexpression.  
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We detected a reduction in satellite cell numbers in PGC-1α overexpressing mice. This 
was surprising, given that oxidative fibers contain more satellite cell. Ex vivo experiments further 
revealed that PGC-1α levels also influence satellite cell response to activating stimuli, and that 
increased PGC-1α in the fiber (satellite cell niche) results in faster activation and proliferation of 
these cells. The effect on satellite cell behavior was at least partially due to reduced fibronectin 
levels in the basal lamina of transgenic mice. Deletion of PGC-1α from satellite cells and their 
niche resulted in the opposite phenotype.  
We also sought to explore the mechanism through which PGC-1α increases protection in 
dystrophic skeletal muscle. In transgenic mice, we detected increased synaptotagmin VII, the 
deletion of which results in myopathy. On the other hand, knocking-down PGC-1α in C2C12 
myoblasts reduced the resealing capacity of the sarcolemma. In addition, an increase in integrin 
7α observed after exercise was absent in PGC-1α knock-out mice. These results suggest 
increased sarcolemma stability and propensity for repair dependent on PGC-1α levels in muscles.  
Finally, in a proof-of-principal study addressing applications in regenerative medicine, 
we wanted to explore whether adenoviral delivery and induction of PGC-1α in human myoblasts 
can improve skeletal muscle formation after myoblast transplantation. Apart from the foreseen 
benefits based on previously published research, we can speculate that PGC-1α might surpass 
our expectations and significantly improve not just the survival and function of newly-formed 
tissue, but also, based on the data presented here, improve the regenerative capabilities of 
skeletal muscle.  
The results reported here could potentially expand the therapeutic benefits of PGC-1α 
induction in skeletal muscle myopathies. However, further research is necessary in order to fully 
understand these effects before using PGC-1α to facilitate skeletal muscle repair and 
regeneration, especially having in mind the discrepancies in PGC-1α induction and oxidative 
fiber phenotypes in relation to satellite cell numbers. 
Introduction 
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3 Introduction 
3.1 PGC-1α – structure, regulation and function 
A balanced metabolism is essential for normal functioning of living organisms. Varying 
conditions require high plasticity in regulating metabolic processes and adaptation to changes 
such as food availability or deprivation, or high physical activity and rest. In the past years, it has 
become clear that adaptations to ever changing conditions are regulated on the transcriptional 
level (1), which drew much attention to transcription factors and their role in controlling gene 
expression. However, recently, coactivators took center stage in regulating metabolic 
equilibrium, as they were recognized as integrating factors that are able to detect and react to 
various stimuli and in turn control multiple downstream signaling pathways though interaction 
with a plethora of transcription factors (2). An excellent example of one such factor is the 
peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α). 
PGC-1α was first detected in brown adipose tissue as a factor controlling the transcription 
program of adaptive thermogenesis (3). It was the first member of the coactivator family to be 
discovered. Two other members, peroxisome proliferator-activated receptor γ coactivator 1β 
(PGC-1β) and PGC-1-related coactivator (PRC), have similarity in sequence and therefore some 
overlapping functions with PGC-1α, but they remain less studied (4, 5). Although primarily 
known for its pivotal role in mitochondrial biogenesis and oxidative metabolism, PGC-1α has 
many other tissue-specific roles (6). It is highly expressed in metabolically active organs such as 
brain, heart, brown adipose tissue (BAT), muscle, kidney, liver. In general, PGC-1α is induced in 
energy demanding conditions. Therefore, stimuli such as fasting, cold or exercise increase its 
expression in liver, BAT, and skeletal muscle, respectively. In turn, in addition to increased 
mitochondrial biogenesis and respiration, PGC-1α induces gluconeogenesis in liver, adaptive 
thermogenesis in BAT and a fiber type switch in skeletal muscle tissue (7). In this text, aspects 
of PGC-1α’s structure, regulation and function in skeletal muscle compared to other organs are 
emphasized.   
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3.1.1 Structure of PGC-1α 
Sequencing of PGC-1α has revealed several distinct regions (Figure 1). PGC-1α does not 
possess histone modifying abilities, but its N-terminus contains an activation domain through 
which it is able to bind histone acetyl-transferases (HAT) cAMP response element-binding 
protein-binding protein/E1A binding protein p300 (CBP/p300) and steroid receptor coactivator 1 
(SRC-1) (8). These enzymes induce structural changes in chromatin, making it more accessible 
to different DNA binding proteins, thereby facilitating transcription. The transcriptional 
repression domain contains a binding site for p160 myb binding protein, which attenuates its 
transcriptional activity (9). The C-terminus of PGC-1α contains an Arg/Ser rich domain and an 
RNA binding domain. Through these regions PGC-1α binds mediator complex (10) and 
processes RNA during transcription (11). In addition, PGC-1α is able to bind and coactivate a 
multitude of transcription factors, some of which bind through the three LXXLL motives present 
in the PGC-1α sequence. After the discovery of the first binding partners of PGC-1α, the nuclear 
receptors peroxisome proliferator-activated receptor γ (PPARγ) and thyroid hormone receptor 
(TR) (3), many other transcription factors were found to interact with PGC-1α. Those include 
additional nuclear receptors such as peroxisome proliferator-activated receptor α (PPARα), 
peroxisome proliferator-activated receptor β/δ (PPARβ/δ), estrogen receptor α (ERα), estrogen-
related receptor α (ERRα), estrogen-related receptor γ (ERRγ), hepatocyte nuclear factor 4 α 
(HNF4α), but also non-nuclear receptors such as forkhead box protein O1 (FoxO1), forkhead 
box protein O3a (FoxO3a), nuclear respiratory factor 1(NRF1), nuclear respiratory factor 2 
(NRF2, also known as GABP) and myocyte enhancer factor 2 (MEF2). 
 
 
Figure 1 Structure of PGC-1α; adapted from (6) 
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Long after the discovery of PGC-1α, different splice variants of this coactivator started to 
emerge (Figure 2). Today, we are aware of the existence of seven isoforms (12); the 
nomenclature has not been agreed upon, and is somewhat simplified in the text below. Apart 
from the full length PGC-1α described initially (now known as PGC-1αa), the discovery of an 
alternative promoter (13-15) unveiled two additional isoforms: PGC-1αb and PGC-1αc, 
transcribed from different start sites. The NT-PGC-1α isoform is transcribed from the proximal 
promoter as PGC-1αa, yet is much shorter due to stop codon formation due to an alternative 
splicing event (16). Recently, three new PGC-1α splice variants have been described: PGC-1α2, 
PGC-1α3 and PGC-1α4 (17). Unlike the full length splice variant, PGC-1α4 was shown to 
induce skeletal muscle hypertrophy but not mitochondrial biogenesis (17). However, apart from 
PGC-1α4, specific functions of the other isoforms are not known. Specificity in expression 
patterns has been described for some of these. For example, exercise in skeletal muscle tissue 
induces expression of isoforms transcribed from the alternative promoter, and these isoforms can 
also be found in BAT and heart, but not liver (13).  
 
 
Figure 2 Different isoforms of PGC-1α; adapted from (12) 
 
3.1.2 Regulation of PGC-1α  
PGC-1α is extensively regulated both on transcriptional and post-translational levels 
(Figure 3). A wide diapason of stimuli activates several signal transduction pathways that 
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converge on regulating the levels and activity of PGC-1α, and some of the most important ones 
are described below.  
  
Figure 3 Transcriptional and post-translational regulation of PGC-1α; from (7) 
 
In the liver, glucagon signals low levels of plasma glucose and activates PKA, which in 
turn by phosphorylating cAMP response element-binding protein (CREB) induces PGC-1α 
expression (18). In response, PGC-1α induces the gluconeogenic program. In BAT, cold triggers 
a similar signaling cascade to induce PGC-1α expression, resulting in activation of the adaptive 
thermogenic program (3, 19).  
In skeletal muscle, PGC-1α is induced by exercise, cold and low energy status. 
Contractions on one hand increase Ca
2+
 signaling and, through the calcineurin A (CnA)-MEF2 
axis or the calcium/calmodulin-dependent protein kinase type IV (CaMKIV)-CREB axis, boost 
PGC-1α levels (19, 20). On the other hand, exercise results in p38 mitogen-activated protein 
kinase (p38MAPK) activation through β2-adrenergic signaling, which leads to increased PGC-1α 
expression through phosphorylation of MEF2 (21) and activating transcription factor 2 (ATF2) 
(22). 5' AMP-activated protein kinase (AMPK) gets activated in low energy states (e.g. during 
exercise), and increases PGC-1α levels through a yet unknown mechanism (23, 24). Another 
regulator of PGC-1α expression in muscle is protein kinase B (PKB, also known as Akt) , which 
reduces PGC-1α levels through phosphorylation of FoxO1 upon insulin signaling (25). In 
addition, p38MAPK and AMPK control PGC-1α activity through direct phosphorylation events, 
which increase its activity (9, 26, 27). Besides phosphorylation, other post-translational 
modifications such as acetylation and methylation are also employed in controlling PGC-1α 
activity or protein stability. Therefore, for example, in low energy states, nicotinamide adenine 
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dinucleotide- dependent deacetylase sirtuin-1 (Sirt1) will deacetylate and activate PGC-1α, a step 
that is counteracted by the histone acetyltransferase GCN5 (28, 29).  
3.1.3 Function of PGC-1α  
Besides being a major driver of oxidative metabolism through increased mitochondrial 
biogenesis (30) and fatty acid oxidation (31, 32), PGC-1α has many other tissue-specific roles 
(Figure 4). Many of these additional roles are also metabolic – like fasting-induced 
gluconeogenesis in liver (33) or adaptive thermogenesis in BAT (3). 
In skeletal muscle, PGC-1α induces glucose uptake, glycogen synthesis and lipogenesis 
(34, 35). In addition, it induces vascularization (36) and oxidative fiber type predominance (37). 
All these adaptations result in increased endurance capacity of muscle tissue. This knowledge 
has been gathered through the use of muscle-specific knock-out and transgenic animals that 
result in loss or overexpression of PGC-1α, respectively.  
However, many of PGC-1α’s roles in skeletal muscle are not primarily metabolic. For 
example, in addition to an oxidative fiber type switch and vascularization, PGC-1α increases 
anti-oxidative defense, reduces inflammation and induces neuromuscular junction (NMJ) 
remodeling (38-42). These adaptations have proven important for skeletal muscle and whole 
body maintenance in aging (42). One possible explanation, that recently drew much attention, for 
the effects of PGC-1α levels in muscle on whole body metabolism and wellbeing, is secretion of 
myokines (43, 44). Skeletal muscle PGC-1α has a protective role in some forms of atrophy and 
dystrophy as well, although the mechanisms behind this are not thoroughly elucidated (39, 41, 
45-49).  
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Figure 4 Roles of PGC-1α in skeletal muscle; adapted from (12) 
 
PGC-1α regulates different pathways in combination with various transcription factors. 
For example, mitochondrial biogenesis and oxidative phosphorylation are induced through 
increase in electron transport chain proteins and mitochondrial transcription factor A (TFAM), 
whose expression PGC-1α drives together with the NRF1, NRF2 and ERRα transcription factors 
(30). On the other hand, vascularization is accomplished partially through increased vascular 
endothelial growth factor (VEGF) production in cooperation with ERRα (36), and a fiber type 
switch, through regulation of troponin I (slow) and myoglobin expression in combination with 
MEF2 (37). However, some pathways regulated by PGC-1α remain vaguely defined, such as 
ones that result in phenotypic alleviation in dystrophy or aging. 
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3.2 Skeletal muscle regeneration and repair  
Skeletal muscle tissue is essential for voluntary activities and enables breathing, posture 
and movement. In addition, it is a very important metabolic organ that comprises ~40% of the 
human body (50). Due to its high significance, it is not surprising that it has a great capacity for 
regeneration. Skeletal muscle is a relatively stable tissue, measured by infrequent turnover of 
myonuclei (51). Yet, upon injury, it will quickly respond to compensate for the loss of damaged 
myofibers. 
Skeletal muscle regeneration is a complex processes that requires the cooperation of a 
multitude of cell types. Apart from auxiliary cells types, such as immune cells (mast cells, 
neutrophils, macrophages) and fibroblasts, many cells with myogenic potential can participate in 
skeletal muscle regeneration (satellite cells, side population cells, perycites, mesoangioblasts, 
bone marrow cells, CD133
+
 cells) (52, 53). In addition, secreted factors coming from 
degenerating/regenerating fibers and immune cells, but also blood vessels and motor neurons, 
actively participate in skeletal muscle regeneration through autocrine, paracrine and endocrine 
signaling.  
Skeletal muscle regeneration can be roughly separated into three phases: 1) skeletal 
muscle degeneration and inflammation, 2) precursor proliferation and myotube formation and 3) 
skeletal muscle maturation and functional recovery (54). This process is triggered by a harmful 
event that results in myotube necrosis; for example, due to damage to the skeletal muscle 
membrane, the sarcolemma, which overwhelms the cell’s capacity for quick resealing. However, 
if the impact of the damage is not too pronounced and affects only a small portion of the 
sarcolemma, repair can prevent myotube death, and consequently, the complex and energy 
consuming process of regeneration (Figure 5) (55).  
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Figure 5 Skeletal muscle regeneration and repair: adapted from (56, 57) and www.shutterstock.com and 
www.clipartpal.com 
  
3.2.1 Repair of muscle fibers – membrane resealing 
The sarcolemma is exposed to everyday mechanical tensions due to contractions of 
skeletal muscles. Therefore, its stability and capacity for self-repair is a prerequisite for 
unimpeded muscle function. Many cell types have the ability to reseal ruptures in their 
membranes, and this process becomes especially important for mechanically active tissues, such 
as skeletal muscle (55). Tears in the sarcolemma initiate a series of events that leads to the 
recruitment and dispatching of internal membrane structures to the site of the damage, resulting 
in patch formation and membrane resealing (58). These processes are not fully delineated. 
Current research suggests that membrane opening results in changes in redox state sensed by the 
mitsugumin 53 (MG53) protein present in membranes (59). This protein participates in 
membrane patch creation and vesicle translocation through an oxidation-dependent 
oligomerization event. In the end, dysferlin and auxiliary proteins participate in Ca
2+
 dependent 
resealing (60, 61).   
Inability to repair membrane damage results in the leaky membrane phenotype, and can 
be detected with membrane impermeable fluorescent dyes, both in vitro and in vivo, as well as by 
measuring serum levels of muscle-specific proteins (e.g. creatine kinase). However, the leaky 
phenotype can also be the outcome of membrane instability, and therefore is not per se a readout 
for resealing problems (62). In that regard, current data indicate that the absence of dystrophin 
Muscle fiber 
Repair Regeneration 
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leads to a destabilized sarcolemma due to Ca
2+
 entry through the stretch-induced channels that 
can become leaky with increased reactive oxygen species (ROS) production (60, 62). However, 
these events are also poorly understood.  
3.2.2 Degeneration of muscle fibers – necrosis and inflammation 
When damage to the fiber or sarcolemma surpasses the cell’s capacity for repair, either 
partial or full necrosis will follow. Limited muscle insults will result in partial fiber necrosis. In 
these circumstances, the membrane will reestablish at the damaged site and regeneration will 
enable recovery of the fibers. In the event of severe injury, complete necrosis will occur, leaving 
an empty fiber scaffold comprised of extracellular matrix components. Regeneration in this case 
designates de novo myogenesis (53, 57).  
The first step in muscle regeneration is muscle degeneration, comprised of necrosis and 
inflammation.  Necrosis is uncontrolled, pro-inflammatory cell death (63). It is characterized by 
increased Ca
2+
 cytosolic concentration, leading to activation of calcium-dependent proteases (e.g. 
calpains) and disintegration of cellular components (53). Within seconds to minutes, the first 
cells to respond to the changes in environment caused by cell debris formation are skeletal 
muscle resident mast cells and macrophages (64, 65). They start to secrete pre-synthesized 
chemokines (e.g. tumor necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-6) in order to attract 
immune cells from the bloodstream (66). The initial recruitment involves neutrophils, which 
invade the muscle within minutes to hours. They secrete more chemokines (e.g. monocyte 
chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), MIP-1β) and 
therefore amplify the inflammatory signal (67, 68). The neutrophils are slowly replaced with 
monocytes after the first day of injury. The recruited monocytes differentiate into macrophages 
once they enter the damaged muscle tissue (64). These cells are very plastic, and depending on 
their environment they can act as more classically activated (proinflammatory, M1), alternatively 
activated (M2a) or anti-inflammatory (M2b and M2c) macrophages (69). Their phenotypic 
make-up is characterized by synthesis and secretion of specific cytokines that can further 
propagate inflammation, favor engulfment of cell debris, or signal reduction in the inflammatory 
phase, respectively (65). In addition, the resulting environment is conductive to progenitor 
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activation and proliferation (M1 macrophage-driven), or differentiation (M2 macrophage-driven) 
(70). 
Inflammation is a necessary step for successful skeletal muscle regeneration, with the 
timing and duration of each wave of inflammation being tightly controlled (71, 72). In that 
respect, delayed or reduced inflammation as well as prolonged or excessive inflammation, can be 
equally detrimental (73, 74). While a hindered inflammatory response slows or blocks the 
regenerative process due to inability to clear necrotic tissue, sustained inflammation leads to 
fibrotic tissue formation and prevention of full functional recovery of muscle tissue (75-77).  
3.2.3 Satellite cells 
Satellite cells (SCs) are mitotically quiescent and transcriptionally inactive adult muscle 
stem cells located at the myofiber periphery, as the name suggests, between the sarcolemma and 
basal lamina (78, 79). When dormant, SCs are characterized by a thin rim of cytoplasm, small 
number of organelles and condensed state of chromatin (80). They represent only 2-5% of 
myonuclei, yet can provide a life-long supply of precursor cells for skeletal muscle regeneration 
and postnatal muscle growth (81). The initial method for their detection was electron 
microscopy. Today, thanks to the discovery of several markers, SCs can be easily observed using 
fluorescence microscopy. A widely used marker is paired-box transcriptional factor Pax7, which 
is specifically expressed only by SCs in skeletal muscle and is essential for SC lineage formation 
and function (82, 83).  
Although a variety of precursors both from and outside of muscle tissue can contribute to 
muscle regeneration, SCs are recognized as cells necessary for this process (84-87). As true stem 
cells, they: 1) can become activated and proliferate in order to regenerate damaged tissue, 2) are 
multipotent and apart from skeletal muscle, can be induced towards adipogenic and osteogenic 
lineages, and 3) have the potential to self-renew, ensuring a constant supply of stem cells for 
future rounds of degeneration/regeneration (88-92).  
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3.2.3.1 Satellite cell niche  
The satellite cell niche represents a local microenvironment that supports SC quiescence 
and controls the behavior of satellite cells (93). Due to their specific location, just outside of the 
muscle fiber, SCs are in a position to receive various signals coming from different environments 
(Figure 6). They can sense changes in the muscle fiber, basal lamina of extracellular matrix 
(ECM) and respond to secreted factors from motor neurons, blood vessels, fibroblasts, immune 
and other cells.  
The immediate niche of SCs is comprised of the basal lamina and myofiber (80), and its 
effects can be explored ex vivo, using isolated fibers. SCs expose α7β1 integrins on the basal 
lamina side of the membrane, through which they bind laminin (94). The apical membrane of 
SCs, on the other hand, expresses the docking molecule M-Cadherin and Notch receptor, through 
which SCs can bind Delta ligand expressed by myofibers upon injury (95-97). This differential 
expression of cell surface receptors forms the basis for cell polarity and asymmetric cell 
expansion (98). 
Many growth factors, synthesized and secreted primarily by fibroblasts, reside in the 
ECM in a bound, and therefore inactive form. Once liberated (e.g. by contraction-induced 
shedding), they can bind to receptors in the SC membrane and induce an appropriate response 
(80). In addition, basal lamina components themselves can influence SC activation and 
proliferation, and therefore their myogenic potential. In that respect, the basal lamina thickening 
observed in aging reduces SCs’ propensity to activate (99).  
Interestingly, SCs are not uniformly present throughout muscle fibers, but rather 
demonstrate a tendency to congregate around blood vessels and the NMJ, suggesting that signals 
coming from these entities are important for SC behavior (100, 101). In addition, they are present 
in higher numbers in oxidative fibers and muscles, compared to glycolytic ones (102). However, 
how the metabolic status of the fiber might influence SCs is not known (103). It is also unclear 
whether there are some intrinsic differences between SCs from glycolytic vs. oxidative fibers, 
and what the reason for the differences in SC numbers might be. Endurance exercise, which 
induces a fast-to-slow fiber type switch, was shown to increase SC numbers (104).   
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Figure 6 Satellite cell niche (105) 
   
3.2.3.2 Quiescence and activation 
As previously mentioned, SCs are metabolically quiescent under homeostatic conditions 
and reside in the resting (G0) state. However, damage and contraction elicit their activation, after 
which they enter the cell cycle. Depending on the stimulus, SCs can just be transiently activated, 
or they can proliferate and fuse in order to repair damaged fibers or contribute to fiber growth 
(106). A very useful marker to detect SC activation vs. quiescence is Ki67, which is expressed in 
all stages of the cell cycle except for G0 (107, 108). However, recent research has challenged our 
understanding of SC dormancy and indicated that the situation is more complex.   
Currently, we can differentiate between two stages of quiescence – full quiescence (G0) 
and alertness (GAlert) (109). It has been demonstrated that SCs in GAlert do not express Ki67, yet 
they are able to respond to injury in a much faster manner compared to cells in G0, and as a 
consequence, regenerate skeletal muscle faster. Interestingly, factors coming from other muscles 
or even other tissues can provoke a transition in SC state, confirming the importance of 
endocrine secreted factors in SC behavior. Mammalian target of rapamycin complex 1 
(mTORC1) signaling and the upstream hepatocyte growth factor (HGF)/c-Met axis of signal 
reception have proven essential for this switch.  
c-Met is a receptor tyrosine kinase present on SCs of the muscle fiber, and together with 
its ligand HFG, initiates the pathway of initial SC activation (110). Upon contraction, Ca
2+
 
signaling leads to increased nitrogen monoxide (NO) levels in myofibers and consequently to 
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activation of matrix metalloproteinases (MMPs), which cleave ECM-bound HGF and allow its 
binding to c-Met (111). Another important modulator of SC activation is myostatin (Mstn), 
which keeps SCs in a quiescent state (112). Interestingly, not only Mstn levels in SCs, but also in 
the SC niche (myofiber) influence SC behavior (113). 
3.2.3.3 Proliferation and maintenance 
Upon injury, quiescent SCs become activated and start proliferating in order to provide 
precursor cells for muscle regeneration. SCs’ return to quiescence is as important as SC 
activation. Repeating rounds of degeneration/regeneration of muscle tissue, or otherwise induced 
constant activation of SCs, or their inability to return to quiescence, all lead to SC depletion and 
skeletal muscle deterioration. Apart from constant injury observed in dystrophy, aging can also 
lead to chronic activation of SCs, resulting in a reduction in SCs numbers (114). 
SCs represent a heterogeneous population of cells according to their marker expression, 
but also to their myogenic and self-renewal potential. Myf5 is the earliest myogenic regulatory 
factor that predisposes SCs to the myogenic commitment (115). Lineage tracing experiments 
using Myf5-Cre/ROSA-YFP mice have demonstrated that ~90% of the SC population are 
Pax7
+
/YFP
+
 – cells that are expressing, were at some point in their life expressing, or are derived 
from progenitors that expressed Myf5. It has been demonstrated in vivo that while both 
Pax7
+
/YFP
+
 and Pax7
+
/YFP
-
 cells can terminally differentiate, only Pax7
+
/YFP
-
 cells can 
significantly repopulate the SC niche (89). Furthermore, although both SC subpopulations can 
divide symmetrically, asymmetrical division was detected only in Pax7
+
/YFP
-
 cells, and is 
dependent on the SC niche. Skeletal muscle maintenance may rely primarily on asymmetric 
division. However, symmetrical division is the preferred choice of self-renewal in response to 
acute damage, such as after cardiotoxin injection, when stem cells needs to replenish and expand 
in order to regenerate muscle (98, 116).  
In addition to SC renewal through asymmetric and symmetric division, myoblasts’ return 
to quiescence is another way of maintaining the SC pool. This was first reported in ex vivo 
settings, where it was noticed that all Pax7
+
 cells on isolated myofibers start expressing MyoD, 
but then a certain proportion of them downregulate it and return to quiescence. However, lineage 
regression was also observed in vivo, where sprouty 1 (Spry1), a negative regulator of receptor 
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tyrosine kinase signaling, proved essential for returning a subset of myogenic progenitors to a 
quiescent state (117).  
3.2.4 Myotube formation – adult myogenesis 
Once SCs become activated, they begin expressing myogenic regulatory factors (MRFs). 
The first to be expressed are Myf5 and MyoD, which destine SCs toward the myogenic lineage. 
Actively proliferating SCs are called myoblasts, and as they progress further down the 
myogenesis pathway, they reduce expression of Pax7 and induce expression of myogenin. 
However, one portion of cells will reduce MyoD and increase Pax7 expression, returning to the 
dormant state (50, 118).  
Once the proliferation phase in over, myoblasts will exit the cell cycle, becoming 
postmitotic mononuclear myocytes (Figure 7). These cells will fuse together in order to form 
multinucleated myofibers, the stage for which myogenin and MRF-4 (myogenic regulatory factor 
4, also known as Myf6 or herculin) expression is characteristic (50). Newly formed muscle fibers 
are initially of small caliber, basophilic due to increased protein synthesis, and with centrally 
located nuclei. Later on, these fibers grow to their original size and the nuclei relocate to the 
periphery. In the absence of pathology, regenerated muscle is morphologically and 
physiologically indistinguishable from uninjured muscle (80). 
 
 
Figure 7 Adult myogenesis (119) 
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These steps represent adult myogenesis in a nutshell, and are in many ways similar to 
embryonic events in skeletal muscle tissue formation. The described sequential expression of 
Pax7 and MRFs enables tracking of myogenesis progression and assessment of the regenerative 
stage after induced injury (120).  
3.2.5 Functional recovery and fibrosis 
After myocyte fusion, the newly formed myotubes will continue to grow until they reach 
their pre-injury size. This process is dependent on protein synthesis, and can be followed using 
histology through assessment of cross-sectional area (CSA). Myotube size also corresponds to 
ability to generate force, and therefore the stages of regeneration can also be evaluated through 
muscle contractility measurements (121).  
Another characteristic of skeletal muscle regeneration is scar tissue formation (54). It is 
comprised of extracellular matrix components, for example various collagens, fibronectin and 
tenascin-C (122). These components are primarily secreted by muscle resident fibroblasts, and 
they provide the initial scaffold on which the skeletal muscle is rebuilt after injury. However, this 
formation of fibrotic tissue needs to be limited in size and duration for successful skeletal muscle 
regeneration to occur (Figure 8).  
Excessive fibrous tissue formation results in the replacement of functional muscle tissue 
with scar tissue, and therefore reduces skeletal muscle performance (123). Fibrosis is 
characterized by sustained transforming growth factor β (TGF-β) signaling, which through 
activated Smad transcription factors leads to overproduction and accumulation of fibronectin and 
other ECM components (77). Imbalances in communication between myoblasts and fibroblasts, 
as well as prolonged inflammation, are recognized as driving forces in this pathology (86, 123).  
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Figure 8 Imbalance in inflammation results in fibrosis (77) 
 
3.2.6 Skeletal muscle regeneration and repair in chronic degenerative 
diseases, acute traumatic injuries and aging  
Skeletal muscle tissue has a vast, albeit not limitless propensity for regeneration. 
Dystrophic conditions and aging are characterized by chronic changes that drive the loss in 
regenerative capacity. This might be due to the SC depletion caused by repetitive 
activation/proliferation, poorer myogenic potential, and SC death (114). The causes might be SC 
intrinsic or extrinsic, such as changes in the SC niche or circulatory systemic factors (124). In 
addition, reduced regeneration can also be observed in acute injuries in humans when a large 
portion of muscle tissue is damaged, without pathological changes affecting SCs (54).  
Muscular dystrophies are a heterogeneous group of muscle disorders characterized by 
skeletal muscle weakness and wasting. Many arise due to various genetic mutations that in most 
cases affect cytoskeletal proteins. Lack of these proteins makes muscles more prone to the 
damaging effects of wear-and-tear stemming from everyday contractions, resulting in repetitive 
cycles of degeneration and regeneration (125). This constant damage is a great burden on the SC 
population, culminating in SC loss and diminished proliferative capacity resulting in reduced 
ability to regenerate. It is thought that SC senescence and apoptosis, due to telomere shortening 
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with every division, but also extrinsic factors such as reduced availability of insulin-like growth 
factor 1 (IGF-1), are responsible for the pathology (114).  
Aging is accompanied by sarcopenia – a decline in skeletal muscle mass and 
performance, which leads to frailty, morbidity and reduced regenerative capacity. Reduced SC 
numbers and proliferation have been detected in aged animals, and changes in the environment 
probably contribute to this muscle phenotype (124, 126). In that regard, recent discoveries have 
identified several intrinsic and extrinsic factors contributing to diminished SC renewal and SC 
senescence: fibroblast growth factor 2 (FGF-2) from the niche increases with aging and draws 
satellite cells out of quiescence, while Spry1, an inhibitor of FGF signaling, maintains SC 
dormancy. The negative effect of FGF-2 on SC maintenance can be overcome by reducing FGF 
signaling or overexpressing Spry1 in SCs (127), which decreases with aging. In addition, an 
increase in p38MAPK signaling accompanied by altered fibroblast growth factor receptor 1 
(FGFR1) signaling was observed in SCs of aged mice and resulted in reduced SC self-renewal. 
These defects could not be overcome in a heterochronic culture experiment, signifying the 
contribution of SC intrinsic changes in the pathology (128).  
Apart from aging and various pathologic conditions, limited regenerative capacity is also 
observed in acute traumatic injuries. This is not due to changes in SC numbers or behavior, but 
simply due to the size of the muscle affected, with fibrosis proceeding faster than myogenesis 
(54). These limitations can be alleviated with transplantation techniques, using biomaterials to 
bridge the gap resulting from the damaged tissue and providing a scaffold for cells participating 
in regeneration. These approaches can be combined with cell therapies and growth factors in 
order to boost vascularization of the nascent tissue (129). 
Loss of SC numbers was also observed in other atrophic conditions, such as denervation 
or immobilization (114). Contrary to that, endurance exercise was shown to increase SC numbers 
and their myogenic potential in aging (104).  
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3.3 PGC-1α in skeletal muscle regeneration and repair  
PGC-1α has emerged as a junction point of many transduction pathways initiated by 
various stimuli that signal alterations in the environment to which muscle needs to adapt (6). At 
the core of these adaptations is increased oxidative metabolism (30-32). Interestingly, oxidative 
metabolism seems to be central to adult myogenesis (130-132), as illustrated by experiments 
performed on ERRα and ERRγ mutants (133-135).  
Muscle-specific overexpression of PGC-1α leads to increased vascularization and 
adaptations in NMJ gene expression, which together with mitochondrial biogenesis and slow 
contractile protein expression result in an oxidative fiber type switch (36, 37, 41). Slow oxidative 
fibers are more resistant to various atrophic conditions (e.g. fasting, glucocorticoids, sepsis, 
cancer cachexia, diabetes) compared to glycolytic fibers, and this protection might result from 
higher expression of PGC-1α in oxidative muscles (45, 136). In addition, vascularization and 
innervation are essential for the proper functioning and survival of muscle tissue upon cell 
transplantation, and are one of the major limiting factors in regenerative medicine (137).  
The major stimulus that initiates PGC-1α induction and consequently the aforementioned 
adaptations in skeletal muscle under physiological conditions is endurance exercise (138, 139). 
Interestingly, such an exercise regimen increases SC numbers and also improves SC myogenic 
capacity in aging rats (104). In addition, it has been long known that oxidative muscles and fibers 
contain higher numbers of SCs than glycolytic ones (102). However, in which way metabolic 
properties of fibers affect SC numbers and behavior is underexplored (103).  
Contrary to PGC-1α transgenic mice, muscle-specific knock-out mice exhibit a mirrored 
phenotype and are prone to mild myopathy (39). Due to the beneficial muscle features driven by 
PGC-1α expression, in addition to exploring its metabolic roles, research has also been directed 
towards evaluating PGC-1α’s effects on muscle pathologies. For example, on several occasions 
researches have assessed the outcome of PGC-1α overexpression in Duchenne muscular 
dystrophy (DMD) mouse model (mdx) (41, 46-48). Oxidative fiber type switch, induced 
expression of markers of regeneration and dystophin-glycoprotein complex components are 
some modulations that were reported to alleviate the dystrophic phenotype. There was even some 
speculation regarding improvement in regenerative potential (47), although most of their 
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conclusions were based on increased protection to muscle tissue (41). This protective effect 
indicates improved membrane stability and/or membrane resealing after damage.  
Protective effects of PGC-1α on muscle tissue were also demonstrated in other 
pathologies, such as mitochondrial myopathy (49), statin induced myopathy (140) and 
amyotrophic lateral sclerosis (ALS) (141). Additionally, PGC-1α was shown to reduce muscle 
loss in fasting and denervation induced atrophy (45) as well as in sarcopenia, where systemic 
effects of overexpressed PGC-1α in muscle tissue were reported, increasing the longevity of 
these mice (42).   
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4 Aims 
Having in mind the beneficial effects of peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α) expression in skeletal muscle and its potential role in skeletal muscle 
regeneration and repair (see PGC-1α in skeletal muscle regeneration and repair), we wanted to 
elucidate several aspects of its function: 
1. PGC-1α in skeletal muscle regeneration: 
 does PGC-1α have an effect on skeletal muscle regeneration 
 does boosting PGC-1α in differentiated myoblasts accelerate regenerative 
processes 
 does loss of PGC-1α in SCs affect proliferation and differentiation alike 
 
2. PGC-1α in satellite cells: 
 does PGC-1α have a specific effect on SCs 
 what are the effects of overexpression or loss of PGC-1α in the SC niche and 
consequently the effects of myofiber metabolism on SC behavior 
 what are the effects of PGC-1α deletion in SCs and possible modifications of SC 
behavior 
 
3. PGC-1α in skeletal muscle repair: 
 does PGC-1α modulate sarcolemma repair 
 what are the resealing properties of PGC-1α KO myoblasts 
 how can PGC-1α improve membrane stability and rupture patching  
 
4. PGC-1α in regenerative medicine: 
 can PGC-1α improve muscle regeneration in vivo by improving environmental 
changes that otherwise limit tissue survival and function after transplantation  
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5.1 Abstract 
Skeletal muscle tissue possesses a great capacity for regeneration upon injury, and this 
mechanism partially depends on oxidative metabolism. PGC-1α is a main modulator of oxidative 
metabolism, but its role in skeletal muscle regeneration has not been addressed yet. Using mouse 
models for muscle-specific overexpression and knock-out of PGC-1α in combination with 
cardiotoxin (CTX) injury, we aimed to elucidate the role of this transcriptional coactivator 
throughout the process of regeneration. Although our results show successful recovery in both 
mouse models, we observed differences at the early stages of regeneration concerning 
inflammation and subsequent necrotic tissue clearance. Results obtained in transgenic animals 
indicate accelerated attraction and invasion of inflammatory cells measured by macrophage 
numbers and chemokine production, culminating in faster resolution of necrosis. Additionally, 
loss of PGC-1α resulted in increased fibrosis after multiple CTX injuries. Differential expression 
of myostatin (Mstn) and insulin-like growth factor 1 (IGF-1) in PGC-1α mouse models are a 
plausible cause for the aforementioned features of regeneration. These effects of PGC-1α 
modulation can become beneficial in the context of acute injury and explain some of the 
previously reported outcomes of PGC-1α overexpression in mouse dystrophy models. 
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5.2 Introduction 
Skeletal muscle comprises 40% of human body weight, and is a very active metabolic 
tissue, important for posture, breathing and movement. It is distinguished by very high plasticity 
and a relatively low nuclear turnover rate (1), yet has a tremendous capacity for regeneration. 
Skeletal muscle regeneration is a highly organized and complex process that involves the 
coordinated activation of multiple cells types and factors (2). Cells indispensable for the 
formation of new muscle tissue are muscle stem cells, named satellite cells (3). Upon injury and 
exercise, these cells give rise to more muscle progenitors that eventually fuse together and form 
new myotubes or repair damaged ones. The whole process of regeneration, characterized by 
satellite cell activation, proliferation and differentiation, can be followed by the expression of the 
transcription factor Pax7 and myogenic regulatory factors (MRFs) (4). While upregulation of 
Pax7, Myf5 and MyoD marks the stage of muscle progenitor proliferation, myogenin (Myog) 
and MRF-4 mark the subsequent myoblast fusion and myotube maturation.  
In parallel to the process of myogenesis, timely participation of other cell types is also 
necessary for successful regeneration to occur. Upon injury, muscle fibers undergo necrosis and 
attract inflammatory cells in order to eradicate cell debris and make room for newly formed 
muscle fibers (5, 6). A precisely ordered response to injury, in particular to macrophage 
attraction and clearance, is essential to successful regeneration as demonstrated in various mouse 
models. The first cells which respond to damage are muscle-resident mast cells and 
macrophages. By secreting tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), they attract 
neutrophils which invade the damaged area within hours (6, 7). Neutrophils continue secreting a 
myriad of chemokines: monocyte chemoattractant protein 1 (MCP-1) and macrophage 
inflammatory proteins (MIP-1α, MIP-1β), which in turn attract monocytes from the blood 
stream. Monocytes give rise to M1 macrophages, the function of which is to phagocyte necrotic 
tissue and form an environment that favors satellite cell activation and proliferation. Over a 
period of several days, M1 macrophages are replaced by M2 macrophages, whose role is to 
suppress the process of inflammation and produce extracellular matrix components that serve as 
a scaffold for the formation of new muscle tissue. The M2 type of macrophages is also essential 
for the switch from the proliferative to differentiative stage of regeneration. However, prolonged 
presence of M2 macrophages leads to uncontrolled activation and proliferation of fibroblasts and 
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overproduction of extracellular components resulting in fibrosis (8). The formation of excessive 
fibrous tissue prevents the full functional recovery of muscle tissue. Timely attraction of 
macrophages and the switch between subclasses, as well as eradication of these cells at the end 
of the regenerative process is a prerequisite for successful activation of muscle progenitor cells, 
as well as their proliferation and differentiation (9).  
The transition from myoblast proliferation to differentiation is an energy demanding 
process and is accompanied by a switch from glycolysis to oxidative metabolism as the ATP 
producing pathway (10). The importance of the estrogen-related receptor α (ERRα) transcription 
factor in skeletal muscle regeneration and differentiation has been previously reported (11, 12). 
Given the significance of the interaction between peroxisome proliferator-activated receptor γ 
coactivator 1 α (PGC-1α) and ERRα for driving oxidative metabolism (13), we hypothesized that 
PGC-1α might have a role in the process of regeneration. 
 PGC-1α is a master regulator of mitochondrial biogenesis and oxidative metabolism (14, 
15). Its overexpression in skeletal muscle leads to a shift from the glycolytic to oxidative 
phenotype (16), high capacity in endurance exercise (17) and lower systemic inflammation (18), 
while muscle specific knock-out induces the opposite effect (19, 20). In addition, PGC-1α 
overexpression protects muscles against atrophy (21), sarcopenia (22) and reduces the dystrophic 
phenotype in mdx mice (23-26), although the complete mechanisms behind these effects have not 
been determined. However, its role in skeletal muscle regeneration has not been investigated yet.  
Considering the importance of oxidative metabolism for skeletal muscle regeneration and 
the protective role of PGC-1α in the context of dystrophic mice and exercise, we sought to 
address the question of the role of PGC-1α in skeletal muscle regeneration in response to severe 
cardiotoxin (CTX) injury using muscle specific overexpression and knock-out mouse models. 
Surprisingly, our results indicate no difference in terms of functional recovery at later stages of 
regeneration when the difference in PGC-1α levels between the mouse models is most 
pronounced. However, we detected differences in early stages of regeneration, where we noticed 
a correlation between necrotic area, macrophage numbers and PGC-1α levels in both of our 
mouse models. We show that PGC-1α levels in mice influence the velocity of response to 
damage by chemokine secretion and recruitment of inflammatory cells which leads to a faster 
clearance of necrotic tissue. In addition, we detected increased fibrosis in the knock-out mice 
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compared to the controls after multiple CTX injury. Therefore, PGC-1α expression affects not 
only initial recruitment of inflammatory cells, but also development of fibrosis. These effects of 
PGC-1α might prove advantageous as a therapy after acute muscle damage, and also explain 
some of the previously described consequences of PGC-1α overexpression in dystrophic mice. 
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5.3 Materials and Methods 
Animals: 
 PGC-1α transgenic mice (mTG) express PGC-1α under the control of muscle creatine 
kinase (MCK) promoter and have been previously described (16). A muscle specific PGC-1α 
knock-out model (mKO) was generated by crossing a PGC-1αflox/flox line (27)  with a Myf5-Cre 
line (The Jackson Laboratory, stock number 007845). The genotype of mice was determined by 
PCR from toe biopsies using specific primers (Table 1). All experimental procedures performed 
on mice were approved by the Swiss authorities. In this study, male 8-12 week old mice were 
used unless stated otherwise. 
Cardiotoxin injury: 
In anesthetized mice (O2/sevoflurane, 3% sevoflurane) kept on a warm plate, lower limbs 
were shaved and cleaned using 70% ethanol. 30μl of control vehicle (phosphate buffered saline, 
PBS) or 30μl (3μg) of CTX (C9759 Sigma) was injected in the belly of the tibialis anterior (TA) 
using insulin syringes (U-100, 300μl, 29Gx1/2”). Mice were sacrificed at various time points and 
TA muscles collected, transversally cut into two pieces and frozen for histology or RNA 
isolation.  
Histology: 
Half of a TA muscle was placed in the OCT (Tissue-Tek, Sakura) in plastic molds and 
frozen in isopenthane precooled in liquid nitrogen. 8μm thick sections were cut with a cryostat 
(Leica CM1950) and stored at -20˚C. Hematoxylin and eosin (Sigma MHS32, HT110232) 
staining (H&E) and Masson’s trichrome (Sigma HT15, HT1079, HT10132) staining were 
performed on dried sections fixed with paraformaldehyde (PFA) according to the manufacturer’s 
instructions, and mounted with Eukitt mounting medium (O. Kindler). For nicotinamide adenine 
dinucleotide (NADH) staining, sections were incubated with NADH (Sigma, N-8129) and 
nitroblue (Sigma, N-5514) for 30 min at 37˚C. Immunostainings were performed on dried fixed 
sections or myotubes, blocked in 3% bovine serum albumin (BSA) in PBS, followed by primary 
antibody incubation (laminin ab11575 Abcam, DAPI 62248 Thermo Scientific, MF20 DSHB, 
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CD68 MCA1957GA Serotec). After washing with PBS, sections were incubated with secondary 
antibodies (goat-anti-mouse IgG2b Alexa488 A21141 Life Technologies, goat-anti-rabbit IgG 
Alexa488 A11008 Invitrogen, goat-anti-rat IgG Alexa488 A11006 Invitrogen, donkey-anti-rabbit 
IgG Alexa647 A31573 Life Technologies) then washed with PBS and mounted with Vectashield 
(H-1000 or H-1200 Vector). 
Myoblast isolation: 
A pure population of myoblasts was isolated using the single fiber technique explained 
elsewhere (28). In brief, muscle fibers were isolated from the extensor digitorum longus (EDL) 
muscle of 2-3 week old mice using collagenase A (Roche Diagnostics) and trituration by pipette, 
and incubated on matrigel (BD Biscience) coated dishes. Satellite cells emerging from the fibers 
were expanded using proliferation media (10% horse serum, 20% fetal bovine serum, 1% 
antibiotic mix, 1% chicken embryo extract, 2mM L-Glutamine, 5ng/ml basic fibroblast growth 
factor in HyClone DMEM media). High purity of the myoblast population was confirmed with 
desmin staining. 
Myoblast differentiation: 
Matrigel-coated plastic dishes were plated with the same number of myoblasts and 
differentiation was induced a day later (mKO) or after the myoblasts started fusing (mTG). A 
different approach was used due to the possibility of different kinetics of proliferation in the case 
of mKO, and induction of transgene at more mature stages of differentiation in the case of mTG 
myoblasts. Differentiation was induced by switching from high to low serum conditions (4% 
horse serum, 1% antibiotic mix, 1% chicken embryo extract in DMEM Glutamax). After two 
days of differentiation, RNA was extracted or the cells were fixed and stained.  
Image acquisition and quantification: 
Immunostained muscle sections and cells were acquired using a Zeiss LSM700 with the 
Zen 2010 software using a 25x objective with 0.5 zoom for sections or a 10x objective for 
myotubes. H&E and Masson’s trichrome stainings were acquired using Olympus IX81 with a 4x 
objective. The entire area of the muscle sections was covered, and for myotubes 25 images were 
acquired. Quantification was performed on the complete area using the ImageJ software (section 
Project 1 
49 
area, necrotic area, intensity of NADH staining, area of macrophage staining, area of collagen 
staining), the Imaris software (nuclei counting in myotubes), or was done by hand (satellite cell 
and fusion index (FI) counting).  
RNA extraction and relative quantitative PCR (qPCR): 
Total RNA was extracted from half of a TA muscle or primary cells using TRI Reagent 
(Sigma) and/or lysing matrix tubes (MP Biomedicals) according to the manufacturer’s 
instructions. After measuring RNA concentration on Nanodrop 1000 (Thermo Scientific), 1μg 
was treated with DNase I (Invitrogen) and used for cDNA synthesis using reverse transcriptase 
Superscript II (Invitrogen). Relative mRNA levels were measured by qPCR on a StepOne 
machine with SYBR green based detection, and normalized to TATA binding protein (TBP) 
expression using the ΔΔCt method. A list of primers is provided in Table 1. 
Muscle contractility measurements in situ: 
TA muscle regeneration was evaluated through measuring in situ isometric muscle 
contraction in response to nerve stimulation, as previously described (29). Mice were 
anesthetized using a pentobarbital solution (ip, 60 mg/kg) and supplemental doses were given as 
required, to maintain deep anesthesia during experiments. The paw was fixed with clamps to a 
platform and the knee was immobilized using stainless steel pins. The distal tendons of muscles 
were attached to an isometric transducer (Harvard Bioscience) using a silk ligature. The sciatic 
nerves were proximally crushed and distally stimulated by a bipolar silver electrode using 
supramaximal square wave pulses of 0.1ms duration. All data provided by the isometric 
transducer were recorded and analyzed on a computer, using the PowerLab software (4SP, AD 
Instruments). All isometric measurements were made at an initial length L0 (the length at which 
maximal tension was obtained during the tetanus). Responses to tetanic stimulation (pulse 
frequency from 6.25, 12.5, 25, 50, 100 and 143Hz) were successively recorded. Maximal tetanic 
force (P0) was determined. Muscle mass was measured to calculate specific force (P0 [g]/weight 
[g]). Finally, the fatigue resistance was assessed. The fatigue protocol consisted of one 
continuous contraction (50Hz for 45s). The time to reach 50% of the initial force was measured. 
After contractile measurements, mice were sacrificed with an overdose of anesthetic solution. 
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Statistical analysis 
All data are presented as AV+/-SEM. CTX values are in most cases normalized to the 
PBS values of the corresponding genotype using unpaired comparison (e.g. each mTG CTX 
sample was normalized on average value of mTG PBS samples). Statistical analysis was 
performed using Student’s t test for comparison of two groups (e.g. in most qPCR data those are 
two PBS- normalized CTX groups) and p≤0.05 was considered significant.  
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5.4 Figures 
  
Table 1. List of primers 
All primers were used for qPCR measurements, except for Cre and LoxP primers which are used for genotyping 
mKO mice 
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Supp Fig 1. Characterization of Myf5-mKO mice 
A) Relative PGC1-α mRNA expression levels in various organs; mRNA levels in mKO mice were normalized to 
WT (control littermate) levels; n=6 per group; B) Body composition: weight and lean weight in mice from 3 to 9 
weeks old; n=8-9 per group; C) Exercise capacity in mKO mice is reduced: time till exhaustion, maximal speed 
reached, VO2 max and respiratory exchange ratio (RER) values before run and at the exhaustion; n=8-9 per group; 
only comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; * p≤0.05, ** p≤0.01, *** 
p≤0.001; Abbreviations: Gastro (gastrocnemius), Sol (soleus), QU (quadriceps), Edl (extensor digitorum longus) 
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Fig 1. In situ TA contractility measurements 10 days after cardiotoxin injection in mTG and mKO mice 
Maximal force (P0), fatigue, TA weight and specific force (P0/weight) in A) mTG and B) mKO mice; only 
comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=7-11 per group; * p≤0.05, ** 
p≤0.01, *** p≤0.001  
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Supp Fig 2. In situ TA contractility measurements 16 days after cardiotoxin injections in mTG and mKO 
mice 
Maximal force (P0), fatigue, TA weight and specific force (P0/weight) for A) mTG and B) mKO mice; only 
comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=7-8 per group; * p≤0.05, ** 
p≤0.01, *** p≤0.001  
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Supp Fig 3. NADH staining of TA 19 days after cardiotoxin injections 
Representative images of NADH stained sections injected either with CTX or control (PBS injected) and signal 
intensity measurement in A) mKO and B) mTG mice. Note: lower values indicate darker staining (signal intensity 0-
255, where 0 translated into no signal and 255 into fully saturated signal); comparison was made between genotypes 
and treatments (t test); Values are plotted as AV+/-SEM; n=5-10 per group; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Supp Fig 4. In vitro myogenesis 
A) Representative IHC image of differentiated myotubes 2 days after switching to low serum media (MF20: green; 
dapi/nuclei: blue) and fusion index (FI) for mKO and mTG mice at the same time point; quantification was done on 
area of 10.2 mm
2
 per dish, 2 dishes per mouse and 3 mice per genotype; red quadrant represents enlarged area of 
white quadrant; B) Relative mRNA expression levels of Pax7 and MRFs at the proliferative state (MB, myoblast) 
and during differentiation (MT, myotubes at 1d, 2d and 3d of differentiation) in mKO. Same measurements were not 
performed for mTG due to the later expression from transgene (notice PGC-1α expression levels at 3d in mTG). 
Gene expression levels in myotubes were normalized to the myoblast levels of the corresponding genotype, except 
for PGC-1α expression levels, where WT PBS expression levels were used for normalization; only comparison 
between genotypes was made (t test); n=3 per group (in duplicate); Values are plotted as AV+/-SEM; * p≤0.05, ** 
p≤0.01, *** p≤0.001 
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Fig 2. Kinetics of Pax7 and MRFs expression after cardiotoxin injury 
Relative mRNA expression 4d, 7d, 10d and 19d post CTX injection in A) mTG and B) mKO mice; CTX expression 
levels were normalized to the PBS levels of the corresponding genotype; only comparison between genotypes was 
made (t test); Values are plotted as AV+/-SEM; n=4-12 per group (genotype and time point); * p≤0.05, ** p≤0.01, 
*** p≤0.001 
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Supp Fig 5. Expression of metabolic genes at basal state and PGC-1α expression during regeneration 
Relative mRNA levels of genes implicated in oxidative metabolism at A) 4d post CTX and B) 7d post CTX; C) 
Relative mRNA levels of PGC-1α at 8h, 4d, 7d and 10d post CTX. Normalization was based on WT PBS expression 
levels; only comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=5-10 per group; 
* p≤0.05, ** p≤0.01, *** p≤0.001; Abbreviations: PRC (PGC-1-related coactivator), Tfam (mitochondrial 
transcription factor A), Gabpa (GA-binding protein alpha), CycS (cytochrome c, somatic), Cox1 (cytochrome 
oxidase subunit 1) 
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Fig 3. Expression of metabolic genes after cardiotoxin 
Relative mRNA expression levels in mTG and mKO mice at A) 4d and B) 7d post CTX. CTX expression levels 
were normalized to the PBS levels of the corresponding genotype; only comparison between genotypes was made (t 
test); Values are plotted as AV+/-SEM; n=5-8 per group; * p≤0.05, ** p≤0.01, *** p≤0.001; Abbreviations: PRC 
(PGC-1-related coactivator), Tfam (mitochondrial transcription factor A), Gabpa (GA-binding protein alpha), CycS 
(cytochrome c, somatic), Cox1 (cytochrome oxidase subunit 1) 
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Supp Fig 6. Expression of genes participating in early stages of regeneration 4d and 7d after cardiotoxin 
injection 
A) data for mKO and B) mTG mice. CTX expression levels were normalized to the PBS levels of the corresponding 
genotype; only comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=5-8 per 
group; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Fig 4. Necrosis at 4d post cardiotoxin 
Representative H&E stained sections with enlarged areas showing necrotic and regenerating fibers and 
measurements of necrotic area normalized to the total section area for A) mKO and B) mTG mice; Values are 
plotted as AV+/-SEM; n=5-8 per group; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Supp Fig 7. H&E stained section 2d post cardiotoxin injury 
Image shows complete muscle damage resulting in necrosis 
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Fig 5. Macrophage staining and quantification 4d post cardiotoxin 
Representative IHC images with enlarged areas showing accumulating macrophages (CD68: green; dapi/nuclei: 
blue; laminin: grey) and quantification results of CD68
+
 area normalized to the total section area for A) mKO and B) 
mTG mice; only comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=5-8 per 
group; * p≤0.05, ** p≤0.01, *** p≤0.001 
  
Project 1 
64 
 
 
Supp Fig 8. Relative mRNA expression levels of M1 and M2 macrophage markers at two time points after 
cardiotoxin injection 
A) mKO mice 2d and 4d after CTX; B) mTG mice 1d and 3d after CTX. CTX expression levels were normalized to 
the PBS levels of the corresponding genotype; only comparison between genotypes was made (t test); Values are 
plotted as AV+/-SEM; n=3-7 per group; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Fig 6. Chemokine and cytokine expression in mTG mice after cardiotoxin 
A) 8h after CTX; B) 1d after CTX) and C) 2d after CTX. CTX expression levels were normalized to the PBS levels 
of the corresponding genotype; only comparison between genotypes was made (t test); Values are plotted as AV+/-
SEM; n=4-6 per group; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Fig 7. Fibrosis after multiple cardiotoxin injections 
A) Representative Masson’s Trichrome stained section with enlarged area and quantification of fibrotic area in mKO 
and mTG mice 3 weeks after the third CTX injection; B) Relative mRNA levels of profibrotic genes at the same 
time point in mKO and mTG mice; C) Relative mRNA levels of IGF-1 and Mstn 19d after single CTX injection in 
mKO and mTG mice. CTX expression levels were normalized to the PBS levels of the corresponding genotype; 
only comparison between genotypes was made (t test); Values are plotted as AV+/-SEM; n=4-10 per group; * 
p≤0.05, ** p≤0.01, *** p≤0.001; Abbreviations: Col (collagen) 
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5.5 Results 
Myf5 Cre-PGC1α knock-out (mKO) and MCK-PGC-1α transgenic (mTG) mouse models 
In order to study the role of PGC-1α in skeletal muscle regeneration, we generated 
muscle specific knock-out mice (mKO). PGC-1αloxP/loxP homozygote mice with floxed PGC-1α 
exons 3-5 (30) were crossed with Myf5-Cre heterozygote mice (The Jackson Laboratory, 
007845). The Myf5 promoter was chosen for achieving PGC-1α ablation at the muscle 
progenitor stage. Analysis of mKO mice confirmed reduction in PGC-1α transcript levels (Supp 
Fig 1). In addition to muscle tissue, Cre-driven ablation also affected brown adipose (BAT) and 
to a lower extent white adipose tissue (WAT) visceral (vis) and subcutaneous (sc) compartments, 
both of which share origins in Myf5
+
 progenitors together with muscle cells (31, 32). Compared 
to Myog-Cre PGC-1α mice (19, 20), mKO mice have lower body weight due to reduced lean 
mass (Supp Fig 1). mKO are also characterized by diminished capacity for endurance exercise 
measured by time and maximal speed achieved during incremental uphill running to exhaustion 
in a closed treadmill. Additional measurements revealed decreased maximal oxygen 
consumption (VO2max) confirming reduced endurance capacity (Supp Fig 1). Since mKO mice 
are not completely backcrossed to the C57BL/6 background while mTG are, we used separate 
littermate controls for both genotypes (wild type, WT). 
Unaffected functional recovery of CTX injected TA in mTG and mKO mice 
Given that PGC-1α is a very important driver of oxidative metabolism (33), and that 
skeletal muscle differentiation and regeneration are dependent on the transition from glycolytic 
to oxidative pathways for energy production (10, 34), we first aimed to see whether different 
levels of PGC-1α in the muscle would affect terminal regeneration in terms of functional 
recovery. In order to answer this question, we performed in situ contractility measurements on 
control (PBS injected) and injured (CTX injected) TA muscles of mKO and mTG animals. 
Measurements at 10 days (10d) time point (Fig 1A) confirmed previously published observation 
of decreased force and increased fatigue resistance in mTG mice prior to injury (35). The same 
measurements also revealed tendencies towards opposite phenotype in mKO (Fig 1B). There was 
no change in recovery of fatigue resistance (recovered 50-80%) or force (recovered 10-20%) 10 
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days after the injury in either genotype. Since the force at this time point recovered to only 20% 
of the initial levels (Fig 1), we decided to perform the measurements at a later time point after 
CTX. At 16d after CTX (Supp Fig 2), force recovery was ~60% of control values, and no 
difference between the genotypes and their controls was present. mKO mice had higher specific 
force after CTX compared to WT (Supp Fig 2B), however there was no difference in terms of 
percentage of recovery (CTX values normalized to PBS values of the corresponding genotype). 
Also, although values for fatigue resistance in mTG at 16d were higher compared to WT, 
recovery in WT was nearly complete (~90%) and hence is not indicative of regeneration, but 
rather the possibility of a fiber type switch in mTG (Supp Fig 2A). Supplementary measurements 
at 19d considering NADH staining (Supp Fig 3) confirmed successful regeneration in terms of 
oxidative capacity in both models, with control and mKO groups fully recovered, and mTG still 
reaching towards its intrinsically higher basal level. 
MRF gene expression during differentiation in vitro indicates slower regeneration in mKO 
In order to assess the role of PGC-1α levels on myogenesis separately from the 
complexity of regeneration in vivo, we tested the efficiency of myotube formation by myoblasts 
isolated from mTG and mKO EDL muscles (Supp Fig 4). We did not notice physiologically 
relevant differences in fusion index (FI) in either of our models 2 days after initiation of 
differentiation (2-4% difference, Supp Fig 4A), whereas mild overexpression of PGC-1α in mTG 
myoblasts was measured (Supp Fig 4B). However, we detected slight changes in MRF gene 
expression levels during myoblast fusion in mKO. More specifically, we measured retarded 
downregulation of MyoD in mKO at 3d after initiation of differentiation, in parallel with delayed 
downregulation of Myog at 2d and 3d after an initial burst in expression, as well as tendencies 
towards slower upregulation of MRF-4 most prominently present at 1d (Supp Fig 4B). 
Importantly, those differences were accompanied by increased PGC-1α expression throughout 
differentiation only in WT mice. The measurements of expression levels of MRFs were not 
performed in mTG due to mild overexpression achieved in vitro (Supp Fig 4B).  
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Gene expression in vivo confirms delayed regeneration in mKO and faster in mTG at early 
time points 
Observed differences in in vitro myogenesis prompted us to check whether the same 
trend regarding the suppressed expression of MRF factors in mKO can be recapitulated in vivo. 
We measured expression of the aforementioned factors at different time points throughout the 
regeneration after the CTX injury, and observed modest, yet interesting differences from 4d to 
10d after CTX (Fig 2). We observed a smaller fold induction of Pax7, MyoD and MRF-4 at 4d in 
mKO (Fig 2B). There was a smaller reduction of Pax7 at 2d and higher MyoD fold increase in 
expression at 7d in mTG (Fig 2A). In addition, a shift to lower Myog and higher MRF-4 fold 
increase was evident in mTG, whereas the opposite trend was detected in mKO (4d-10d). 
Expression levels of several genes relevant for mitochondrial biogenesis and oxidative 
metabolism at 4d (Fig 3A) and 7d  (Fig 3B) post CTX revealed neither considerable impairment 
in regeneration in mKO nor an advantage in mTG mice, which was in line with the 
downregulated PGC-1α levels in mTG mice at those time points (Supp Fig 5C). Importantly, the 
same genes from Fig 3 were upregulated in mTG and downregulated in mKO mice in 
contralateral TAs (Fig 5A and 5B) at 4d and 7d post PBS injection, confirming correct genotypes 
of mice.  
Since we did not detect a phenotype at later stages of regeneration by measuring recovery 
of muscle performance (Fig 1 and Supp Fig 2), we focused our attention on early stages of 
regeneration. Relative gene expression of several genes confirmed slower regenerative response 
in mKO mice at 4d and 7d post CTX (Supp Fig 6). In particular, we detected higher expression 
of interleukin 4 receptor alpha (IL-4Rα) in mKO and lower in mTG – a receptor essential for 
necrotic area clearance after CTX (36). During early phases post injury, matrix metalloproteinase 
(MMP) expression rapidly increases as well, contributing to extracellular matrix remodeling 
(37). However, sustained expression of MMPs is implicated in tissue destruction (38). We 
measured higher levels of MMP-9 in mKO and a tendency towards lower levels in mTG at 4d 
(Supp Fig 6). The same time point was characterized by high levels of hepatocyte growth factor 
(HGF), which is responsible, among other things, for satellite cell activation (39, 40). However, 
at 7d we detected slower downregulation of HGF in mKO (expression levels at 4d were 
unchanged) and the opposite trend in mTG (Supp Fig 6). Another growth factor essential for 
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myoblast proliferation and differentiation alike, and therefore for the entire process of 
regeneration, is insulin-like growth factor 1 (IGF-1) (41). Expression levels at 4d revealed higher 
induction in mTG and lower in mKO (Supp Fig 6). These observations might be related not only 
to intrinsic properties of myoblasts and myocytes due to differential PGC-1α expression, but also 
due to the complex interplay between various cell types that participate in the early phases of 
regeneration. In light of the latter, it is worth mentioning that production of growth factors such 
as HGF and IGF-1 in injured skeletal muscle is mediated primarily by macrophages. 
mTG indicates accelerated clearance of necrosis, which coincides with faster accumulation 
of macrophages 
One of the prominent populations of cells that invade damaged muscle tissue after injury 
is macrophages. Their role in early stages is to clear the cell debris accumulating due to necrosis 
of damaged muscle fibers (6). By measuring the area occupied by purple swollen fibers on H&E 
sections 4d after CTX, we detected larger necrotic area in mKO (Fig 4A) and tendency towards 
smaller necrotic area in mTG mice (Fig 4B) compared to WT controls. Given that the muscles 
are completely damaged by CTX injury, and that all fibers degenerate (Supp Fig 7), we can 
conclude that the differences in area are due to the velocity of clearance of necrosis. Since the 
removal of cell debris is a function of macrophages, we measured the area of the sections 
occupied by CD68
+
 cells at the same time point after CTX (Fig 5). We observed that the staining 
for macrophages coincides with the regenerating area, and therefore detected reduced area 
occupied by CD68
+
 cells in mKO sections (Fig 5A) and the opposite phenotype in mTG mice 
(Fig 5B).  
Differences in cytokine expression at early time points suggest earlier recruitment of 
macrophages in mTG  
The transition from M1 to M2 macrophages is described as a physiological process which 
unfolds during regeneration and is associated with the progression from myoblast proliferation 
towards their fusion (8). These populations of macrophages secrete distinct subsets of cytokines 
that prepare an environment suitable for myoblast expansion and myotube formation. We 
measured expression of several macrophage markers including the pan macrophage marker 
F4/80, the pro-inflammatory M1 markers CD68 and IL-6, as well as the anti-inflammatory M2 
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markers IL-10, transforming growth factor beta (TGF-β), arginase 1 (Arg-1), IL-1Ra and CD206 
at two early time points after CTX injury, in order to assess the possibility of a macrophage 
subclass switch in either of the mouse models (Supp Fig 8). Our results demonstrate higher 
expression of several markers at 1d, followed by faster reduction at 3d in mTG mice (Supp Fig 
8B). In mKO mice, we also noticed higher expression at 2d, with prolonged induction of 
macrophage markers at 4d compared to controls (Supp Fig 8A). In both genotypes, the kinetics 
seems not to be connected to a specific subclass of markers (M1 vs. M2), but rather to be 
independent of it. These results indicate that muscles with overexpressed PGC-1α can respond to 
injury in a swifter manner, which therefore leads to faster clearance of necrosis and early 
regeneration.  
The first cells that respond to injury are resident macrophages and mast cells. In response 
to injury, they secrete TNF-α and IL-6 which attract neutrophils within hours (8, 42). Neutrophils 
will continue producing TNF-α, but also chemokines MCP-1, MIP-1α and MIP-1β in order to 
attract monocytes from the blood stream, which will give rise to macrophages once they enter the 
muscle tissue. To test the hypothesis of faster attraction of immune cells to injured areas in mTG 
animals, we measured chemokine and early cytokine expression at 8h, 1d and 2d after CTX (Fig 
6). For all the genes tested, peak expression was detected at 1d in both mTG and WT. However, 
there was a difference in gene expression kinetics at these three time points between genotypes. 
In that sense, mTG showed faster induction in TNF-α at 8h followed by faster reduction at 2d 
CTX, and a higher peak of MCP-1 at 1d CTX. Importantly, a quicker drop in expression was 
measured for all the chemokines tested at 2d CTX in mTG (Fig 6). These data indicate that 
overexpressing PGC-1α in skeletal muscle primes the muscle for rapid reaction in case of injury 
by fast production of chemokines which will attract immune cells, clear the cellular debris and 
create appropriate conditions for myogenesis to take place. On the other hand, tardy recruitment 
of inflammatory cells after injury, an enduring presence of macrophages, or block in the shift 
from the M1 to M2 subclass all lead to unsuccessful or slower regeneration (43-45).  
Multiple CTX injury leads to increased fibrosis in mKO mice 
Prolonged occurrence of macrophages, especially M2 subtype, is connected to expansion 
of fibroblasts and excessive secretion of extracellular matrix (ECM) components (46). Although 
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these factors contribute to the regenerative process, their removal at later stages of regeneration 
is necessary in order to regain fully functional skeletal muscle tissue. Intrigued by the differences 
in macrophage recruitment seen at early stages of regeneration, and bearing in mind connection 
between inflammation and fibrosis, we decided to take a closer look at fibrotic tissue formation 
at later stages of regeneration.  
This time, we took advantage of multiple CTX injuries as a model of chronic damage, in 
order to exacerbate preexisting conditions in muscle of our two mouse models. Three weeks after 
the last CTX injection, we did not observe statistically significant differences in the area of 
muscle sections occupied by fibrotic tissue in mTG, but mKO revealed increased accumulation 
of fibrosis compared to WT (Fig 7A). This was accompanied by increased expression of major 
collagens and alpha smooth muscle actin (α-SMA) in mKO and opposite profile in mTG (Fig 
7B). Interestingly, although myostatin (Mstn) expression considerably drops with injury, mTG 
mice have lower and mKO higher levels of Mstn at 19d after single CTX injection (Fig 7C). In 
addition, IGF-1 levels are upregulated to the similar extent in mTG and mKO mice, despite the 
lower starting levels in mTG observed in PBS injected TAs (Fig 7C). 
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5.6 Discussion 
The PGC-1α cofactor is a well-known master regulator of oxidative metabolism and 
mitochondrial biogenesis (33), yet its role in skeletal muscle regeneration has not been 
addressed. In this study, we show that modulating PGC-1α levels does not affect the outcome of 
regeneration and myogenesis despite the energy demanding nature of these processes (34, 47). 
Interestingly, however, it does influence response to injury by modifying chemokine expression 
in the muscle and macrophage attraction, and as a consequence alters the speed of necrotic area 
clearance. 
Despite the undisturbed regeneration in mTG and mKO measured primarily by in situ 
contractility and confirmed by NADH staining at later stages after CTX, we decided to look 
closely at the kinetics of MRFs as indication of pace of regeneration. Mild differences in the 
expression of MRFs both in vitro and in vivo at different time points lend credence to the notion 
of faster regeneration in mTG and slower in mKO mice. A closer look at the expression of 
growth factors (HGF, IGF-1) and factors contributing to cell debris removal and remodeling of 
the extracellular matrix (IL-4Rα, MMP-9) not only confirms the difference in the pace of 
regeneration between the genotypes, but also suggests an effect by non-myogenic cells on 
observed differences. Namely, recent studies report the importance of IL-4Rα expression on 
fibro/adipogenic progenitors (FAPs) proliferation and contribution to necrosis clearance after 
injury (36) whereas MMP-9, although implicated in ECM remodeling upon injury (37), is 
connected to tissue damage and pathogenesis when present in high amounts (38). The latter 
factors were expressed at higher levels in mKO and lower in mTG at 4d CTX, further bolstering 
the aforementioned differences in the progression of regeneration, which is dependent on PGC-
1α levels.  
Early stages after injury are characterized by necrosis of the damaged muscle fibers, 
followed by inflammation and removal of necrotic tissue by macrophages and other cell types 
(48). We measured faster clearance of necrosis accompanied by larger area occupied by 
macrophages (CD68
+
 cells) in mTG and the opposite phenotype in mKO at 4d CTX. In order to 
better assess the nature of the macrophages present at that time point, we measured expression of 
several receptors and cytokines in the muscle tissue. The importance of the switch from 
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classically-activated inflammatory (M1) to alternatively-activated and anti-inflammatory (M2) 
macrophages has been recently reported (45, 49). We did not observe prevalence of one over the 
other subclass between the two time points (1d and 3d for mTG; 2d and 4d for mKO) in our 
genetic models. Instead, we detected downregulation in all factors in mTG and sustained 
upregulation in mKO at the second time point (3d for mTG, 4d for mKO). These results suggest 
an intriguing possibility of faster attraction of immune cells upon injury given higher expression 
of PGC-1α. Interestingly, Rowe et al. recently demonstrated that PGC-1α induction in skeletal 
muscle of adult mice leads to macrophage infiltration and activation leading to MCP-1 
production (50). Delayed infiltration or prolonged presence of immune cells has been associated 
with impaired regeneration (43, 44, 51). However, the importance of inflammation in the course 
of successful regeneration has been confirmed in multiple studies (52-56). 
Since PGC-1α levels drop considerably already 8h after damage in mTG mice, we 
hypothesized that PGC-1α overexpression preconditions the muscle for swift response to injury, 
rather than inducing response upon injury. In order to take a closer look at this, we measured the 
expression of early chemokines at 1d and 2d after CTX. We detected a prominent drop in 
expression of MIP-1α, MIP-1β and TNF-α from 1d to 2d in control mice. However, this drop 
was even more prominent for mTG. More importantly, we observed higher expression of MCP-1 
in mTG at 1d and lower at 2d compared to control mice. This indicates that mTG can respond 
faster to injury by increasing expression of important chemokines, whose function is to attract 
immune cells. Overexpression of TNF-α, which comprises the first response, probably comes 
from resident mast cells and macrophages whose contribution to regeneration is not fully 
understood (57, 58). TNF-α has been shown to attract neutrophils through MIP-2 induction (59). 
Neutrophils are the first immune cells that invade damaged muscle, appearing within hours. 
Massive production of chemokines such as MIP-1α, MIP-1β and MCP-1 by neutrophils and 
resident macrophages (42, 60, 61), serves as a signal to attract monocytes from the blood stream. 
Accumulating monocytes will differentiate into macrophages upon entering the tissue, and 
within a day, they will become the predominant inflammatory cells in the damaged tissue, 
replacing the neutrophils (58). Prolonged presence of neutrophils has turned out to be detrimental 
to the tissue, at least partly due to overproduction of the aforementioned chemokines (62-64). In 
that context, faster upregulation and especially downregulation of the critical chemokines in 
mTG might contribute to faster attraction of macrophages and faster regeneration, minimizing 
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the damaging effects of prolonged proinflammatory signaling. It is important to notice that the 
described inflammatory process is somewhat simplified, as cells other than neutrophils and 
macrophages can produce cytokines (e.g. eosinophils, mast cells, T cells). More importantly, 
muscle cells can modulate inflammatory response via interaction with inflammatory cells (5, 6).  
In addition, although the presence of macrophages has proven to be essential in different 
contexts of injury, there might be other cells that substantially contribute to phagocytosis of 
damaged tissue, like FAPs (36). Furthermore, the relevance of neutrophils in muscle 
regeneration is not definite (6).  
Whereas timely clearance of proinflammatory phase is crucial for limiting the damaging 
effect to the host tissue, resolution of the second wave of macrophages, taking part in wound 
healing, is equally essential. Namely, sustained activity of M2 macrophages is connected to 
increased proliferation of fibroblasts and secretion of ECM components in the muscle tissue 
which results in fibrosis (46). Due to the link between inflammation and fibrosis, we aimed at 
assessing the fibrous tissue formation in the context of chronic injury. We observed increased 
fibrosis in mKO mice, with increased expression of collagens after multiple CTX injuries. Lower 
expression of collagens without the effect on fibrosis formation was seen in mTG mice in the 
same injury model. This coincided with the differential expression of IGF-1 in mTG and mKO 
after the injury. Interestingly, although Mstn is repressed during regeneration, we detected 
considerable differences in the expression at the basal level in our mouse models. Mstn is a 
member of TGF-β family, and known inducer of fibrosis (65). Mstn-/- mice are protected against 
fibrosis formation upon notexin injury, although Mstn is repressed during the regeneration in WT 
mice as well (66). At the same time, Mstn
-/-
 mice exhibit faster recruitment of macrophages, 
comparable to mTG mice. Similar results regarding swift inflammation and reduced fibrosis are 
reported for IGF-1 transgenic mice (67). Therefore, IGF-1 overexpression, Mstn
-/-
 and PGC-1α 
overexpression mice share similar regenerative phenotype, and consequently, increased IGF-1 
expression in mTG mice after injury and decreased Mstn levels prior to injury can at least 
partially explain the differences that we observed.  
The process of myoblast fusion is dependent on mitochondrial metabolism (68, 69). Due 
to that, the importance of several factors, drivers of oxidative metabolism, has been implicated 
and elucidated in the context of skeletal muscle differentiation and regeneration (11, 70-72). Of 
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special interest to this study is the role of the ERRα transcription factor, a distinctive binding 
partner of PGC-1α (73). Indeed, many of the effects of PGC-1α signaling, primarily regarding 
mitochondrial metabolism, are accomplished in partnership with ERRα (13, 74). Recent study 
demonstrated increased expression of both PGC-1α and ERRα during differentiation (11). In the 
same study, knock-out of ERRα negatively affected myogenesis in vitro, albeit unchanged 
expression of various metabolic and contractile proteins, the latter being explained by a 
compensatory increase in ERRγ and PGC-1α expression levels. Adenoviral ERRα induction on 
the other hand, led to improved myogenesis accompanied by increased PGC-1α levels as well. 
Our in vitro data investigating the effects of PGC-1α expression on myogenesis confirmed 
increased expression of this coactivator during differentiation. However, we did not observe 
pronounced alterations in myotube formation 2d post induction of differentiation, when the 
majority of nuclei were fused. It is important to note that at this time point we detected very mild 
PGC-1α expression from the transgene, and therefore the data are not indicative of PGC-1α 
overexpression in the context of myogenesis. Results from the mKO primary myoblasts on the 
other hand suggested a reduced pace of differentiation, but without a prominent effect on fusion 
index and formation of myotubes. It is conceivable that the modulation of PGC-1α in vitro might 
be evident with prolonged differentiation, as well as with more thorough examination of 
myotube formation, and future studies might look closer into these aspects. 
The importance of ERRα for myogenesis has been recently investigated in the context of 
regeneration in vivo (12). Upon knock-out of ERRα, mice exhibited delayed regeneration 
characterized by perturbations in oxidative gene expression, but contrary to the in vitro study, 
ERRγ and PGC-1α expression levels were reduced throughout the process. However, increased 
PGC-1β and PRC levels at 3d post CTX in control mice, but not in KO, served as an explanation 
for the delayed regeneration seen in ERRα knock-out mice. In our study, we observed reduction 
in expression of the majority of oxidative genes tested upon CTX injection, with slow recovery 
towards basal levels during regeneration. An exception to this was PRC, which was upregulated 
in both mTG and mKO at 4d CTX. Interestingly, ERRα levels were reduced in both genotypes at 
the two time points tested, unlike previously published observations. These differences might 
come from slightly different kinetics of regeneration, induced by e.g. CTX potency (producer, 
concentration), keeping in mind that the expression levels of genes often drastically change 
within relatively small intervals of time during early stages of regeneration. 
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PGC-1α was previously linked with an anti-inflammatory state. In muscle specific PGC-
1α knock-out mice, higher levels of systemic inflammation as well as inflammatory cytokine 
expression have been detected (20). In humans, type-2 diabetes has been correlated with lower 
PGC-1α levels and higher systemic levels of proinflammatory cytokines TNF-α and IL-6 (75). 
Recent in vitro work from our lab demonstrated anti-inflammatory effects of overexpressed 
PGC-1α via suppression of nuclear factor kappa B (NFκB) pathway (19, 76). Additionally, this 
study indicates a role of PGC-1α in modulating inflammation in the context of injury. In this 
regard, we propose that PGC-1α contributes to preparing the muscle for a prompt reply to injury 
by accelerating the process of cytokine secretion by resident cells, which in turn leads to faster 
attraction of macrophages, and clearance of damaged tissue. Based on the observation that PGC-
1α expression drops as early as 8h after CTX in mTG, and that expression recovers slowly and 
reaches a considerable disproportion between the genotypes not earlier than 7d post CTX, we 
consider the direct effect of PGC-1α on modulation of gene expression upon injury less probable. 
However, in which way PGC-1α overexpression changes conditions in muscle, and whether it 
indirectly influences the resident inflammatory cell repertoire or through a direct influence 
modulates the secretome of muscle cells, awaits further investigation.  
Interestingly, reduced macrophage accumulation associated with impaired regeneration 
was observed in ob/ob and db/db, but not high-fat diet (HFD) WT mice (all models of type-2 
diabetes) (77), whereas another study reports impaired regeneration upon HFD due to reduced 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels partially through reduced activation of 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) (78). One reason for the latter could be 
reduced IGF-1 levels. As mentioned earlier, mTG mice exhibit increased IGF-1 levels upon 
injury, the major producer of which are macrophages, whereas the opposite is observed in mKO. 
In addition, leptin treatment in leptin deficient ob/ob mice reverts the obesity and diabetes (79) 
and restores PGC-1α expression to the control level (80). Based on this, we could speculate that 
the reduced PGC-1α levels observed in type-2 diabetes can contribute to the impaired muscle 
regeneration phenotype seen in diabetic mice, and that increased PGC-1α levels could alleviate 
the pathology.  
The effect of chemokine secretion ultimately resulting in necrosis clearance, which is 
dependent on PGC-1α, can be beneficial in diseases where delayed inflammation upon injury 
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leads or contributes to disease progression. One such example is dysferlinopathy, where not only 
membrane resealing, but also diminished neutrophil attraction to the site of injury followed by 
reduced secretion of chemokines contributes to dystrophy (81). The therapeutic potential of 
ectopic PGC-1α expression in the context of muscle diseases has been addressed in several 
studies – mitochondrial myopathy (82), statin-induced atrophy (83), and particularly Duchenne 
muscular dystrophy (DMD) (23-26). The beneficial consequences of PGC-1α overexpression in 
the DMD mouse model (mdx) go well beyond increased utrophin level, which was once seen as a 
primary effector. Intriguingly, while viral PGC-1α delivery in neonatal mdx mice leads to 
reduced central nucleation as an indicator of muscle degeneration/regeneration (24), the same 
treatment in 3-week old animals showed the same level of central nucleation with reduced 
markers of ongoing damage (25). The authors of the latter study interpret this observation as 
indicating the possibility of an additional valuable effect of PGC-1α modulation in the dystrophy 
model – improved regeneration. Our study supports this notion, and contributes to the list of the 
therapeutic effects of PGC-1α overexpression in the context of chronic injury. 
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6.1 Abstract 
Satellite cells (SC) are quiescent adult muscle stem cells indispensable for skeletal 
muscle regeneration, however intrinsic and extrinsic factors influencing their number and 
activation remain incompletely understood. SCs are present in higher numbers in oxidative vs. 
glycolytic fibers and increase with exercise, concomitant with the induced expression of PGC-
1α. As PGC-1α is a prominent driver of oxidative metabolism in skeletal muscle and mimics the 
trained phenotype including the oxidative fiber predominance, we were interested in exploring 
the potential effects of this coactivator on satellite cells.  
By using a PGC-1α overexpression mouse model (MCK-mTG) and two knock-out 
models (Myf5-mKO and HSA-mKO) in combination with in vivo and in vitro approaches, we 
were able to reveal differences both in SC number and activation/proliferation following various 
stimuli. Increase in PGC-1α expression in fibers (MCK-mTG) surprisingly results in decreased 
SC numbers. However, SCs from these mice have a higher propensity for activation and 
proliferation. The opposite effect was not observed if PGC-1α was ablated from fibers alone 
(HSA-mKO), but when PGC-1α was missing both in SCs and fibers (Myf5-mKO), a reduction in 
SC activation and proliferation was detected without a difference in the resting number of SCs. 
These observations correlated with the differential expression of fibronectin between MCK-mTG 
and Myf5-mKO but not HSA-mKO, and its addition in culture media resulted in a reduction in 
SC activation and proliferation on isolated fibers. 
Thus, the higher levels of PGC-1α in fibers lead to modifications in the basal lamina 
components of the SC niche, which affect the readiness of SCs to respond to injury. In addition, 
PGC-1α expression in SCs and muscle fibers is required for proper SC activation and 
proliferation. Therefore, by increasing PGC-1α levels, we can not only induce the trained 
phenotype and improve muscle function, but also enhance SC function.  
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6.2 Introduction 
Satellite cells (SC) are adult muscle stem cells located at the periphery of the muscle 
fibers, between the sarcolemma and basal lamina (BL) (1), in the vicinity of blood vessels  (2) 
and the neuro-muscular junction. This location within the muscle tissue exposes SCs to signals 
coming from within and outside of the fiber, and comprises the specific environment termed the 
SC niche. Although metabolically inactive and quiescent (G0) in resting conditions, SCs quickly 
become activated in response to a stimulus such as injury or strenuous exercise (3). These stem 
cells are indispensable for skeletal muscle regeneration (4-7), even though many other cell 
progenitors (pericytes, mesoangioblasts, side population cells, CD133
+
 progenitors) can take part 
in and contribute to the process (8). Despite being present in relatively small numbers (2-5% of 
total myonuclei), they are characterized by a vast proliferative and regenerative potential (3). 
However, chronic damage such as that seen in dystrophies as well as aging, leads to depletion of 
SC numbers, resulting in reduced regenerative capabilities (9, 10). Therefore, proper activation 
of SCs, as well as their return to quiescence, is essential to preserving their number and function.  
Various markers which can contribute to rapid and easy detection of SCs have been 
discovered over the years, with Pax7 being the most widely used. Pax7 is a transcription factor 
specifically expressed only in the SC population in muscle tissue, present both in quiescent and 
activated satellite cells (11) . It has been shown that SCs in adult mice do not constitute a 
homogeneous population, and that approximately 90% of them express Myf5 at some point in 
their lifetime and are committed progenitors, whereas only around 10% are true stem cells (12). 
Upon activation, satellite cells increase in size, enter the cell cycle, and start expressing Myf5 
and MyoD, becoming myoblasts. Although SC activation is poorly understood, hepatocyte 
growth factor (HGF) signaling through the c-Met receptor on SCs is considered the first step in 
this process (13). It has been shown for other stem cells that such an activation process is 
characterized by a switch from glycolysis to oxidative metabolism as the energy producing 
pathway (14). One part of the proliferating Pax7
+
/MyoD
+
 cells will continue on the 
differentiation path, and they will reduce Pax7 and  increase myogenin expression, exit the cell 
cycle forming mononucleated postmitotic myocytes (15) and start fusing in order to form 
myotubes. Another part of the Pax7
+
/MyoD
+
 cells will, however, reduce MyoD expression and 
return to quiescence (16).  
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The simplicity of SC quiescence and the G0 phase was recently questioned, when 
Rodgers et al. defined an alternative quiescent state, named GAlert (17). They showed that even 
upon distant injury, SCs can respond by switching to an alerted state for a limited time through 
an increase in mammalian target of rapamycin complex 1 (mTORC1) signaling and increased 
mitochondrial biogenesis. Entering the cell cycle from GAlert proved to be more efficacious than 
from G0.  
High expression of fibroblast growth factor 2 (FGF-2) by muscle fibers (18) and a 
reduction in sprouty 1 (Spry1) by SCs (19) are both connected to the inability of SCs to return to 
quiescence upon activation and subsequently to SC depletion, seen in old age. SCs from old 
animals were also characterized by reduced regenerative capabilities (20). Heterochronic 
parabiotic pairings in mice, however, showed that intrinsically, SCs from old and young mice are 
no different in their regenerative potential, but that it is rather the environment that leads to the 
aging effects seen in SCs (21).  
One of the parameters that change with age regarding the SC niche is the BL. 
Accumulation of extracellular matrix (ECM) components leads to the thickening of the BL (22), 
and prevents SCs from sensing changes in the environment coming from outside the muscle 
fiber, and subsequently results in a reduced propensity to activate when needed. Whereas the 
ECM in skeletal muscle comprises mainly collagens type I and III, the main building blocks of 
the BL are laminins, collagen IV, perlecan, but also fibronectin (FN) and tenascin-C (TNC) (23, 
24). ECM components are produced primarily by fibroblasts, and their overproduction leads to 
fibrosis (25). Although it was recently reported that local transient FN secretion by SCs is an 
important step in the cascade of SC activation and subsequent proliferation (26), excess FN in 
the BL was correlated with reduced ability of SCs to respond to injury (27). In addition, TNC 
was shown to prevent the interaction of FN with Syndecan-4 (Sdc4) (28) and in this way block 
the expansion of Pax7
+
/Myf5
-
 cells on fibers (26).  
It has been noticed that SC numbers vary by muscle type, such that oxidative muscles 
contain more SCs per fiber than glycolytic ones (29). Also, exercise increases SC numbers in 
mice, rats and humans (30-32). Interestingly, oxidative muscles exhibit higher resistance to a 
variety of atrophic conditions compared to glycolytic muscles (33), including aging (34) and 
dystrophy (35). Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a major 
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driver of oxidative metabolism and mitochondrial biogenesis (36, 37), and is induced by exercise 
(38). It is expressed at higher levels in oxidative vs. glycolytic fibers (39), and it protects 
oxidative fibers against fasting and denervation induced atrophy (40). Skeletal muscle 
overexpression of PGC-1α leads to a fiber type switch towards oxidative muscles and mimics a 
trained phenotype (39), but also improves pathologies in dystrophic mouse models (41-44). 
Therefore, we hypothesized that PGC-1α overexpression (MCK-mTG) in muscle fibers might 
induce an increase in SC numbers in the same manner as it mirrors other features of oxidative 
fibers. At the same time, we were wondering about the differences between the lack of PGC-1α  
in fibers (HSA-mKO) and in SCs as well (Myf5-mKO), especially in regard to the possible  
switch from glycolytic to oxidative metabolism by activating SCs (17, 45).  
To our surprise, we detected a reduction in SC numbers in our transgenic model in 
various muscles, along with a reduction in expression of several myogenic regulatory factors 
(MRFs). In both knock-out models, SC numbers were unchanged. Interestingly, we noticed that 
the pace of SC activation correlated with PGC-1α expression levels in MCK-mTG and Myf5-
mKO mice in several paradigms (downhill running (DHR), phosphate buffered saline (PBS) 
injected muscles) which resulted in faster proliferation upon cardiotoxin injury (CTX) as well as 
in vitro (Pax7
+
/MyoD
-
, Pax7
+
/MyoD
+
, Pax7
-
/MyoD
+
 cells on isolated fibers). However, PGC-1α 
expressed by SCs but not by fibers (HSA-mKO), did not affect the proliferation rate. 
Additionally, we showed that the differences in SC proliferation were at least partially due to 
differential expression of BL component FN. Deciphering the intrinsic and especially extrinsic 
factors that influence SC activation and quiescence is essential for keeping these cells in culture 
and expanding prior to using them in stem-cell based therapies. Here we add one piece to the 
puzzle by classifying PGC-1α as both a direct and indirect contributor to SC behavior. We show 
that PGC-1α in SCs is necessary for timely activation upon stimulus, and that overexpression of 
PGC-1α in fibers is enough to modulate the SC niche and indirectly increase SC readiness to 
engage in activation.  
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6.3 Materials and Methods 
Animals: 
In this study we used three mouse models: muscle specific PGC-1α transgenic model 
(mTG) which expresses PGC-1α under the control of muscle creatine kinase (MCK) promoter 
(39) and two muscle specific PGC-1α knock-out models, in which PGC-1α exons 3-5 are 
knocked-out under Myf5-driven Cre (Myf5-mKO) (characterized in Project 1) or human α-
skeletal actin (HSA)-driven Cre (HSA-mKO) (46). Male mice, 8-16 weeks old, were used and 
wild type (WT) littermates served as controls. All animal experimental procedures performed in 
this study were approved by the Swiss authorities.  
Cardiotoxin injury: 
Mice were anasthesized using O2/sevoflurane gas mixture (3% sevoflurane). Lower part 
of hind limbs was shaved, and belly region of tibialis anterior (TA) muscle injected with  control 
vehicle (30μl PBS) or cardiotoxin (30μl containing 3μg of CTX, C9759 Sigma) using insulin 
syringes (U-100, 300ul, 29Gx1/2”). Mice were sacrificed and muscles collected at various time 
points. In the repeated injury model, CTX was injected three times with a three week interval 
between injections. Three weeks after the last injection, the mice were sacrificed and TAs 
collected. TAs were transversally cut into two pieces and frozen for histology or RNA isolation. 
Downhill running:  
 
Mice were put in open treadmill (Exer Treadmill Columbus Instruments) at - 10˚ and let 
run with alternating speed: 5min at 7m/min followed by 5min at 12m/min, for the 60 min 
duration period. 3h after running, mice were sacrificed and quadriceps (QU) muscles collected. 
Immunohistochemistry (IHC): 
TA, extensor digitorum longus (EDL), soleus (SOL), and QU muscles were immediately 
after isolation covered by OCT (Tissue-Tek, Sakura) and frozen in isopenthane precooled in 
liquid nitrogen. Frozen muscles were cut at 8μm thick sections using cryostat (Leica CM1950) 
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and kept at -20˚C until staining. Sections were dried at room temperature (RT), then fixed with 
4% paraformaldehyde (PFA), premeabilized in methanol and antigen retrieved in citrate buffer 
using microwave. After blocking (1h at RT) and overnight (o/n) incubation at 4˚C with primary 
antibodies, sections were washed with PBS, incubated with secondary antibodies for 1.5h at RT, 
then washed again and mounted with Vectashield with DAPI. Blocking was performed using 
1:100 diluted mouse IgG Fab fragment 015-000-007 Jackson Immunosearch in 3% bovine serum 
albumin (BSA) in PBS. Antigen retrieval was not used for myoblast staining. Primary antibodies 
are: Pax7 DSHB, Ki67 TEC-3 Dako, laminin ab11575 Abcam, desmin ab15200; secondary 
antibodies are: biotin goat-anti-mouse IgG Fcγ1 115-065-205 Jackson Immunosearch, 
streptavidin Alexa568 S11226 Invitrogen, goat-anti-rat IgG Alexa488 A11006 Invitrogen, 
donkey-anti-rabbit IgG Alexa647 A31573 Life Technologies, goat-anti-rabbit Alexa488 A11008 
Invitrogen, goat-anti-rabbit IgG Cy3 111-165-045 Jackson Immunoresearch.  
Fiber isolation, culture and Immunocytochemistry: 
Muscle fibers were isolated from EDL muscle of 12-16 week old animals, described in 
details elsewhere (47). Briefly, isolated muscles were digested in 2mg/ml Collagenase A (Roche 
Diagnostics) solution (DMEM, 2mM L-Gln, 1% antibiotic cocktail) for 1.5h, and fibers further 
separated using glass Pasteur pipettes. Single fibers were either fixed immediately (T0) in 10% 
PFA or after 3 day incubation (T3) in culture media (DMEM, 2mM L-Glutamine, 10% fetal 
bovine serum, 0.5% chicken embryo extract, 1% antibiotic cocktail). For treatments, 100μg/ml 
human plasma FN (Merck Millipore, FC010) or 5μg/ml human TNC (Merck Millipore, CC065) 
was added to the media. Fixed fibers were permeabilized in 0.5% Triton X-100 in PBS, blocked 
in 20% horse serum in PBS 30min at RT and incubated with primary antibodies (Pax7 DSHB, 
MyoD C-20 sc-304, DAPI) o/n at 4˚C. After washing with PBS, fibers were incubated with 
secondary antibodies (goat-anti-mouse IgG1 Alexa568 A21124 Invitrogen, goat-anti-rabbit 
Alexa488 A11008 Invitrogen) for 1.5h at RT, washed with PBS and mounted on glass slides 
with Vectashield.  
Myoblast isolation, culture and Immunocytochemistry (IHC): 
Myoblast were isolated from EDL of 2-3 week-old male mice using single fiber 
technique (48); EDL fibers were separated using collagenase A (Roche Diagnostics) and 
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incubated in plastic dishes coated with matrigel (BD Biscience). After a couple of days, 
proliferating myoblasts coming from fibers were propagated further in culture media (HyClone 
DMEM, 10% horse serum, 20% fetal bovine serum, 1% chicken embryo extract, 2mM L-
Glutamine, 5ng/ml basic fibroblast growth factor, 1% antibiotic cocktail) and used for assessing 
myoblast proliferation rate. For that purpose, same number of cells were plated on plastic dishes 
in low concentration and fixed in 4% PFA after different incubation periods (e.g. 2d and 4d post 
plating). Cells were permeabilized in 0.5% Triton X-100 in PBS, blocked in 3% BSA in PBS and 
incubated o/n at 4˚C with primary antibody (desmin ab15200) in 3% BSA in PBS. After washing 
in PBS, cells were incubated 1h at RT with secondary antibody (goat-anti-rabbit IgG Cy3 111-
165-045 Jackson Immunoresearch), washed with PBS and mounted using Vectashield with 
DAPI.   
Image acquisition and quantification: 
Images covering the whole area of muscle transversal sections were captured using Zeiss 
LSM700 microscope with the Zen 2010 software using a 25x objective with 0.5 zoom. Satellite 
cell number (Pax7
+
/DAPI
+
) was expressed per area unit for all muscles. Area was measured 
using ImageJ software. SCs/myoblasts were quantified by hand on Leica DM5000B microscope. 
For that, approximately 60 fibers/mouse for T0 or approximately 20 fibers/mouse for T3 were 
used, and cell numbers expressed per fiber. Proliferating myoblasts (single cells) were quantified 
prior fixation on 10 random fields on Leica DMI4000B microscope using 10x objective or after 
staining (desmin
+
/DAPI
+
) on 100 fields on Zeiss LSM700 microscope using 10x objective. 
Myoblast quantification was done by hand or using the Imaris software. 
RNA extraction and relative quantitative PCR (qPCR): 
RNA was isolated from muscles using lysing matrix tubes (MP Biomedicals) and TRI 
Reagent (Sigma) according to the manufacturer’s instructions, and concentration was measured 
on Nanodrop 1000 (Thermo Scientific). 1μg of RNA was digested with DNase I (Invitrogen), 
after which cDNA synthesis was performed using reverse transcriptase Superscript II 
(Invitrogen). qPCR measurements were done on a StepOne machine with SYBR green based 
detection, and used for assessing relative gene expression levels. TATA binding protein (TBP) 
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served as a housekeeping gene and normalizations were calculated with ΔΔCt method. A list of 
qPCR primers is in Table 1. 
Statistical analysis 
Data are expressed as AV+/-SEM. Statistical analysis was based on Student’s t test and 
used for comparison of two genotypes under same conditions (e.g. mTG vs. WT). p≤0.05 was 
considered significant.   
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6.4 Figures 
 
Table 1. qPCR primer list 
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Fig 1. SC numbers and MRFs expression in MCK-mTG and Myf5-mKO mice 
SC numbers per area in TA, SOL and EDL muscles and relative mRNA levels of Pax7 and MRFs in TA of A) mTG 
mice and B) Myf5-mKO mice compared to controls (WT); mRNA levels in mTG and Myf5-mKO were normalized 
to littermate control levels; Values are plotted as AV+/-SEM; n=4 per group for SC quantification and n=6 per 
group for mRNA measurements; * p≤0.05, ** p≤0.01, *** p≤0.001 
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Fig 2. SC numbers in mTG and Myf5-mKO TAs after cardiotoxin injections  
A) SC numbers per area 4d post CTX in mTG and Myf5-mKO and proliferating SCs per area (Pax7
+
/Ki67
+
) in 
Myf5-mKO; B) 19d post CTX; C) Representative IHC images (laminin: green, dapi/nuclei: blue; Pax7: red) of SCs 
4d and 19d after CTX. Red quadrants from sections are enlarged and SCs marked with white stars; Values are 
plotted as AV+/-SEM; n=5-10 per group per time point; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Supp Fig 1. SC numbers and relative gene expression after multiple cardiotoxin injuries and in one-year old 
mTG mice 
A) SC numbers in mTG and Myf5-mKO mice 3 weeks after triple CTX injections (each injection was separated by 
3-week period); B) SC numbers and relative gene expression in one-year old mTG mice. mRNA levels in mTG were 
normalized to WT levels; Values are plotted as AV+/-SEM; n= 5-8 per group; * p≤0.05, ** p≤0.01, *** p≤0.001 
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Fig 3. SC numbers and proliferation in culture on fibers in mTG and Myf5-mKO mice  
A) Representative IHC images (dapi/nuclei-blue; MyoD-green; Pax7-red) of SCs on freshly isolated fibers (T0) and 
SC quantification per fiber in mTG and Myf5-mKO mice. Approximately 60 fibers per mouse were used and 5 mice 
per group; B) Representative IHC images (dapi/nuclei: blue; MyoD: green; Pax7: red) of SC progeny on fibers kept 
for 3d in culture media (T3) and quantification results. Total proliferative output of SCs and separate quantification 
of Pax7
+
/MyoD
-
, Pax7
+
/MyoD
+
, and Pax7
-
/MyoD
+
 cells per fiber. Approximately 20 fibers per mouse and 5 mice 
per group were used; Values are plotted as AV+/-SEM; * p≤0.05, ** p≤0.01, *** p≤0.001  
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Supp Fig 2. Myoblast proliferation outside SC niche  
A) Live myoblast quantification 1 and 2 days after plating equal number of myoblasts (MB), and fold change in 
numbers between these two days. Cells were quantified on 10 fields per dish, 2 dishes per mouse and 3 mice per 
genotype. Representative bright field image with enlarged white quadrant is included; B) Desmin positive cell 
quantification 2 and 4 days after plating equal number of myoblasts and fold change between these two days. Cells 
were quantified on area of 38.7 mm2 per dish, 2 dishes per mouse and 3 mice per genotype. Representative IHC 
image (dapi/nuclei: red; desmin: green) with enlarged white quadrant is included; Values are plotted as AV+/-SEM 
  
Project 2 
101 
 
 
Fig 4. SC numbers and MRFs expression in HSA-mKO mice 
A) SC numbers on freshly isolated fibers and quantification of SC proliferative output after 3d in culture media (T3), 
including separate quantification of Pax7
+
/MyoD
-
, Pax7
+
/MyoD
+
, and Pax7
-
/MyoD
+
 cells per fiber. Approximately 
60 fibers per mouse and 5 mice per group for T0 and 20 fibers per mouse and 5 mice per group for T3 were used; B) 
SC number per area and relative mRNA levels of Pax7 and MRFs in TA muscle. mRNA levels in HSA-mKO mice 
were normalized to WT (control littermate) levels; Values are plotted as AV+/-SEM; n=5-6 per group; * p≤0.05, ** 
p≤0.01, *** p≤0.001  
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Fig 5. SC activation in MCK-mTG and Myf5-mKO mice 
A) Proliferating SC numbers (Pax7
+
/Ki67
+
) per area in uninjected and PBS injected TAs of mTG mice; n=7-8 per 
group; B) pS6
+
 SCs (SCs in alerted quiescent state) before and 2d after DHR running in QUs of mTG mice; n=5-6 
per group C) Relative mRNA levels of PGC-1α, Pax7 and MyoD 3h after DHR in QUs of Myf5-mKO and mTG 
mice. mRNA levels were normalized to WT SED levels; n=4-7 per group; D) Relative mRNA levels in the basal 
state in TAs of Myf5-mKO and mTG mice; n=5-6 per group. mRNA levels in mTG and Myf5-mKO were 
normalized to WT levels; Values are plotted as AV+/-SEM; * p≤0.05, ** p≤0.01, *** p≤0.001 
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Fig 6. Extracellular matrix and basal lamina gene expression in mTG, Myf5-mKO and HSA-mKO mice 
A) and B) Representative images of freshly isolated fibers from mTG and WT mice; C) images of WT and mTG 
fibers after 3d in culture media, prior to fixation. WT fibers look translucent and silky while mTG fibers appear 
matte and with cracks on the surface; D) Relative mRNA levels of ECM components in mTG and Myf5-mKO mice; 
E) Relative mRNA levels of basal lamina (BL) components in mTG and Myf5-mKO mice; F) Relative gene 
expression in HSA-mKO mice; mRNA levels in mTG, Myf5-mKO and HSA-mKO mice were normalized to WT 
(control littermate) levels; Values are plotted as AV+/-SEM; n=6 per group; * p≤0.05, ** p≤0.01, *** p≤0.001 
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Fig 7. Fiber treatment with fibronectin and tenascin-C in culture 
WT fibers were isolated and incubated for 3d in culture media supplemented with 100μg/ml FN or 5μg/ml TNC. 
Total proliferative output (Pax7
+
/MyoD
-
, Pax7
+
/MyoD
+
, and Pax7
-
/MyoD
+
 cells) of SCs was quantified and 
expressed per fiber. Approximately 20 fibers per mouse and 4 mice per group were used; Values are plotted as 
AV+/-SEM; * p≤0.05, ** p≤0.01, *** p≤0.001  
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6.5 Results 
PGC-1α overexpression in fibers results in reduced SC numbers in muscles  
MCK-mTG mice have muscles with a higher percentage of oxidative fibers at the 
expense of glycolytic ones (39). Their muscles are also rich in blood vessels and have greater 
endurance than their WT littermates. On the other hand, muscle specific knock-out mice exhibit 
the opposite phenotype (49). The change in the fiber type is followed by a change in metabolism, 
and the effect of PGC-1α in muscle on whole body metabolism has been extensively studied 
(50). Another important difference between fiber types is their resistance to atrophy, dystrophy 
and sarcopenia, and the role of PGC-1α on these aspects has been investigated as well (40, 42, 
51). However, the connection between PGC-1α levels and SC numbers has not been addressed 
yet. Keeping in mind that oxidative fibers contain more SCs than glycolytic fibers (29), we 
expected to detect higher number of SCs in MCK-mTG mice.  
For this reason, we first checked the expression of Pax7 and MRFs in the basal state of 
MCK-mTG and Myf5-mKO TA muscles (Fig 1A and 1B). Interestingly, we detected a decrease 
in several MRFs and Pax7 in MCK-mTG mice and an increase in Myf5-mKO. Next, we 
determined the SC numbers (Pax7
+
/DAPI
+
) in cross-sections of TAs, and detected lower 
numbers in MCK-mTG and no change in Myf5-mKO mice (Fig 1). The same change 
considering SC numbers was observed for MCK-mTG SOL. Importantly, we confirmed that in 
WT mice, oxidative muscles such as SOL tend to have more SCs than highly glycolytic muscles 
such as EDL (Fig 1A). 
PGC-1α levels modulate SC proliferation after CTX injury 
SCs are muscle stem cells that are activated upon injury, when they enter the cell cycle 
and proliferate in order to regenerate damaged muscle (3). Decrease in SC numbers is a hallmark 
of chronic diseases such as Duchenne muscular dystrophy (DMD), but is also seen during aging 
(9, 10). This reduction is associated with SC senescence, inability to return to quiescence after 
the proliferative phase, and as a consequence - impaired regeneration (18, 52). In order to see 
how lower numbers of SCs in MCK-mTG affect their ability to cope with acute injury, we 
quantified SCs in TA cross-sections 4 days and 19 days after CTX both in MCK-mTG and 
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Myf5-mKO TAs (Fig 2). To our surprise, we spotted a reduction in proliferative capacity in 
Myf5-mKO mice at 4d post CTX, accompanied with reduced numbers of proliferating SCs, 
whereas in MCK-mTG we measured mild tendency towards higher proliferative output (Fig 2A). 
At 19d time point, we observed significant difference in SC proliferation in MCK-mTG and 
tendencies of lower values for Myf5-mKO (Fig 2B). 
To test whether lower numbers of SCs in MCK-mTG would impair regeneration in 
chronic injury, we performed a multiple CTX injury experiment and quantified SC numbers on 
TA cross-sections 3 weeks after the last CTX injection (Supp Fig 1A). We could not detect a 
difference in the fold change of SC numbers in either of the two genotypes, suggesting that PGC-
1α does not affect SC return to quiescence. In addition, gene expression relevant for SC behavior 
and SC numbers seemed unaltered with aging in MCK-mTG mice (Supp Fig 1B).  
Immediate niche, not PGC-1α dependent inflammatory conditions upon injury alone, 
influences SC behavior  
One reason for the observed differences in MCK-mTG and Myf5-mKO mice after CTX 
injury could be modulation of inflammatory response and necrotic area clearance (see Project 1). 
Skeletal muscle regeneration is a very complex process, in which both muscle and non-muscle 
cells simultaneously participate in order to clear away the damaged tissue and form new muscle 
tissue (53, 54). In order to assess the SCs’ proliferative potential depending on PGC-1α 
expression, we took the ex vivo approach by isolating single muscle fibers and keeping them in 
culture for several days. Comparison of SC numbers and their progeny at T0 (on freshly isolated 
fibers) and at T3 (after 3 days in culture) let us evaluate the SCs’ proliferative capacity while in 
the immediate niche of their muscle fiber (Fig 3). Firstly, we confirmed that MCK-mTG have 
lower numbers of SCs (Pax7
+
/DAPI
+
) per fiber, whereas SC numbers were unchanged for Myf5-
mKO (Fig 3A). Next, we quantified quiescent SCs (Pax7
+
/MyoD
-
/DAPI
+
), committed 
progenitors (Pax7
+
/MyoD
+
/DAPI
+
) and myoblasts (Pax7
-
/MyoD
+
/DAPI
+
) per fiber at T3. In line 
with the in vivo observations, we detected higher relative proliferative output (T3/T0) in MCK-
mTG fibers (Fig 3B). In Myf5-mKO fibers, on the other hand, relative proliferative output was 
unchanged, yet there were lower numbers of quiescent SCs and myoblasts, indicating slower 
progression in differentiation (Fig 3B). These results indicate that the differences seen in SC 
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numbers after CTX injury are not only due to changes in the inflammatory stages of regeneration 
(see Project 1). Therefore, fiber properties, either in the form of secreted factors or proteins 
present in the sarcolemma and BL, are enough to evoke this phenotype, at least for MCK-mTG 
mice.  
In order to test if the observed differences in Myf5-mKO mice are due to fiber properties 
and not SCs alone, we isolated primary myoblasts from the two PGC-1α knock-out mouse 
models and tested their proliferative rate using immunocytochemistry (Supp Fig 2). The high 
purity of the primary population was verified by desmin staining. qPCR data confirmed PGC-1α 
ablation in Myf5-mKO myoblasts and unchanged PGC-1α expression in MCK-mTG myoblasts 
(see Supp Fig 4B in Project 1). Myoblast proliferation was assessed by comparing cell numbers 
between two incubation periods, in order to minimize the influence of variations in the numbers 
of cells plated. Quantification was performed on live cells (Supp Fig 2A), as well as fixed and 
stained myoblasts (Supp Fig 2B). We did not observe differences in the proliferation rates of 
either MCK-mTG or Myf5-mKO myoblasts (Supp Fig 2).  
Loss of PGC-1α both in SCs and fibers and not fibers alone, leads to reduced SC proliferation 
rate 
Thus far, we were able to see that overexpression of PGC-1α in fibers (MCK-mTG) has 
an effect on SC numbers and their proliferation, probably due to modified properties of the 
immediate niche. However, the differences observed in proliferation rate in Myf5-mKO mice 
were harder to interpret since in these mice PGC-1α was ablated from the SC stage. In isolated 
myoblasts of Myf5-mKO mice, we did not detect reduced proliferation rates (Supp Fig 2), 
suggesting that the effects observed in fibers (Fig 3B) and muscles in vivo (Fig 2A) are probably 
not cell intrinsic. In order to better assess the input from fibers, we used the HSA-mKO mouse 
model in which PGC-1α is exclusively deleted in fibers. 
Although qPCR data for Pax7 and MRFs in TA of HSA-mKO indicated the possibility of 
an opposite SC phenotype compared to MCK-mTG mice, we measured no difference in SC 
numbers on TA cross-sections (Fig 4B). These results were substantiated by quantifications 
performed on freshly isolated fibers (Fig 4A). In addition, there were no differences in 
proliferative output measured by numbers of SCs and their progeny on fibers at T3 (Fig 4A). 
Project 2 
109 
Collectively, the data suggest that PGC-1α overexpression in fibers is enough to modify the 
niche and influence SC activation/proliferation, whereas deleting PGC-1α from fibers does not 
change the SC behavior. PGC-1α deletion in SCs and fibers together, seems necessary for 
reduction in SC proliferation.  
PGC-1α levels in fibers and SCs modulate SC activation upon injury 
Described modifications in SC proliferation in MCK-mTG and Myf5-mKO mice could 
be due to a faster activation of SCs and entering the cell cycle from quiescence. Recently, 
Rodgers et al. described an alternative state of quiescence in SCs, termed GAlert, which enable 
cells to faster respond to injury (17).  
We investigated the activation status of SCs in our mouse models in several experiments. 
In PBS injected muscles, we detected higher numbers of proliferating SCs (Pax7
+
/Ki67
+
/DAPI
+
) 
in MCK-mTG outside of the injured part of a muscle (Fig 5A). This was not the case with a 
completely uninjured muscle (Fig 5A). In addition, QU muscles of Myf5-mKO mice 3h after 
DHR showed lack of upregulation of MyoD compared to WT controls, whereas Pax7 expression 
was reduced in both genotypes (Fig 5C). Similar experiment with MCK-mTG mice also resulted 
in a decrease in Pax7 expression, while an increase in MyoD expression was significant in MCK-
mTG group and only tendency was observed in WT controls (Fig 5C). These results indicate 
faster activation of SCs in MCK-mTG and slower in Myf5-mKO upon a stimulus.  
In order to better define the observed differences and assesse them through newly defined 
GAlert state, we quantified Pax7
+
/pS6
+
/DAPI
+
 cells on QU of sedentary (uninjured) and running 
MCK-mTG mice (Fig 5B). Our results did not indicate increased SC alertness in either of the 
experimental groups. SC numbers were just slightly increased upon running in both genotypes. 
Myostatin (Mstn) is a known inhibitor of SC activation and proliferation (55). Therefore, 
it is worth mentioning that we measured decreased expression of Mstn and increased expression 
of HGF and c-Met in MCK-mTG TAs, which can contribute to the observed differences in SC 
activation (Fig 5D). Opposite expression profile regarding Mstn was detected in Myf5-mKO 
TAs (Fig 5D).  
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Fibronectin is at least partially responsible for the proliferative rate of SCs seen in PGC-1α 
mouse models 
Due to the observed difference in fiber translucence when viewed under the light 
microscope (Fig 6A, 6B and 6C), we decided to look closer into the ECM components which 
surround isolated fibers (Fig 6D). Thickening of BL, which happens in aging, leads to the 
reduced responsiveness of SCs (22). For that reason, we looked at gene expression of collagens 
and glycoproteins, especially the ones which comprise the closest layer of the ECM (Fig 6E). We 
noticed that the variety of collagens are downregulated in MCK-mTG and exhibit tendencies 
towards higher expression in Myf5-mKO (Fig 6D), but more importantly, we detected the 
opposite expression patterns in two components of BL – FN and TNC (Fig 6E and 6D). 
Interestingly, the same difference was not observed in HSA-mKO TAs (Fig 6F), which also did 
not exhibit the phenotype connected to SC proliferation (Fig 4A). 
We decided to focus our attention on FN and TNC for several reasons: increased 
expression of FN is present in fibrotic conditions (25), and is additionally associated to the 
similar SC phenotype that we observed in Myf5-mKO mice (27); TNC on the other hand blocks 
the interaction between FN, secreted by SCs upon activation, and Sdc4 (28), intercepting in that 
way Wnt7a signaling and SC proliferation (26). To test whether these components can block the 
SC proliferation on fibers in vitro, we incubated WT fibers for 3 days in culture media with 
addition of FN or TNC. Approximately 40% reduction in proliferation output was detected in FN 
treated fibers, whereas TNC did not induce changes (Fig 7).  
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6.6 Discussion 
PGC-1α is a coactivator which induces mitochondrial biogenesis (36, 37), drives the 
switch from glycolytic to oxidative fibers (39), increases with exercise (38) and is also 
responsible for some of the positive effects of exercise. Despite the reported effects of exercise 
(30-32) and oxidative fibers (29) on SC numbers, the impact of PGC-1α on SC biology has not 
been investigated. In this study, we primarily consider the effects PGC-1α might have on the SC 
niche, and therefore the indirect effects of fiber properties on SC behavior. The role the 
metabolic status of a fiber can have on SCs is expected to be great, but in which way it could 
affect SC activation is not known (45). This is especially interesting having in mind recent 
advances in understanding the importance of metabolic reprogramming in stem cell biology. In 
cancer and stem cells, glycolysis and fatty acid oxidation (FAO) are characteristic of dormant 
cells, aerobic glycolysis with the active pentose-phosphate pathway is representative of the 
proliferative state, and mitochondrial oxidative phosphorylation (OXPHOS) is distinctive of 
differentiation (14). In muscle stem cells, there is a paucity of data in this regard, and generally, 
while glycolysis is linked to SC quiescence, increase in mitochondrial metabolism favors 
proliferation and differentiation (45). 
Unexpectedly, we show here that MCK-mTG muscles have lower SC numbers compared 
to WT littermates. This is the first example that we are aware of, where PGC-1α overexpression 
in muscle does not reflect the oxidative muscle characteristics. Although SC presence is an 
imperative of successful regeneration, lower SC numbers do not necessarily imply reduced 
regenerative capability. Namely, although decline in SC numbers reported in aging served as an 
explanation for impaired regeneration in these conditions, SC regenerative potential and role of 
extrinsic factors in this context are increasingly seen as a causation of pathology (56). Actually, 
both decreased and increased numbers in aging (22) and DMD (9, 57) have been reported.  This 
could be due to technical reasons (methods used), but also due to variations in age or stage of 
disease tested. One could imagine that in the case of constant low damage, SCs will become 
activated and proliferate to a certain extent, increasing in numbers. However, under chronic 
conditions, this will eventually lead to SC exhaustion and therefore lower SC numbers.  
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Nevertheless, the lower SC numbers we detected in MCK-mTG mice did not lead to 
impaired regeneration (see Project 1) and were not linked to SC depletion. On the contrary, SCs 
from MCK-mTG mice exhibited higher proliferation potential both in vitro and in vivo. In vivo 
results, obtained after CTX injury, could be partially due to systemic effect and therefore not 
directly the consequence of SCs and/or their immediate niche. Indeed, we detected increased 
attraction of macrophages and necrotic area clearance in mTG mice after CTX injury (see 
Project 1). These effects can provide an environment which favors SC proliferation and 
myogenesis (58). In order to minimize the contributing factors of other cells in muscle tissue, we 
looked at SC proliferation potential on isolated fibers. The SC niche in vivo comprises of 
effectors emerging from the muscle fiber and surrounding ECM, but also factors coming from 
blood vessels, macrophages and other locally present cells (59). On isolated fibers, the focus is 
on the immediate niche, consisting mostly of factors emanating from muscle fibers and the 
surrounding BL. 
As with the results obtained in vivo, we observed increased SC proliferation in MCK-
mTG on isolated fibers. qPCR results on TA muscles indicated reduced expression of various 
EMC and BL components in MCK-mTG mice. BL thickening is associated with aging and is 
related to lower SC activation and diminished regenerative ability (22). Indeed, heterochronic 
parabiotic experiments infer that SCs from old and young mice do not involve intrinsic 
differences, but that rather differential environmental cues evoke this effect (21). Nevertheless, 
the impact of cell intrinsic aspects of SC aging such as elevated p38α/β mitogen-activated 
protein kinase (MAPK) activity and increase in senescence marker p16, should not be 
underestimated (52, 54).  
Specifically, we detected reduced expression of FN and TNC in MCK-mTG muscles. 
The importance of FN in SC activation was recently demonstrated. Bentzinger et al. showed that 
SCs increase the expression and locally secrete FN upon activation (26). FN interacts with Sdc4, 
potentiating in that way Wnt7a signaling through frizzled-7 (Fzd7)/Sdc4, and favoring 
symmetric division of stem SCs (60). However, chronically elevated levels of FN are a hallmark 
of fibrosis and BL thickening (22, 25, 61, 62). In addition, Ross et al. reported increased basal 
expression of FN in like-acetylglucosaminyltransferase myodystrophy (LARGE
myd
) mice, which 
correlated with increased SC numbers and reduced proliferative potential on fibers ex vivo (27). 
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This phenotype is the opposite of what we detected in MCK-mTG mice. On the other hand, 
accumulation of TNC, an extracellular glycoprotein highly expressed in development, 
regeneration and cancer, is also linked to fibrosis (63, 64). Importantly, TNC was shown to 
obstruct the aforementioned interaction of FN with Sdc4 and therefore block stem SC 
proliferation (26, 28). Hence, the decreases in FN and TNC seen in MCK-mTG could have 
provided an explanation for the increased SC proliferative potential detected on fibers.  
Additionally, we were interested in the effects PGC-1α ablation in SCs and/or fibers 
might have on SCs. The opposite proliferative potential of SCs on fibers and in vivo, compared 
to MCK-mTG mice, was observed in Myf5-mKO. Interestingly, reversed ECM expression 
patterns, particularly regarding FN and TNC were detected as well. Indeed, we were able to 
show that WT fibers treated with FN in vitro had reduced SC proliferation. Absence of effects in 
TNC treated fibers could be due to the concentration used. In order to distinguish whether the 
observed effects are due to PGC-1α loss in fibers or SCs, we performed the same measurements 
with HSA-mKO mice. Surprisingly, loss of PGC-1α in fibers did not affect SC behavior, or 
notably, BL composition. We conclude that increased PGC-1α expression in fibers leads to lower 
expression of ECM components, in particular FN, which in turn affect SC activation and 
proliferation. Loss of PGC-1α both in SCs and fibers is needed in order to trigger opposite 
response from the one observed in MCK-mTG mice.   
The alterations in proliferation output detected both in vivo and in vitro in MCK-mTG 
and Myf5-mKO mice could be due to faster activation of SCs with overexpression of PGC-1α in 
their niche. To test for this, we quantified proliferating SCs in uninjured and PBS injected MCK-
mTG TAs. Although activated SCs were very rare in uninjured TAs, there were higher numbers 
of activated SCs 4 days after PBS injection (Pax7
+
/Ki67
+
/DAPI
+
) in MCK-mTG compared to 
WT. In addition, 3 hours after DHR, QUs of Myf5-mKO had unchanged expression of MyoD 
whereas controls showed increased expression. Importantly, DHR was accompanied by an 
increase in PGC-1α expression only in WT controls. According to the same parameters, DHR 
experiment in MCK-mTG mice demonstrated tendencies of faster activation of SCs in MCK-
mTG mice compared to controls. Altogether, these results suggest faster activation of SCs in 
MCK-mTG and slower in Myf5-mKO mice.  
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In addition to that, we detected higher expression levels of both HGF and c-Met in TAs 
of MCK-mTG. c-Met is a receptor tyrosine kinase, present primarily on quiescent and activated 
SCs, and HGF is a growth factor  that can be found inactive and bound to the ECM of the muscle 
(3). Upon contraction, Ca
2+
 signaling increases nitrogen monoxide (NO) free radical levels 
which activate matrix metalloproteinases and therefore cause HGF detachment and activation. 
HGF then binds to the c-Met receptor on SCs and leads to SC activation and proliferation. This 
cascade is considered the initial pathway in SC activation (65, 66). Therefore, increased 
expression of HGF and c-Met could predispose SCs in MCK-mTG muscles to faster activation 
upon stimulus. In Myf5-mKO muscles, we detected unchanged c-Met levels and increased HGF, 
which could have a compensatory role. 
Another interesting observation is related to the expression levels of Mstn. Mstn is 
considerably downregulated in MCK-mTG in the basal state, but is increased in Myf5-mKO. It is 
a member of transforming growth factor beta (TGF-β) family, an important regulator of fibrosis 
(67) and muscle mass (68). In addition, several studies reported that Mstn reduces SC and 
myoblast proliferation (55, 69-71). Although initial studies connected this effect with muscle 
hypertrophy and improved regeneration in Mstn
-/- 
mice (69, 71, 72), the contribution of SCs to 
increased muscle mass upon blocking Mstn was recently challenged (73-75). Nevertheless, Mstn 
seems to be expressed by quiescent SCs (55), but more importantly, exogenous Mstn can block 
SC activation and proliferation in vitro (71). Therefore, even if the expression levels detected in 
our mouse models primarily represent differences in fibers and not SCs, Mstn from fibers can 
still modulate SC behavior upon stimulus by blocking SC activation. 
Up until recently, SC quiescence was very poorly understood. We are now aware of an 
alternate quiescent state named GAlert (17). SCs can transition from the G0 to the GAlert state due 
to distal injury. SCs in the GAlert state are not activated as they do not express Ki67 or MyoD. 
However, these cells can rapidly start proliferating upon injury compared to SCs in the G0 state 
and therefore provide a regenerative advantage. Interestingly, this alertness is dependent on 
mitochondrial activity and mTORC1 signaling. Given that PGC-1α is a key regulator of 
mitochondrial metabolism, we were interested in investigating the SC quiescence status in MCK-
mTG mice. Quantification of pS6
+
 SCs (Pax7
+
/DAPi
+
) on QU sections of sedentary and running 
MCK-mTG mice showed no difference between genotypes nor treatments (sedentary and 
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running), indicating that the observed differences in SC proliferative output and activation in 
MCK-mTG mice are not due to increased SC alertness.  
Based on our results, we can conclude that PGC-1α overexpression in the niche induces 
reduction of FN and Mstn, as well as increase in c-Met and HGF, which enables faster SC 
activation and proliferation, without influencing their quiescence. Knowledge of the effects of 
PGC-1α overexpression in SC niche could be advantageous in stem-cell based transplantations, 
where knowing the modulators of SC proliferation and self-renewal is of paramount importance 
for successful therapeutic solutions. 
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7.1 Abstract 
Improper membrane resealing and compromised membrane stability are central to many 
muscular dystrophies. PGC-1α is the main driver of oxidative metabolism and provides 
beneficial effect in several dystrophic models with not fully elucidated mechanisms. However, 
its contribution to membrane resealing has not been investigated yet. Here we show that knock-
down of PGC-1α in C2C12 myoblasts results in reduced resealing capacity after the laser 
injuries. We were able to identify several genes with the potential role in sarcolemma repair, 
which expression depended on the PGC-1α levels in cells and mice, with synaptotagmin VII 
(Syt7) being the most prominent one. Syt7 expression was massively induced in vitro after viral 
overexpression of PGC-1α, and its protein levels were increased in PGC-1α overexpressing 
transgenic mice. In addition, we show that eccentric exercise does not cause explicit damage to 
the sarcolemma of PGC-1α mKO mice, but fails to induce Integrin 7α (Itga7) expression, which 
stabilizes sarcolemma and makes it resistant to future injuries. Collectively, our results 
demonstrate that PGC-1α can positively affect membrane resealing process through upregulation 
of Syt7, and membrane stability through increased Itga7 levels upon exercise. These results 
provide further explanation to the beneficial effects of PGC-1α in muscular dystrophies. 
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7.2 Introduction 
The repair of damaged cell membranes is an evolutionarily preserved process which 
represents an important strategy in the survival of many cell types. In mammalian organisms, it 
is of particular importance for damage-prone tissues, such as secreting epithelial cells of the 
mammary gland and mechanically active skeletal and cardiac muscle tissue (1). By counteracting 
the alternative fate, cell death, resealing reduces energy expenditure and prevents loss of 
irreplaceable cells types such as cardiomyocytes.  
It was suggested that membranes can self-reseal in cases of minor injuries, closing the 
rupture by tending to the favorable low energy state (2), whereas tears bigger than 1μm require 
extracellular Ca
2+ 
(1) in order to trigger membrane patch formation out of vesicles which will 
eventually close the opening in the membrane in a manner similar to exocytosis (3-6). In that 
respect, patching relies on intracellular sources of membranes, the origin of which remains 
undetermined but can include lysosomal (7), enlargeosomal (8) and other compartments. Recent 
research, however, suggests that apart from patching relaying on exocytosis (9), endocytosis (10) 
and membrane shedding (11) are alternative mechanisms observed in membrane resealing. Type 
and size of injury are probably determinants of which mechanism will take place (11). In 
addition to extracellular Ca
2+
, intracellular Ca
2+
 seem to be necessary for the membrane repair as 
well (12).  
Similarly, knowledge of the proteins necessary for successful resealing is still expanding 
and the majority of the work has been done on sea-urchin eggs and fibroblasts, and has not been 
confirmed for muscle cells. Although the rupture closing process is shared between different 
organisms, the discovery of muscle specific proteins implicated in resealing would not be 
surprising having in mind the importance of such a process for a tissue subject to contraction-
induced damage. In general, proteins essential for vesicle fusion, transport, exocytosis, as well as 
Ca
2+
 sensors, have tended to attract most research attention. In that respect, soluble N-
ethylmaleimide-sensitive factor attachment protein (SNAP) receptor (SNARE) proteins 
(synaptobrevins,  SNAPs and syntaxins) (13), synaptotagmins (14), kinesins, myosins (13, 15), 
and cytoskeletal proteins (16), have proven to be important in the different cell types examined. 
In skeletal muscle, however, the situation is far less clear. 
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Inability to repair damage to the sarcolemma results in myofiber necrosis. This triggers 
the sequence of events known as regeneration, which rely on the participation of muscle stem 
cells to produce new muscle fibers. Constant tears in the muscle membrane induced by repetitive 
contractions will eventually result in a dystrophic phenotype characterized by inflammation, the 
presence of regenerating fibers and fibrosis. To date, the role of dysferlin (Dysf) (17), 
mitsugumin 53 (MG53) (9), annexin A6 (anxa6) (18) as well as intracellular Ca
2+
 channel 
mucolipin-1 (MCOLN1) (12) in resealing  of skeletal muscle cells has been confirmed. Dysf is a 
structural protein localized in the sarcolemma and intracellular membrane compartments. 
Mutations in Dysf lead to limb-girdle muscular dystrophy type 2B (LGMD 2B) or Miyoshi 
myopathy. Upon injury, non-functional protein in mice leads to accumulation of vesicles below 
the sarcolemma, blocking the Ca
2+
 dependent fusion step and membrane repair (17). MG53, on 
the other hand, seems to function upstream of Dysf, leading to vesicle nucleation and transport to 
the injury site. This process has been shown to be dependent on changes in the oxidative state 
when the integrity of the muscle membrane is compromised (9). Beside these proteins, relevance 
has also been attributed to synaptogamin VII (Syt7) and annexin A1 (anxa1), whose importance 
in resealing has been confirmed in fibroblasts (14) and HeLa cells, respectively (19). Syt7 is a 
ubiquitously present Ca
2+
 sensor (20) similar to Dysf, while anxa1 is one of the binding partners 
of Dysf (21). In addition, it is important to note that mouse knock-out models for Dysf, MG53, 
MCOLN1 and Syt7 (22) exhibit myopathy phenotypes. 
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a master 
regulator of oxidative metabolism in various tissues, with additional tissue-specific functions 
(23). It induces mitochondrial biogenesis and respiration, concomitant with a reduction in 
reactive oxygen species (ROS) production (24). In skeletal muscle, PGC-1α overexpression leads 
to a fiber type switch favoring slow-twitch, oxidative fibers (25) as well as increased 
angiogenesis (26), resulting in a trained muscle phenotype. Although the majority of research has 
focused on the role of this coactivator in metabolism and its implications in type 2 diabetes, 
some has investigated the effects of PGC-1α in muscle dystrophies.  
PGC-1α muscle specific knock-out mice were reported to exhibit a mild dystrophic 
phenotype, with increased inflammation and membrane permeability upon exercise (27). In 
addition, several studies focused on PGC-1α overexpression in mdx mice, a model of Duchenne 
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muscular dystrophy (DMD), and reported alleviation in dystrophy (28-31). Mdx mice are 
naturally occurring mice (32) with a mutation in dystrophin, a structural protein connecting the 
cytoskeleton with the extracellular matrix (ECM). Although the initial explanation for the muscle 
function improvement seen upon PGC-1α overexpression in mdx mice was increased expression 
of utrophin and remodeling of the neuromuscular junction, the net effect soon turned out to be 
far more complex. For example, we recently demonstrated that induced PGC-1α levels can 
improve initial phases of skeletal muscle regeneration, including macrophage attraction and 
necrotic tissue removal (see Project 1), and this effect can also contribute to the improvement of 
the dystrophy phenotype of mdx-PGC-1α mTG mice. In addition, positive effects on the 
dystrophic phenotype were also achieved when PGC-1α was induced in dystrophin-utrophin 
double knock-out mice, as well as with the induction of PGC-1β which does not affect the 
expression of neuromuscular junction (NMJ) genes (31). However, the possible role PGC-1α 
might have on membrane permeability has not been further explored. 
Other forms of muscular dystrophies are also linked to the leaky membrane phenotype, 
dysferlinopathies being one of them. Dysf
-/-
 mice do not exhibit reduced membrane stability as 
seen in mdx mice, but rather demonstrate an inability to repair membrane ruptures formed upon 
damage (17). However, increased membrane permeability is a hallmark of both dystrophies. 
In addition to the previously published observations, we propose that PGC-1α can 
alleviate dystrophic phenotypes also by improving membrane resealing and stability. We 
demonstrate that knock-down (KD) of PGC-1α in C2C12 myoblasts results in impaired 
membrane resealing after laser injury. This is probably due to the differential expression of 
several genes that can contribute to the resealing process, the most prominent one being Syt7. 
Viral overexpression (OE) of PGC-1α in C2C12 myoblasts and myotubes massively induces 
Syt7 expression. In addition, Syt7 protein levels are increased in PGC-1α overexpressing mice. 
Previously published ChIP-Seq data revealed binding of PGC-1α to the Syt7 promoter, 
indicating a direct effect of this coactivator on the expression of Syt7 (33). In addition, this study 
indicates that eccentric exercise has little effect on Myf5-PGC-1α mKO mice compared to wild 
type (WT) control, proposing overall undisturbed membrane stability in the absence of PGC-1α. 
However, PGC-1α was necessary for the induction of Integrin 7α (Itga7) expression upon 
exercise, indicating a contribution to the protective state of the sarcolemma in cases of 
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subsequent damaging contractions. Collectively, our results suggest a direct effect of PGC-1α on 
membrane resealing, with potential therapeutic applications in the other forms of muscle 
dystrophies apart from DMD, one being dysferlinopathy. 
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7.3 Materials and methods 
C2C12 cells and transduction  
C2C12 myoblasts (MBs) were propagated in the growth media (DMEM, 10% fetal 
bovine serum (FBS), 1% antibiotic cocktail) in plastic dishes up until 80% confluency. For 
myotube (MT) formation, cells were allowed to proliferate until reaching confluency, after which 
differentiation was stimulated by changing the media to the differentiation media (DMEM, 2% 
horse serum (HS), 1% antibiotic cocktail) for 4 days.  
For the overexpression experiments, adenoviruses expressing only GFP (Ad-GFP, control 
virus) or GFP and PGC-1α (Ad-GFP-PGC-1α virus) were added to cells in culture. For achieving 
downregulation, adenoviruses expressing GFP and scrambled siRNA (Ad-GFP-scrambled, 
control virus) or GFP and siRNA against PGC-1α (Ad-GFP-siPGC-1α virus) were used. MBs 
were transduced with the respective viruses for 2 days without reaching confluency, whereas 
MTs were transduced for 2 days, starting after 4 days of differentiation. Prior to collection, cells 
were washed twice with PBS, and then suspended in Trizol for RNA extraction or sucrose buffer 
for protein isolation. 
Animals 
Mice overexpressing PGC-1α (mTG) under the control of muscle creatine kinase (MCK) 
promoter have been described elsewhere (25). Myf5-Cre mouse line (The Jackson Laboratory, 
stock number 007845) or HSA-Cre mouse line were crossed with a PGC-1αflox/flox mice in order 
to generate muscle specific PGC-1α knock-out models (mKO). All procedures involving mice 
were approved by the Swiss authorities. 8-12 week old male mice were used in this study. 
RNA isolation, cDNA synthesis and qPCR 
Total RNA was isolated from C2C12 MBs/MTs or tibialis anterior (TA)/gastrocnemius 
(Gastro) muscle using TRI Reagent (Sigma) and/or lysing matrix tubes (MP Biomedicals) 
following manufacturer’s instructions. RNA concentration was measured with Nanodrop 1000 
(Thermo Scientific), and 1μg of RNA was treated with DNase I (Invitrogen) and employed for 
cDNA synthesis using RT Superscript II (Invitrogen). Relative gene expressions were estimated 
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using the ΔΔCt method: qPCR reactions ran on a StepOne machine with SYBR green based 
detection, and TATA binding protein (TBP) expression was used for normalizations. A list of 
qPCR primers is provided in Table 1. 
Protein isolation and Western Blotting (WB) 
Total protein content was extracted from cells in culture or previously mechanically 
crushed TA/Gastro muscles using a sucrose buffer (50mM TrisHCl pH7.5, 1mM EDTA, 1mM 
EGTA, 1mM Na3VO4, 50mM NaF, 5mM Na4P2O7x10H2O, 250mM sucrose, 1mM DTT, 0.25% 
Nonident 40 supplemented with a protease inhibitor cocktail from Roche and a phosphatase 
inhibitor cocktail 2 from Sigma-Aldrich) and polytron homogenizer. Protein concentration was 
determined according to the Bradford method. Proteins were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) prior to electrotransfer on a 
polyvinylidene difluoride (PVDF) membrane. After blocking in 5% non-fat milk, the membranes 
were incubated with a primary antibody: α-tubulin (2125S, Cell Signaling), Dysf (VP-D503, 
Vector Laboratories), Syt7 (105173, Synaptic Systems), KifC3 (10125-2-AP, ProteinTech) or 
PGC-1α (AB3242, Millipore) overnight at 4˚C. The membranes were then washed and incubated 
with an HRP-conjugated secondary antibody for 1h at room temperature (RT). After washing, 
the membranes were incubated briefly with the ECL Substrate (Pierce) and the signal was 
detected on an X-ray film. The intensity of the protein bands of interest was quantified using the 
ImageJ software. α-tubulin was used as a loading control.  
Laser injuries 
For the laser injuries, C2C12 myoblasts were grown on poly-D lysine coated glass-
bottom Nunc Lab-Tek chamber slides (VWR 734-2058) and transduced with Ad-GFP-siPGC-1α 
or control Ad-GFP-scramble virus 2 days prior to injuries. Ahead of the experiment, growth 
media was exchanged with 10mM HEPES buffer pH7.2 containing 1mM Ca
2+
 and 2.5μM FM 1-
43 dye (Invitrogen T35356). The laser injuries were performed on a LSM510 microscope using a 
40X objective, 1AU pinhole, maximal power of 405nm, 458nm, 488 nm lasers, and 4000 
iterations on an area of 8.4μm x 8.4μm. As resealing incompetent and competent controls, 
untransduced C2C12 myoblasts in 10mM HEPES buffer pH7.2 containing 1mM EGTA and 
1mM Ca
2+
 respectively, were used. Images were acquired every 4s for 4min after injury. One 
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image was obtained prior to injury as well. Calculations based on the FM 1-43 dye intensity 
changes in the injured and uninjured regions were performed using the Zen2009 software. 
Downhill running (DHR) and Evans Blue dye (EBD) injections in mice 
For the 3 hour (h) time point, mice were acclimatized to the open treadmill (Exer 
Treadmill Columbus Instruments) shortly before the run. Animals received intraperitoneal 
injection of Evans Blue solution (10x weight [g] in [μl] of 1% w/v solution of EBD in PBS) 16h 
prior to running. Mice ran for 1h on the open treadmill at -10˚ downhill at a speed alternating 
every 5min (7m/min and 12m/min). 3h after the run, mice were sacrificed, and muscles and 
blood were collected. 
For the 7 day (d) time point, mice were not injected with EBD. They were acclimatized to 
the treadmill 15min for two days prior to the run. The running protocol was the same as for the 
3h time point, and was executed for two consecutive days in order to boost the damaging effect 
of lengthening contractions. Blood was withdrawn from the tail vein prior to running, as well as 
right after the first and second day of running. 7d after the second run, mice were sacrificed and 
muscles and blood were collected. 
For both experiments, TA, quadriceps (QU) and soleus (SOL) muscles were dissected 
and frozen either directly in N2 (l) for the RNA isolation, or in isopenthane precooled in N2 (l)  
for the histology. 
Lactate dehydrogenase (LDH), creatine kinase (CK) and EBD level measurements 
Plasma was isolated using Lithium heparin coated tubes (Microvette, Sarstedt) and used 
for measuring the enzymatic activity of LDH and CK based on spectrophotometric assays 
(Cobas c111, Roche). 
Evans Blue staining was observed on the cross-sections of TA, QU and SOL muscles of 
animals subject to running, as well as sedentary ones. Muscles were cut on 8μm thick sections 
using a cryostat (Leica CM1950). Images were acquired using a Leica DM5000B microscope 
and a 20x objective. Quantification of the signal intensity coming from EBD was performed on 
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10 images from random parts of each QU section using ImageJ software. In addition, the 
presence of EB positive fibers was evaluated on TA, QU and SOL muscles. 
Statistical Analysis 
The experimental groups were compared using the Student’s t-test, and p≤0.05 was 
considered significant.  
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7.4 Figures 
 
 
Table 1. List of qPCR primers  
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Fig 1. Impaired membrane resealing after knock-down (KD) of PGC-1α  
A) representative images from the live cell imaging; C2C12 MBs transduced with Ad-GFP-scrambled (control) do 
not accumulate excessive FM 1-43 dye in the membranes due to successful resealing; C2C12 transduced with Ad-
GFP-siPGC-1α (PGC-1α KD) cannot reseal and gather increasing quantity of dye over time B) ΔF normalized 
additionally to the GFP fluorescence before laser injury and plotted over time C) Intensity of the fluorescent signal 
normalized to the uninjured part of the membrane (ΔF) over time D) ΔF between the two time points (ΔΔF); Values 
are plotted as AV+/-SEM; n=13 (control cells), n=28 (PGC-1α KD cells); * p≤0.05, ** p≤0.01, *** p≤0.001  
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Fig 2. Relative mRNA expression levels upon KD of PGC-1α in C2C12 MBs and MTs  
Expression levels in MBs and MTs transduced with Ad-GFP-siPGC-1α are compared to the MBs and MTs 
transduced with Ad-GFP-scrambled respectively. TBP was used for the normalization of the data; Values are plotted 
as AV+/-SEM; n=1-3 per group 
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Fig 3. Relative mRNA expression levels upon overexpression (OE) of PGC-1α in C2C12 MBs and MTs, and 
PGC-1α ChIP-Seq peaks around Syt7 promoter 
A) Expression levels in MBs and MTs transduced with Ad-GFP-PGC-1α are compared to the MBs and MTs 
transduced with Ad-GFP respectively. TBP expression levels were used for the normalization of the data; Values are 
plotted as AV+/-SEM; n=1-3 per group; B) PGC-1α ChIP-Seq peaks (in green box) located within ±10kb region 
around transcription start site (TSS) in Syt7 
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Fig 4. WB on C2C12 MTs with KD or OE of PGC-1α 
Band intensity for any of the proteins tested is not changed upon KD of PGC-1α (Ad-GFP-siPGC-1α in red box vs. 
Ad-GFP-scrambled in yellow box) including PGC-1α itself which levels were below detection limit; Upon OE of 
PGC-1α (Ad-GFP-PGC-1α in green box vs. Ad-GFP in blue box), Dysf levels stayed unchanged, whereas PGC-1α 
and KifC3 levels were increased; α-tubulin served as a loading control 
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Fig 5. Relative mRNA expression levels in TA muscles of MCK-mTG, Myf5-mKO and HSA-mKO mice:  
Expression levels were compared to control littermate mice (WT). TBP expression levels were used for the 
normalization of the data; Values are plotted as AV+/-SEM; n=6 per group 
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Fig 6. WB on TA and Gastro muscles of MCK-mTG mice:  
Increase in Syt7 levels at band at ~70kDa (arrow) and PGC-1α levels at band ~90kDa in MCK-mTG are obvious 
and therefore not quantified. Levels of Dysf and Kifc3 were quantified using ImageJ software and presented as 
AV+/-SEM; representative bands for WT and TG for two muscles are marked in orange for all proteins; n=3 per 
group; * p≤0.05, ** p≤0.01, *** p≤0.001 
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Fig 7. Injury after DHR in Myf5-mKO mice:  
A) CK and LDH levels were measured before running, right after the first and second run, as well as 7 days after the 
second run. Relative mRNA level of PGC-1α 7 days after the exercise compared to sedentary WT littermates; B) 
CK and LDH enzymatic activity, and relative mRNA level of PGC-1α, in sedentary animals and 3h after the DHR; 
C) Relative mRNA expression levels 3h after the exercise compared to sedentary WT littermates; D) EBD 
fluorescence intensity in QU muscles of sedentary and running animals including representative images. Values are 
ploted as AV+/-SEM; n=4-6 per group. For the CK and LDH activity, as well as for EBD intensity, we were 
interested in the difference between genotypes and not the effect of exercise on the genotype. For the gene 
expression measurements however, we were interested in the effect of exercise, not the difference between 
genotypes. 
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7.5 Results 
PGC-1α is necessary for proper resealing in myoblasts 
Membrane resealing is an essential process in contractile tissues, where it repairs cells 
otherwise destined for necrosis (34). Proof for this can be found in dystrophies that develop over 
time in cases of diminished ability to reseal the sarcolemma, as seen in patients and mouse 
models with mutations in genes such as Dysf (17) or Syt7 (22). In order to explore the effects of 
PGC-1α in membrane resealing, we used C2C12 myoblasts transduced with viruses expressing 
scrambled siRNA (control) or siRNA against PGC-1α (PGC-1α KD). Successfully transduced 
myoblasts (GFP expressing) were subject to laser injury on a defined part of the membrane, and 
the effect of the resealing was observed over time by measuring the fluorescence intensity of FM 
1-43 dye (Fig 1). Although the experiment was hindered by the overlapping emission spectra of 
GFP and FM 1-43 dye, bleaching of the GFP signal at the time of the injury made it possible to 
differentiate between the GFP and FM 1-43 fluorescence. Assessing the changes in fluorescence 
intensity between two time points in the course of resealing permitted the detection of a marked 
difference between control and PGC-1α KD myoblasts (Fig 1D). These results indicate that lack 
of PGC-1α reduces the ability of myoblasts to close the rupture in their membranes. 
Syt7 represents the most promising target gene implicated in resealing and regulated by 
PGC-1α 
Our approach to finding possible genes responsible for the effect seen in resealing was to 
compare existing microarray data on C2C12 myotubes transduced with Ad-GFP-PGC-1α and the 
literature on membrane resealing and exocytosis (33). In this way, selected potentially interesting 
genes that we wanted to test further. Based on this approach, we could speculate that knocking-
down PGC-1α might induce the opposite effect of the one observed in the microarray data of 
PGC-1α overexpression, and therefore lower the levels of certain proteins necessary for closing 
membrane ruptures. First, we decided to check the expression of the shortlisted genes on PGC-
1α KD myoblasts and myotubes (Fig 2). Although the laser injury experiment was performed 
only on myoblasts due to technical limitations (e.g. difficulty to differentiate cells on glass), the 
expression measurements were done in myotubes as well in order to increase the experimental 
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window when knocking-down PGC-1α, given the higher expression of PGC-1α in myotubes 
compared to myoblasts (35). To our surprise, there was no decrease in the expression of any of 
the tested genes, and some even underwent a slight increase with KD of PGC-1α (Fig 2). 
However, KD of 60%-70% was not enough to lower the expression of glucose transporter type 4 
(Glut4), estrogen-related receptor α (ERRα) and cytochrome c (CycS) (Fig 2) – known 
downstream target genes of PGC-1α (23). Therefore, we found this system to be suboptimal for 
testing the outcome of PGC-1α KD on changes in gene expression.  
Next, we wanted to test the effect of PGC-1α overexpression (OE) in myoblasts and 
myotubes, and verify the increased expression of at least the genes found in the microarray data 
(Fig 3). Some genes, such as synaptobrevin 1 (Vamp1) and Ras-associated protein Rab-3A 
(Rab3a), did not corroborate our microarray data and demonstrate an increase in expression. 
However, the most promising finding was the induction of kinesin family member C3 (KifC3) 
and Syt7 in PGC-1α OE myoblasts and myotubes (Fig 3A). The latter was in line with the ChIP-
Seq PGC-1α peaks found in the Syt7 promoter region (Fig 3B). Importantly, massive 
overexpression of PGC-1α also led to a rise in the expression of the abovementioned 
downstream target genes (Fig 3A). 
To test this further, we checked the expression of several genes on the protein level as 
well, first using C2C12 myotubes with KD and OE of PGC-1α (Fig 4). Western Blot data 
revealed no changes in PGC-1α levels after KD, as well as no changes in Dysf and KifC3 levels, 
in line with the qPCR results (Fig 4). On the other hand, OE of PGC-1α led to considerable 
upregulation of PGC-1α on the protein level, followed by unchanged expression of Dysf and 
increased levels of KifC3, again confirming the qPCR data (Fig 4). 
Next, we decided to move to an in vivo system, and measure the mRNA expression of the 
aforementioned genes in our mouse models (Fig 5). For this, we used TA muscles of transgenic 
mice which overexpress PGC-1α in the myotube stage (MCK-mTG) and two knock-out lines 
which lack PGC-1α from the myoblast or myotube stage (Myf5-mKO and HSA-mKO). ERRα 
was used as a control gene in these measurements, in order to confirm the effect of PGC-1α 
overexpression or knock-out (Fig 5). We observed upregulation of KifC3 in MCK-mTG, albeit 
no downregulation in either of the KO mouse models (Fig 5). Additionally, we were able to 
detect a small increase in Vamp1, Rab3a and MG53 in MCK-mTG mice, which were in vitro 
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tested only in the myoblast stage. Synaptotagmin-like 2 (Sytl2) and Ras-related protein Rab-27B 
(Rab27b) were increased in HSA-mKO and Myf5-mKO mice respectively (Fig 5). They belong 
to the protein families implicated in vesicle trafficking and therefore could play a role in 
resealing (36). Dysf was also expressed at higher levels in Myf5-mKO and this could represent a 
compensatory effect for impaired resealing (Fig 5). Interestingly, we did not observe a difference 
in the expression of Syt7 in any of the mice tested (Fig 5). This was not in line with our findings 
in vitro, where we saw massive upregulation of this gene with PGC-1α OE (Fig 3).  
In order to approach this question from a different angle, we performed western blot on 
TA and Gastro muscles from MCK-mTG mice (Fig 6). We confirmed no difference in Dysf 
expression, as well as upregulation of KifC3 in mTG mice. In addition, we observed the presence 
of several isoforms of Syt7. Interestingly, the isoforms at ~70kDa and ~55kDa displayed 
opposite expression patterns within each genotype, as well as between the genotypes (Fig 6). In 
addition, we detected different Syt7 isoforms between hypocampus and muscle tissues. 
However, since the main Syt7 isoform was shown to be Syt7α (37) running above 66kDa in 
muscle tissue (22), we focused our attention on this band (marked with an arrow in Fig 6) in 
order to assess the difference in expression levels between the genotypes. Indeed, we could 
clearly observe an increase in the expression of the main Syt7 isoform in mTG compared to WT 
muscles (Fig 6). 
Eccentric exercise does not cause overt damage to PGC-1α KO mice, indicating 
uncompromised sarcolemma integrity 
Previous studies demonstrated reduced exercise capacity accompanied by increased 
damage to muscle fibers in PGC-1α mKO mice (27). This phenotype resembles the dystrophic 
phenotype observed in mdx mice, albeit in a much milder form. In order to test for the same 
effect in our Myf5-mKO mice, we first subjected the mice to one bout of downhill running and 
evaluated the muscle damage by measuring the enzymatic activity of LDH and CK in the plasma 
of the mice 3h after the run (Fig 7B). In addition, we assessed membrane permeability by 
looking at the Evans Blue dye (EBD) accumulation in the muscle fibers due to eccentric exercise 
(Fig 7D). By measuring the levels of CK and LDH as well as EBD fluorescence 3h post exercise, 
we were able to detect only tendencies towards higher damage in the mKO mice (Fig 7B and 
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7D). EBD positive fibers were rare and scattered between the genotypes regardless of exercise 
status (sedentary vs. running), and therefore were not quantified. Damage levels tended to be 
higher in the basal state in mKO mice, without exercise, although this was dependent on the 
variability within the group of animals of the same genotype (Fig 7B). Hence, we did not notice 
the increased damage at the basal level when we performed an additional experiment with two 
bouts of running on two consecutive days and measured CK and LDH activity at several time 
points in the course of the experiment (Fig 7A). However, in this experimental setup, we 
observed increased CK activity in mKO mice after the second bout of DHR.  
PGC-1α levels are known to increase with exercise (38, 39). We measured the difference 
in PGC-1α mRNA expression levels prior to and after DHR, and detected an increase in the WT 
running group 3h after the exercise (Fig 7B). The same increase was not detected in the mKO 
group. This boost in expression returned to the control levels 7 days after the run (Fig 7A). In 
order to examine a potential correlation between the increase in PGC-1α and membrane stability 
and resealing, we measured expression of genes important for sarcolemma resealing – Dysf and 
MG53. Their expression stayed unchanged in both genotypes 3h after exercise (Fig 7C). 
Additionally, we measured the expression of Itga7, a protein know to be regulated by exercise 
and important for membrane stability and muscle protection against injury (40, 41). We were 
able to detect an increase in Itga7 expression 3h after DHR in the WT running mice (Fig 7C), 
which was in line with a previously published study (41). However, Itga7 levels were unchanged 
in the mKO running mice (Fig 7C). These data suggest that PGC-1α expression in mice is 
necessary to induce a rise in Itga7 levels upon exercise, which is known to provide protection to 
the muscle membrane. 
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7.6 Discussion 
Membrane stability and resealing are important determinants in skeletal muscle 
homeostasis. Mutations in several genes have been shown to compromise sarcolemma integrity 
and therefore result in repeated degeneration/regeneration cycles, leading eventually to 
dystrophic conditions (42). It has been repeatedly demonstrated that PGC-1α relieves dystrophy 
in mdx mice (28-31), with several possible lines of explanations for the mechanism – from 
increased utrophin levels to increase in regenerative capacity. However, thus far, the role PGC-
1α might play directly in membrane resealing and stability has not been closely examined. 
Here we show that PGC-1α is necessary for sarcolemma resealing after laser injury in 
C2C12 myoblasts. Although no reduction in genes implicated in resealing was observed with the 
KD of PGC-1α, higher Syt7 and KifC3 expression was detected in response to PGC-1α 
overexpression. In addition, KifC3 levels were increased in muscles of MCK-mTG mice on both 
transcript and protein levels. KifC3 belongs to the kinesin family of proteins, whose function is 
to transport cargo along the microtubules primarily in the  anterograde manner (43). The 
importance of kinesins in membrane resealing has been demonstrated in sea-urchin eggs and 
fibroblasts (13, 15). However, the role of these molecular motors, and especially KifC3, in 
sarcolemma resealing has not been proven. Therefore, we can merely speculate that increased 
expression of this transporter might be beneficial in terms of membrane repair in skeletal muscle, 
although KifC3 was shown to be involved in retrograde transport in kidney cells (44). 
The more interesting finding concerns Syt7, a ubiquitously expressed Ca
2+
 sensing 
protein implicated in lysosomal exocytosis (45). Its relevance in fibroblast resealing and myositis 
in mice have been previously shown (22). Interestingly, increased Syt7 expression was detected 
in C2C12 cells with OE of PGC-1α, but not in mTG mice. One possible explanation for this 
might come from the differential expression of various isoforms. Syt7 has several isoforms, 
whose presence and expression varies between tissues (37). These isoforms can also be variably 
expressed between cells in culture and adult muscle. Therefore, in case we indeed have 
differential and opposite expression of several isoforms, the net effect can still be no change in 
the total mRNA levels. Importantly, the Syt7 specific primers we used in this study recognize all 
three isoforms of Syt7, detecting the total expression levels of the gene transcripts. 
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Hence, we decided to assess the Syt7 expression at the protein level and evaluate the 
possible presence of different isoforms. We observed multiple bands in murine hypocampus 
sample and muscle samples that differed between the two tissues. Previous research on Syt7 
isoforms revealed the Syt7α isoform as the main one (37). This isoform runs at a size higher than 
66kDa in the muscle samples (22). With this in mind, we can observe an increased quantity of 
Syt7 in mTG mice compared to WT controls (band at ~70kDa). It is interesting to mention that 
the several bands in our blots, possibly representing several isoforms of Syt7, are regulated in the 
opposite direction between genotypes, probably leading to unchanged protein levels overall. This 
is consistent with our qPCR data, where we detected unchanged transcript levels for all Syt7 
isoforms combined. Additionally, ChIP-Seq data demonstrated PGC-1α binding to the Syt7 
promoter, suggesting direct regulation in expression of Syt7 by PGC-1α (33). 
In order to examine the effect of membrane resealing in vivo, we performed a DHR 
experiment on the Myf5-mKO mice. Previous work on PGC-1α mKO mice suggests presence of 
a mild myopathy phenotype, accompanied by a lower tolerance to contraction-induced damage 
(27). Our data confirm these observations, as a modest increase in CK is observed in the plasma 
of mKO mice compared to WT after DHR.  
However, it is worth mentioning that DHR and laser injures evaluate different parameters 
of the sarcolemma homeostasis. While both lead to a leaky membrane, essentially different 
processes might lie at their core (46). This is perhaps best demonstrated by comparing the 
response of mdx and Dysf
-/-
 mice to laser injuries and DHR. Both mouse models exhibit 
dystrophy, which is associated with increased membrane permeability. However, while fibers 
from Dysf
-/-
 mice are not able to repair membrane ruptures after laser injuries, fibers from mdx 
mice are (17). On the other hand, mdx mice sustain profound damage to their muscle fibers after 
DHR, while Dysf
-/-
 mice respond to it in a rather mild manner, similarly to PGC-1α mKO mice 
(17). Therefore, the concepts of membrane stability, which is reduced in mdx mice, and 
membrane repair, which is compromised in Dysf
-/-
, should be differentiated. 
Some research proposes that the increased leakiness of the sarcolemma observed in the 
mdx model after exercise could be due to higher Ca
2+
 entry into the fibers through stretch-
activated channels, which then boosts ROS production leading to membrane lipid peroxidation 
(46). Essentially, this suggests that membrane tears are not responsible for the injury observed 
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after the DHR, and therefore do not lead to severe damage in the mouse models for impaired 
membrane resealing. This would in turn indicate, based on our results, that PGC-1α might be 
indeed directly involved in the membrane repair process. 
Contrary to that, the beneficial effects observed with PGC-1α overexpression in mdx 
mice might be due to multiple factors as previously suggested, one of them possibly being 
decrease in ROS production which would reduce membrane permeability. In addition, our results 
indicate that increase in Itga7 after exercise is dependent on PGC-1α expression. Itga7 is a 
structural glycoprotein which connects the ECM with the cytoskeleton through laminin-actin 
linkage (47). Since Itga7 expression protects muscle from damage by stabilizing the sarcolemma 
(40), and lack of it induces injury after the DHR (41), we can speculate that the alleviation in the 
dystrophic phenotype seen in mdx-PGC-1α mTG mice can be also due to increase in Itga7 
expression. Interestingly, we observed a slight increase both in Dysf and Itga7 expression at the 
basal level in Myf5-mKO mice. This could be a compensatory mechanism, similar to what has 
been recently observed for Dysf in DMD (48) and for other proteins implicated in membrane 
resealing in muscular dystrophy patients (49). 
Therefore, future work should try to further delineate the role of PGC-1α in membrane 
stability and repair, and confirm its effect in resealing by determining if increasing the 
expression of PGC-1α in Dysf-/- mice can rescue the overall phenotype, especially in terms of 
membrane repair after laser injury. Nevertheless, our results support the therapeutic potential of 
PGC-1α in muscle dystrophies. 
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8 Sinergia Project: Improving human muscle 
engineering by PGC-1α expression and molecular 
imaging using positron emission tomography 
(PET) (Project 4) 
Main contributors: Ivana Dinulovic, Thomas Betzel, Deana Haralampieva, Simone Amatamey, 
Daniel Eberli, Christoph Handschin 
*This is a collaborative interdisciplinary project between three Swiss institutions, supported by 
an SNSF grant. 
 
Contribution of participating laboratories: 
Christoph Handschin, Daniel Eberli and Simon Amatamey designed and supervised the study. 
Laboratory of Prof. Christoph Handschin (Biozentrum, University of Basel): 
Ivana Dinulovic performed experiments concerning the cloning strategy, virus generation, 
functionality, toxicity and production. Optimizations related to the titer determination of viruses, 
high titer batch production and cellular transduction were an integral part of her work. Markus 
Beer provided assistance with the final steps of virus production. 
Laboratory of Dr. Daniel Eberli (University Hospital Zurich, University of Zurich): 
Experiments concerning muscle regeneration in vivo were performed by Deana Haralampieva 
and Souzan Salemi, and are not presented here due to the preliminary status of the data. 
Laboratory of Prof. Simon Ametamey (ETH Zurich): 
PET experiments in vitro and in vivo, as well as CT, biodistribution and autoradiography 
measurements were performed by Thomas Betzel, Stefanie Kramer and Claudia Keller, and are 
partially presented in this chapter as a proof of functionality of the mutated hD2R virus. 
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8.1 Introduction 
Skeletal muscle is an organ crucial for locomotion, breathing and metabolism, and is 
therefore indispensable for healthy life of an individual. Although this tissue possesses a 
remarkable capacity for self-repair and is relatively stable, with a low turn-over rate of nuclei, 
limitations to successful regeneration are many (1). In that regard, muscle pathologies as well as 
aging and injuries affecting a large volume of muscle, prevent restoration of highly functional 
muscle tissue in humans (2). 
The field of regenerative medicine has been aiming to improve skeletal muscle 
restoration by transplanting cells, implanting biomaterials, or a combination of both (3). 
Although basic research has revealed that many cell types including perycites, hematopoetic 
stem cells, mesoangioblasts, to name only a few, can actively participate in skeletal muscle 
regeneration (4), major attention in clinics has been devoted to skeletal muscle specific 
progenitors – satellite cells (5) . And rightfully so, since recent findings have confirmed the 
essential role of these cells in successful regeneration in mice after injury compared with other 
contributing cell populations (6-9). 
One of the major persisting limitations in the treatment of large muscle beds, such as in 
muscle dystrophies, is the systemic delivery of treatment. Intramuscular injections of myoblasts 
are necessary since injected cells cannot cross the endothelium and home in on muscles (5). In 
addition, multiple injections in the same muscle are often required due to the limited migration of 
injected cells (10). This problem currently restricts the transplantation approaches to the 
treatment of small muscles, such as sphincter muscles in the urethra and esophagus, whose 
impairment leads to incontinence and reflux, respectively.  
However, many other obstacles exist within the field of cell transplantation, one of them 
being the low survival rate of injected cells caused by reduced innervation and vascularization of 
the newly formed tissue (11). A dense vascular network is essential, as oxygen and nutrient 
delivery as well as toxic metabolic byproduct removal, limits cell survival. Even though previous 
attempts implicating vascular endothelial growth factor (VEGF) have managed to alleviate this 
problem to some extent (12), the hurdle, especially regarding innervation, remains. Adequate 
innervation of skeletal muscle tissue ensures tissue maturation and function and prevents muscle 
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atrophy (13, 14). However, although motor unit formation has been demonstrated in cases of 
myoblast injection, synchronous contractions of nascent muscle tissue upon nerve stimulation 
have not been verified (15).  
It is important to note that small muscle injuries, such as sphincter injuries, occur mainly 
in the elderly. For example, urinary incontinence develops as a result of surgical injury 
secondary to prostate surgery in men (15), but age-related factors also contribute to the condition 
since the ability of skeletal muscle to regenerate diminishes with age (16). Therefore, ageing 
additionally impedes muscle tissue formation and functionality upon transplantation treatments.  
Peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1α) is a transcriptional 
coactivator and regulator of oxidative metabolism (17). It has been demonstrated that PGC-1α 
leads to VEGF expression favoring angiogenesis (18), and in addition controls the expression of 
neuromuscular junction (NMJ) genes (19). PGC-1α overexpression improves the phenotype not 
only in the mouse model for Duchenne muscular dystrophy (DMD) (19-22), but also in 
mitochondrial myopathy (23) and statin-induced muscle damage (24). In addition, PGC-1α 
protects muscle against denervation-induced atrophy (25). Muscle specific PGC-1α transgenic 
mice possess increased exercise endurance, which is related to a fiber-type switch from the 
glycolytic to the oxidative phenotype (26), while muscle specific knock-out mice exhibit 
mirrored characteristics (27). Importantly, PGC-1α also reduces sarcopenia (28), and is therefore 
a promising factor that alleviates aging-related conditions.  
As these changes brought about by PGC-1α would be highly beneficial in reducing the 
aforementioned transplantation impediments, we sought to induce PGC-1α overexpression in 
skeletal muscle precursor cells prior to transplantation into injured muscle tissue and assess the 
outcomes on muscle tissue formation in vivo. For this purpose, we chose to use adenoviruses as 
delivery vectors. We wanted to assess PGC-1α driven benefits not only in vitro and ex vivo 
relying on histology, contractility and gene expression measurements, but also to follow tissue 
formation in vivo using a non-invasive technique – positron emission tomography (PET).  
PET is a highly sensitive technique used to monitor spatio-temporal and quantitative 
aspects of reporter gene expression in live animals and humans (29). It is based on the detection 
of gamma rays coming from positron-emitting radionuclides incorporated into biological 
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molecules (30). PET is mainly employed in oncology in combination with glucose analog 2-
deoxy-2-[
18
F]-fluoro-D-glucose (FDG) as a tracer, although applications in neurology and 
cardiology are emerging (31-33). FDG enables tracking cells with high glucose consumption, 
such as proliferating cancer cells, although it can also be used for monitoring contracting muscle 
cells. This functional imaging is often combined with X-ray computed tomography (CT) for 
precise assessment of anatomical location (34).  
An evaluation of the results obtained from in vitro studies, in vivo measurements and ex 
vivo experiments would provide us with a clear picture of the hypothesized advantages of PGC-
1α induction on muscle regeneration and therefore potential applications in human subjects. 
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8.2 Overview of study design 
In this study, human muscle precursor cells (hMPCs, here used interchangeably with 
myoblasts) isolated from rectus abdominis muscle biopsies from healthy human subjects, were 
used for cell transplantations. Myoblasts were transduced with adenoviruses harboring sequences 
of human dopamine type 2 receptor (hD2R; used for PET purposes), human (h) PGC-1α or 
hVEGF prior to their injection in vivo. The expression of these genes of interest (GOI) is under 
the control of cytomegalovirus (CMV) promoter. As a control, previously generated adenovirus 
expressing green fluorescent protein (GFP) was used. In order to minimize the effect of immune 
rejection in mice, nude mice were used for subcutaneous and intramuscular post-crush injury 
injections (Figure 1).  
In vitro techniques were employed to generate the aforementioned adenoviruses, 
optimize transduction settings and evaluate their toxicity. Additional experiments should 
complement in vivo and ex vivo results, and take a closer look at myotube formation and 
maturation, as well as NMJ formation. 
For in vivo assessment, we were primarily interested in repetitive observations of injected 
cells in order to monitor their survival and migration. For this application, we decided to use 
D2R as a reporter (35) in combination with [
18
F]-Fallypride as a tracer. D2R is predominantly 
expressed in striatum (36) but only at a very low level in the muscle, ensuring that only injected 
muscle cells previously transduced with adenovirus containing D2R would be detected. 
Furthermore, PET enables us to assess additional aspects of engineered tissue in vivo, using a set 
of established tracers. In that respect, we plan to use fluoroiminidasole ([
18
F]-FMISO) for 
measuring tissue hypoxia, [
64
Cu]-NODAGA-RGD for assessing tissue vascularization and the 
aforementioned FDG for glucose consumption measurements. All these tracers in combination 
with D2R transduced injected cells will assure thorough evaluation of the survival, growth and 
functionality of the nascent tissue.  
Importantly, the engineered muscle tissue will be eventually isolated at different time 
points after cell transplantation, and evaluated ex vivo. Experiments concerning contractility 
properties, myotube and NMJ formation, vascularization, and gene expression will provide data 
complementing the in vitro and in vivo results well.  
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We hypothesized that myoblast gene therapy by adenoviral delivery of PGC-1α prior to 
cell transplantation would improve the resistance, survival and growth of the formed tissue by 
increasing its vascularity, endurance and innervation. In addition, we were interested in 
determining if VEGF expression in combination with PGC-1α would provide additional benefit 
in terms of tissue survival. After the design and production of the desired viral vectors, followed 
by initial tests in vitro, experiments are planned to be executed in two animal models – 
subcutaneous injections for assessment of tissue formation, growth, survival and vascularization, 
and intramuscular injection after crush injury for examining the participation of the transplanted 
cells in skeletal muscle regeneration.  
These experiments are intended to serve as a proof-of-concept study for evaluating the 
benefits of PGC-1α overexpression in muscle cells, and future approaches in human patients for 
the treatment of small muscles injuries (Figure 1).  
 
 
Figure 1 Schematic representation of study design and potential application in humans 
Sc inj (subcutaneous injection), im inj (intramuscular injection); adapted from Smaldone and Chancellor, World J 
Urol, 2008, wecort.com and clipartist.info 
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8.3 Plasmid design 
Our objective was to test the potential beneficial outcomes of PGC-1α and VEGF 
overexpression in myoblasts prior to injection in vivo, for which we intended to generate two 
separate adenoviruses. In addition, it was essential to track injected cells in vivo and to estimate 
their contribution to the formation of new muscle with and without PGC-1α or VEGF 
overexpression. For this purpose, we planned to generate an additional adenovirus, expressing 
D2R, as a PET reporter gene. The expression of each gene was designed to be under the control 
of a CMV promoter in order to assure robust expression of the transgene (Figure 2). 
Each vector was designed to contain a different fluorophore, expressed under a separate 
CMV promoter. For achieving this, we decided to use GFP together with PGC-1α, red 
fluorescent protein (RFP) with D2R and yellow fluorescent protein (YFP) with VEGF. The 
expression of these fluorescent proteins should coincide with the expression of the transgene, and 
therefore enable easier detection of transduced cells both on muscle sections after 
transplantation, but also prior to transplantation for assessing the cell transduction efficiency. 
Importantly, given appropriate filters, it is possible to differentiate between all three fluorescent 
proteins when expressed in the same cell.  
In addition, each vector is designed to have specific tags for easier detection and/or 
distinguishing of the transgene from the endogenous protein. In that respect, the PGC-1α 
construct includes an HA tag on its N-terminus, the D2R sequence has 6xHis and V5 tags on its 
C-terminus, while VEGF contains Myc and DDK (same sequence as FLAG) on the C-terminus 
(Figure 2).   
As a control, we aimed to use adenovirus expressing only GFP under a CMV promoter, 
and this virus had already been generated and regularly used in our laboratory.  
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Figure 2 Constructs of final plasmids used for adenoviral generation 
Adapted from www.genetherapynet.com 
8.3.1 Cloning of pAdTrack-CMV-hPGC-1α 
A construct containing human PGC-1α with C-terminal Myc and His tags in a pcDNA4 
backbone was ordered from Addgene. To change the tags, we subcloned the hPGC-1α sequence 
into a pcDNA 3.1 vector using the Directional TOPO Expressional Kit (Invitrogen) according to 
the manufacturer’s instructions. This subcloning technique is based on a PCR reaction using 
specific primers and Pfu ULTRA high-fidelity polymerase (Agilent). A separate PCR reaction 
using primers designed to cover the insertion sites confirmed successful insertion of required 
sequence (Figure 3). 
 
Figure 3 PCR reactions loaded onto gel 
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Chemically competent XL-10 Gold bacteria (Stratagene) were transformed and grown 
overnight on LB plates with ampicillin (Amp), after which several colonies were selected. PCR 
on the selected colonies enabled us to confirm the correct orientation and size of the insert 
(Figure 4). 
 
Figure 4 Colony PCR for hPGC-1α  
All tested colonies resulted in insertion of PCR product, but only colony No. 5 contained HA tag, as revealed upon 
sequencing 
Several colonies were chosen for further expansion in Luria-Bertani broth (LB) with 
Amp for purposes of sequencing and glycerol stock preparation. Thorough sequencing identified 
clones with correct insertion, including the desired tag. However, we were also able to detect 
three point mutations in the hPGC-1α sequence, two of which were silent and therefore did not 
require further attention. Due to a G to A switch, the third mutation resulted in Gly in position 
482 being exchanged with Ser (G482S). Since this mutation was previously associated with 
incidence of type 2 diabetes (37), we decided to correct it using site-directed mutagenesis 
(SDM). SDM was carried out according to the protocol adapted from the Stratagene Quick 
Change Site-Directed Mutagenesis Kit, and is based on the PCR reaction using Pfu ULTRA 
high-fidelity polymerase (Agilent). Mutagenic primers were designed using the Quick Change 
Primer Design application (Agilent). The PCR product was confirmed on a gel (Figure 5), and 
the rest was used for transforming bacteria and subsequent sequencing of the plasmid, which 
confirmed successful mutagenesis. 
 
Figure 5 SDM PCR for hPGC-1α 
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Finally, we were ready to subclone the hPGC-1α with the N-terminal HA tag into a pAd-
Track-CMV vector. For that, we decided to use sticky end ligation, and therefore digest both the 
pcDNA3.1 vector containing the hPGC-1α and pAd-Track CMV vector with KpnI and XhoI 
restriction enzymes according to the manufacturer’s instructions (NEB). After phosphatase 
treatment of the pAd-Track-CMV vector and subsequent heat inactivation, the digested bands 
were gel purified (Figure 6). 
 
Figure 6 Double digest mixes loaded onto gel 
 
The bands of interest were extracted using the QIAquick Gel Extraction Kit (Qiagen) and 
their concentration was measured on Nanodrop. Ligation of the purified bands was performed 
using Quick T4 ligase (NEB) and an insert:vector ratio of 3:1, after which the bacteria were 
transfected with the ligation reaction and plated on kanamycin (Kan) containing Luria-Bertani 
Agar (LA) plates. The following morning, there was only one colony present on the plate. After 
expansion in liquid media containing Kan and plasmid isolation, sequencing results confirmed 
correct ligation (Figure 7). 
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Figure 7 Schema for hPGC-1α cloning into pAd-Track-CMV vector 
 
8.3.2 Cloning of pShuttle-CMV-mRFP-hD2R 
A IRAUp969E0451D vector containing hD2R was ordered from ImaGenes, whereas a 
pcDNA3 plasmid containing monomer (m) RFP was obtained from Addgene. We first subcloned 
the sequence of interest into the pcDNA 3.1 TOPO expressional vector (Invitrogen) according to 
the manufacturer’s instructions, in order to simplify the next cloning steps and to add 6xHis and 
V5 tags on the C-terminus of the hD2R. This subcloning step is PCR-based, and requires Pfu 
ULTRA high-fidelity polymerase (Agilent) and the design of specific primers (Figure 8).  
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Figure 8 PCR reactions loaded onto gel  
Markers and ctrl PRC are same as in Figure 3 
 
An additional PCR reaction using primers overlapping the insertion sites on the plasmid 
isolated from the transfected bacteria confirmed successful subcloning (Figure 9).  
 
Figure 9 Colony PCR for hD2R  
Marker lane is same as in Figure 4 
 
Next, we wanted to ensure that the ligand binding by the hD2R would not initiate a signal 
transduction pathway in the cells that would be transduced with it. For that reason we performed 
SDM in order to mutate Phe into Ala in position 411 (F411A) (Figure 10). This mutation is 
known to block the inhibition of adenylyl cyclase thorough D2R, without compromising ligand 
binging to the receptor (38). The approach for SDM was similar to the one described above for 
the hPGC-1α sequence. Of the utmost importance for successful SDM is that the mutagenic 
primers are polyacrylamide gel electrophoresis (PAGE) purified, and not only desalted. 
1
0
0
b
p
 m
ar
k
er
 
1
k
b
p
 m
ar
k
er
 
ct
rl
 P
C
R
 
h
D
2
R
 P
C
R
 
1
k
b
p
 
m
ar
k
er
 
1
 
2
 
3
 
4
 5
 
hD2R clones 
Project 4 
162 
 
Figure 10 SDM PCR for hD2R 
 
After bacterial transfection and propagation, the isolated plasmids were used to confirm 
accomplishment of the desired mutation. 
Regarding the mRFP contatining vector, we first checked for the presence of the correct 
sequence and existence of restriction endonuclease sites. In the process of generating new 
adenoviruses, it is necessary to perform the digestion step prior to the formation of the 
recombinant adenovirus plasmid in AdEasier cells, using either PmeI or EcoRI restriction 
enzymes. For that reason, we had to make sure that the desired sequences do not contain cutting 
sites for both of the enzymes. As this was the case for the mRFP sequence, an SDM reaction was 
necessary to mutate the EcoRI site. 
Finally, we were ready to combine the hD2R and mRFP sequences into the backbone of 
the pShuttle-CMV vector. Since the first trial using a specifically designed linker to combine the 
purified digested sequences into a single vector failed, we decided to use sticky end ligation. The 
easiest cloning approach required introducing a DraIII cutting site into the mRFP containing 
vector. To achieve this, we once again used SDM.  
After the successful mutation was obtained, we preformed double digests following the 
suggestions for the optimal activity of the endonucleases used (NEB) for the three vectors:  the 
pcDNA3.1 TOPO – hD2R was digested using KpnI and DraIII, pcDNA3 – mRFP was digested 
with XbaI and DraII, while pShuttle-CMV was digested with KpnI and XbaI. After phosphatase 
treatment of the digested pShuttle-CMV vector and subsequent heat inactivation of all three 
digests, the digestion mixes were gel purified. 
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The bands of interest were cut and DNA fragments isolated using the QIAquick Gel 
Extraction Kit (Qiagen), while DNA concentration was measured using Nanodrop. Ligation was 
performed using Quick NEB ligase and an insert:insert:vector ratio of 3:3:1. The bacteria were 
transfected with the ligation soup and the colonies were screened for the presence of the correct 
plasmids using colony PCR (Figure 11). 
 
Figure 11 Colony PCR for ligation of hD2R and mRFP 
 
From the propagated colonies, the plasmids were isolated and tested again for the 
presence of the desired sequences using PCR, and then sent for complete sequencing (Figure 12). 
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Figure 12 Schema for hD2R and mRFP cloning into pShuttle-CMV vector 
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8.3.3 Cloning of pShuttle-CMV-YFP-hVEGF 
A pCMV6-Entry plasmid with human VEGF165 (transcript variant 4) already containing 
C-terminal Myc and DDK (FLAG) tags was ordered from Origene. A YFP-pcDNA3 plasmid 
was ordered from Addgene. After initial sequencing of both plasmids, a strategy for subcloning 
the genes of interest into the pShuttle-CMV vector was defined based on the existing restriction 
endonuclease sites. Again, we aimed for the sticky end ligation of the sequences into the final 
plasmid.  
First, for the purpose of generating viral particles containing YFP, we had to mutate the 
existing EcoRI restriction site in the YFP sequence for the same reasons previously explained for 
the mRFP vector. Next, we created a NruI restriction site in the VEGF165 vector via SDM, in 
order to apply the sticky end approach for ligation. After we confirmed the desired changes in 
the sequences, we continued with double digests of the three vectors: the pShutlle-CMV vector 
was digested with KpnI and XbaI, the mRFP containing plasmid was digested with XbaI and 
NruI, while the VEGF expressing vector was incubated with KpnI and NruI. All the digests were 
carried out according to NEB’s suggestions. After phosphatase treatment and heat inactivation of 
the pShuttle-CMV vector, the desired DNA sequences were obtained after the gel separation step 
(Figure 13).                   
 
Figure 13 Double digest mixes loaded onto gel  
Smear is due to DNA carrier digested by NruI 
 
The bands of interest were extracted and three-part ligation was performed using NEB 
Quick ligase with an insert:insert:vector ratio of 3:3:1. The bacteria were transformed using the 
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ligation mix and the next day, several clones were checked for the presence of the correct 
plasmid using colony PCR (Figure 14). 
 
Figure 14 Colony PCR for checking presence of YFP sequence 
Colony 9 was later confirmed to have adequate sequence 
 
Several clones were sent for sequencing and one containing the appropriate ligation 
product was found (Figure 15). 
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Figure 15 Schema for hVEGF and YFP cloning into pShuttle-CMV vector 
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8.3.4 Testing plasmid functionality 
Prior to generating viruses, it is important to check the functionality of all plasmids. For 
that purpose, we transfected AD293 cells using Lipofectamine 2000 (Invitrogen). Detection of 
GFP/RFP/YFP positive cells by microscopy confirmed a high rate of transfection. Two days 
later, the cells were collected in Trizol for RNA isolation, or in a sucrose buffer for protein 
isolation. Quantitative PCR (qPCR) and Western Blotting  (WB) were used for assessing gene 
expression from the plasmids. A list of human specific qPCR primers is provided in Table 1. Out 
of the three PGC-1α antibodies tested, only one (4C.13, Millipore) gave an additional band for 
PGC-1α in the case of positively transduced cells (Figure 16B). For D2R detection, none of the 
three D2R antibodies tested resulted in specific detection. However, we were able to detect a 
massive upregulation of the GOIs in all three vectors (Figure 16A and 16C) and therefore 
continued with viral generation. 
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Figure 16 Functional plasmids according to GOI expression (qPCR) after transfection into AD293 cells 
(A and C) qPCR of GOIs, (B) WB for GOIs 
#Note: For qPCR and WB protocols, see section Materials and Methods in Project 3   
GFP-PGC-1α  GFP  GFP  
PGC-1α AB3424 Ab HA tag 12CA5 Ab 
PGC-1α 4C.13 Ab HA tag Ab, 12CA5 
GFP-PGC-1α  GFP  GFP-PGC-1α  
V5 tag-HRP Ab 
mRFP-hD2R  mRFP 
6xHis tag-HRP Ab 
mRFP 
hD2R AB5084P Ab 
mRFP mRFP-hD2R  mRFP-hD2R  
V5 tag-HRP Ab 
C 
B 
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8.4 Virus generation and amplification  
All viruses were generated according to a previously established and published protocol 
(39). Here, the procedure is briefly explained and summarized in Figure 17.  
 
Figure 17 Steps in virus generation, amplification, titration and usage  
Adapted from nl.wikipedia.org and  www.labome.com 
 
In brief, the final plasmids containing GOIs in the backbone of one of the shuttle vectors 
(pAdTrack-CMV or pShuttle-CMV) were digested with EcoRI or PmeI and electroporated into 
recombination-competent AdEasier cells. The next day, very small colonies were selected, the 
plasmids isolated and correct recombination checked with PacI digestion (Figure 18). Digestion 
of correctly recombined plasmids should give one band above 20kDa and one band at 3kDa or 
4.5kDa after separation on the gel. LacZ plasmids served as controls for bacterial recombination.  
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Figure 18 Correct recombination of plasmids with GOIs in AdEasier cells 
 
The correct plasmids were linearized with PacI and AD293 cells transfected using 
Lipofectamine 2000 (Invitrogen). AD293 are packaging cells which express the E1 region of the 
viral genome and therefore enable viral particle formation. Generation of the first viral particles 
takes 2-3 weeks and can be monitored through appearance of fluorescent plaques. However, in 
order to achieve a high titer, one needs to perform several rounds of virus amplification. Each 
phase consists of infecting packaging-competent cells, incubation until the appearance of a 
prominent cytopathic effect and cell detachment, cell collection and opening using a freeze-thaw 
approach in order to liberate the viral particles. It is important to note that before embarking on 
extensive amplification, one needs to check the functionality of the viral particles using an 
approach analogous to the one previously described for the final plasmids containing the GOIs.  
Cell transplantation experiments in mice require large numbers of cells and therefore 
large batches of viruses. Due to inaccuracy in the titer determination procedure, we decided to 
perform a single amplification producing sufficient quantities of viruses for all the experiments 
to come, instead of producing small batches as needed. For this, we used many large plating 
surface area dishes, and the obtained viruses were used for titer determination and tests in vitro 
and in vivo. 
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8.4.1 Optimization of titer determination and testing virus functionality 
Titer was determined using a protocol adapted from the AdEasy Viral Titer Kit (Agilent). 
The method was tested using AD293 cells, COS-7 and primary hMPCs. Application of the 
simplified method for titer determination, which does not require staining, was possible do to the 
expression of fluorescent proteins by our viruses. In short, the cells were plated, transduced and 
the fluorescent positive cells were quantified using a fluorescent microscope and their number 
compared to the total number of cells per field.  
As expected, titers were dependent on the cell line, as shown in the example below 
(Figure 19). In addition, this method turned out to be suboptimal for large cells because of the 
low number of cells that can fit into one field of view, resulting in imprecise quantification and 
therefore unreliable results. For that reason, hMPCs could not be used for titer assessment with 
this approach, and we decided to determine the titer with AD293 cells, as was suggested in the 
protocol. 
 
 
 
 
Figure 19 Example of titer determination of same batches of viruses using AD293 cells or hMPCs and picture 
of transduced AD293 cells expressing GFP or RFP 
 
 
 
pShuttle- mRFP-hD2R 11 pAdTrack-hPGC1-α 5 pAdTrack-hPGC1-α 2 pAdTrack pShuttle-mRFP-hD2R 31 
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It was therefore decided that the multiplicity of infection (MOI – the ratio of the number 
of viral particles to cells) for transducing hMPCs would be calculated based on the AD293 titer. 
We tested virus functionality in hMPCs, at two different MOIs (Figure 20) using two clones for 
both viruses. 
 
 
 
 
 
 
 
 
 
MOI 10X MOI X 
pAdTrack 
pAdTrack-hPGC-1α 2 
pAd-mRFP-hD2R 11 
pAdTrack-hPGC-1α 5 
pAd-mRFP-hD2R 31 
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Figure 20 Cell transduction and virus functionality at two different MOIs 
Testing two clones for each virus (hPGC-1α 2 and 5; hD2R 11 and 31) 
#Note: For qPCR protocol, see section Materials and Methods in Project 3 
 
As we can see in Figure 20, the viruses are well-designed based on their transduction 
capability (GFP/RFP) and qPCR expression of the GOIs (hPGC-1α/hD2R) in hMPCs. In 
addition, there is a dose dependence in expression based on the transduction efficiency (the 
percentage of cells transduced). The lower MOI tested resulted in healthier cells (based on 
morphology), yet resulted in only modestly lower levels of gene expression. Importantly, 
expression of PGC-1α-regulated genes increased in cells transduced with the hPGC-1α virus, 
which confirmed the presence of functional viral particles (a list of human specific qPCR primers 
is provided in Table 1).  
However, for the hD2R virus, a different approach was required. Since we generated a 
virus containing mutated hD2R, unable to activate the signal transduction pathway (38), the best 
way to test its functionality was to check for its ligand binding properties. We decided to 
evaluate the hD2R virus with PET, using [
18
F]-Fallypride as a ligand. These experiments were 
performed by members of Prof. Amatamey’s lab.  First, they tested the virus on transduced 
hMPCs in vitro, using cells transfected with a wild-type D2R plasmid (kindly provided by Prof. 
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Kovoor) as a control. Indeed, they were able to detect significant activity in transfected cells 
compared to untransfected ones (Figure 21). 
 
Figure 21 Upper panel: [
18
F]-Fallypride (ligand) binding to hMPCs transduced with increasing amounts of 
hD2R viruses  
Upper panel: two viral clones (D2R 11 and D2R 31); untransduced cells served as a negative control. Lower panel: 
[
18
F]-Fallypride binding in hMPCs transfected with increasing amount of D2R plasmid (positive control) using 
Lipofectamine (Lipo). Stronger signal can be observed in transduced vs. transfected cells, which is probably due to 
differences in vectors, i.e virus vs. plasmid. 
 
Next, we decided to check the performance of the virus in an in vivo setting. In this way, 
we could test for the feasibility of cell tracking in vivo. For this experiment, ~25% transduced 
hMPCs were injected subcutaneously in the dorsal region of mice, and 2-4 weeks later the signal 
was measured by PET (Figure 22A and 22B).   
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Figure 22 CT-PET experiment in vivo 
30 million Ad-RFP-hD2R transduced hMPCs  (~25% RFP
+
) were injected subcutaneously into nude mice. Signal 
was measured using [
18
F]-Fallypride injected via tail vein (A) 2 weeks later and (B) 4  weeks later; (C) 
Autoradiography  confirmed presence of transduced cells. Native muscle tissue served as negative, and brain tissue 
as positive control. Haloperidol is D2R blocking agent and therefore demonstates [
18
F]-Fallypride binding 
specificity. 
 
A specific signal was difficult to detect due to high signal spillage from internal organs. 
In addition, a decrease in signal was observed with time (from 2 to 4 weeks post-transplantation). 
The presence of transduced cells was also confirmed post mortem by autoradiography on 
cryosections of engineered tissues (Figure 22C). Therefore, injection of ~7.5 million RFP
+
 
hMPCs (~25% of the 30 million injected hMPCs) was enough to detect the signal in vivo. 
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8.4.2 Determination of virus titer and optimal MOI 
After viral functionality was validated, viruses were produced in high amounts in the way 
previously described (see Virus generation and amplification). Based on the functionality results, 
we decided to continue with only one clone of each of the viruses generated. The titers of the 
final viral batches were determined in AD293 cells (Figure 23). We were able to produce ~10ml 
of high titer batches of all the viruses.  
 
 
Figure 23 Viral titer determination of final batches including images of AD293 cells transduced with either 
hPGC-1α (green) or hD2R (red) virus 
 
hPGC-1α hD2R 
Bright  
field 
GFP 
RFP 
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Optimal MOIs, based on the titers determined in AD293 cells, were tested for hMPCs. 
For the hD2R virus, an MOI of 100 gave ~25% transduced cells, whereas for the AdTrack and 
hPGC-1α viruses, an MOI of 1000 resulted in 100% transduction efficiency. We followed 
fluorescent protein expression for several days after cell transduction using different MOIs for 
the hPGC-1α virus (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Bright field and fluorescent images of hMPCs transduced with hPGC-1α and hD2R viruses over 
period of 8 days 
Three different MOIs for hPGC-1α virus were tested in combination with MOI of 100 for hD2R 
 
We were able to notice that the maximum fluorescent intensity was achieved at the 4-day 
time point, whereas at later time points fluorescence was diminished due to cell death of 
transduced cells. This could be due to the high MOI, as the effect tended to be alleviated with 
lower MOIs, or due to the CMV promoter which drives a massive expression from the viral 
genome, possibly negatively impacting endogenous transcriptional processes and therefore the 
cell’s own needs. 
PGC 200 
(20% GFP+, 
25% RFP+) 
2 days 4 days 10 days 2 days 4 days 10 days 
PGC 500 
(50% GFP+, 
25% RFP+) 
2 days 4 days 10 days 
PGC 1000 
(100% GFP+, 
25% RFP+) 
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8.4.3 Kinetics of gene expression and virus toxicity 
For the experiments in vivo, we were interested in transducing cells with multiple viruses 
at the same time without overwhelming the transcriptional apparatus of the cells. PET 
experiments with the hD2R virus demonstrated that the transduction rate of ~25% of injected 
cells is enough to track hMPCs in vivo. However, the minimal dose of the hPGC-1α virus that 
could still have an impact on mitochondrial gene expression and desired phenotypic changes was 
not known. For that reason, we decided to test several MOIs for hPGC-1α, in combination with 
25% transduction for the hD2R virus and using 100% transduction for the GFP virus (AdTrack) 
as a control in vitro.   
Although as previously mentioned, we observed the death of transduced cells over time 
in vitro, we did not detect an increase in creatine kinase (CK) levels in the media (Figure 25A). 
In addition, no difference was observed with increasing MOI for the hPGC-1α virus. Increased 
CK levels would indicate damaged cell membranes due to the toxic effect of the viruses. In fact, 
at 2 days after transduction, we measured a decrease in CK levels in the hPGC-1α transduced 
cells, which could indicate that increased hPGC-1α provides additional protection to the cell 
membrane. However, as the results were normalized to the total CK levels in cells, the difference 
in % CK between the AdTrack (GFP) and hPGC-1α transduced cells is partially due to the 
increase in total CK in the hPGC-1α transduced cells, at least for the highest MOI tested (Figure 
25B). Given that the CK levels are low in myoblasts and increase with myotube formation, this 
result could indicate that viral overexpression of hPGC-1α drives higher CK expression possibly 
due to faster differentiation. In addition, no difference in % CK was detected 6 days after cell 
transduction.      
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Figure 25 Creatine kinase activity of untransduced and transduced hMPCs at two different time points 
(A) CK activity in media as a percentage to total CK in cells; (B) total CK levels in cells  
• no viruses = no viruses added 
• PGC 200 = PGC MOI 200 (20% GFP+) and D2R MOI 100 (25% RFP+) 
• PGC 500 = PGC MOI 500 (50% GFP+) and D2R MOI 100 (25% RFP+) 
• PGC 1000 = PGC MOI 1000  (100% GFP+) and D2R MOI 100 (25% RFP+) 
• GFP 1000 = GFP MOI 1000 (100% GFP+) and D2R MOI 100 (25% RFP+) 
A 
B 
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Next, we measured gene expression in hMPCs at 2 and 6 days post-transduction, 
compared to the untransduced controls (a list of human specific qPCR primers is provided in 
Table 1). At the 2-day time point, we measured a massive overexpression of hD2R and hPGC-1α 
in transduced cells. There was a dose-dependent response in hPGC-1α expression with 
increasing MOI (Figure 26A). Interestingly, we detected a tendency towards lower hD2R 
expression in hPGC-1α and hD2R transduced cells compared to AdTrack (GFP) and hD2R 
transduced cells (Figure 26B). This could be due to competition between transgenes, although 
the effect was not significant. Importantly, hPGC-1α overexpression led to an increase in the 
expression of downstream target genes (Figure 26C) in a dose-dependent manner.   
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Figure 26 GOI gene expression and hPGC-1α target gene expression in hMPCs 2 days and 6 days after 
transduction 
 
#Note: For qPCR protocol, see section Materials and Methods in Project 3 
• no viruses = no viruses added 
• PGC 200 = PGC MOI 200 (20% GFP+) and D2R MOI 100 (25% RFP+) 
• PGC 500 = PGC MOI 500 (50% GFP+) and D2R MOI 100 (25% RFP+) 
• PGC 1000 = PGC MOI 1000  (100% GFP+) and D2R MOI 100 (25% RFP+) 
• GFP 1000 = GFP MOI 1000 (100% GFP+) and D2R MOI 100 (25% RFP+) 
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Table 1 List of qPCR primers 
 
At the 6-day time point, although analogous data were obtained regarding hD2R and 
hPGC-1α expression as well as expression of hPGC-1α regulated genes, lower levels were 
observed for all the genes measured (Figure 26D, 26E and 26F). This is consistent with our 
previous observation (see Determination of virus titer and optimal MOI) of cell death of 
transduced cells in vitro. However, at least based on the hPGC-1α target gene expression at 6 
days, this increase in hPGC-1α was enough to account for the effect, as similar induction of 
cytochrome C oxidase subunit 5b (Cox5b), cytochrome c (CycS) and estrogen-related receptor α 
(ERRα) is detected in PGC-1α transgenic mice (previous observations).   
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8.5 Current state of research 
The results obtained in vitro confirm the validity and usability of the generated viruses. 
They also indicate the possibility of at least several-week long transgene expression in hMPCs. 
However, the results in vitro cannot predict cell behavior or survival in vivo. Since we expect 
swift cell differentiation in vivo upon transplantation, it is possible that the transgene will be 
rapidly diluted in existing myotubes and therefore the effect on cell death might be negligible. 
The first in vivo experiments using the hPGC-1α expressing virus will shed light on these 
questions.  
However, if the CMV promoter turns out to be suboptimal and responsible for cell 
toxicity in vivo, one could test other promoters which could be more useful for these purposes. In 
that regard, hPGC-1α can be driven from the muscle creatine kinase (MCK) promoter, and 
therefore expressed in the postmytotic stage of muscle cells. This should provide a 
physiologically closer model, driving hPGC-1α expression at the differentiated stage and at 
lower levels compared to the CMV promoter. Alternatively, one could aim at using inducible 
promoters for timely-defined and controlled expression from the transgene. 
To date, we have been able to generate the viral vectors, test their functionality and 
toxicity in vitro, find optimal transduction settings, and produce batches of high titers required 
for cell transplantation applications. In addition, the PET results confirmed the possibility of 
spatio-temporal tracing of injected cells using the hD2R virus. Optimizations of [
18
F]-Fallypride 
tracer synthesis and the timeline of signal detection have been achieved. Conditions related to 
cell transplantation and ex vivo assessment of regeneration have also been defined. Therefore, 
final in vivo results with the hPGC-1α expressing virus are expected in the near future. 
In this study, adenoviruses were chosen as delivery vehicles, due to their high 
transduction efficiency, capacity to generate high titer batches and inability to integrate into the 
genome (40). However, they induce a considerable immune response and as such are a 
suboptimal choice for skeletal muscle gene therapy in the clinic (41). Therefore, if treatments 
concerning PGC-1α overexpression prove beneficial in terms of muscle regeneration, prior to 
application in humans, alternative delivery options for hPGC-1α would need to be selected.  
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9 Discussion and outlook  
Our aim was to explore the role of peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α) in skeletal muscle regeneration and repair from several angles and 
using various approaches – in vitro, in vivo, ex vivo and in situ in combination with cardiotoxin, 
eccentric exercise, laser injuries and overexpression in cells prior to their transplantation into 
injured muscle. We hypothesized that PGC-1α would improve regeneration as its expression 
rises with differentiation of myoblasts into myotubes (1), alleviates some dystrophic and atrophy 
phenotypes (2-6), reduces inflammation (7-9) and reactive oxygen species (ROS) levels (10), is 
responsible for the oxidative endured muscle phenotype (11), leads to increased oxidative 
metabolism (12-14), improves vascularization (15), modulates neuromuscular junction (NMJ) 
(2) and preserves muscle integrity compromised by aging (16). Indeed, we were able to reveal 
several important parameters of regeneration that are influenced by PGC-1α levels in muscle.   
Namely, we detected an initially faster regenerative response in PGC-1α transgenic mice 
upon cardiotoxin (CTX) injury, through prompter modulation of chemokine expression resulting 
in faster accumulation of macrophages and clearance of necrotic tissue. This response was 
dependent on PGC-1α, since muscle-specific transgenic and knock-out mice exhibited opposite 
phenotypes. We proposed that plausible drivers of these effects are insulin-like growth factor 1 
(IGF-1) and myostatin (Mstn), whose expression levels seem to be dependent on PGC-1α. IGF-1 
transgenic and Mstn
-/-
 mice were reported to have an analogous phenotype to the one we 
observed in PGC-1α transgenic mice (17, 18).    
We speculated that the prompter response to injury observed in PGC-1α transgenic mice 
might be due to the specific inflammatory cell milieu that exists in the muscle prior to injury. In 
that respect, it would be interesting to explore in detail the muscle mast cell and macrophage 
phenotype in PGC-1α transgenic and knock-out animals. These are the first cells that respond to 
injury (19, 20), and therefore might modulate the subsequent inflammatory stages, such as 
neutrophil and monocyte attraction.     
Skeletal muscle regeneration in vivo can be followed using several injury models: 
intramuscular toxin injections, mechanical infliction of a wound, and eccentric contractions (21). 
Discussion and Outlook 
190 
Although very harsh and physiologically distant, cardiotoxin injection is one of the most widely 
applied injury models. Toxin injection model is prevalent in the literature probably due to the 
ease of accomplishing injury and reproducibility, offering a large body of literature for 
comparison. Therefore, we decided to study the role of PGC-1α in skeletal muscle regeneration 
using cardiotoxin injection model.  
However, we also experimented with crush injury (mechanical model) and downhill 
running (eccentric contraction model) in search of a less damaging and physiologically closer 
injury model. We hypothesized that the less damage might let the differences between genotypes 
become more pronounced. Crush injuries were performed on the belly region of the TA muscle, 
and only part of the muscle was affected (Figure 1), in contrast to the cardiotoxin injection, 
which damaged the whole muscle. 
 
 
#
Figure 1 Hematoxylin and eosin (H&E) staining on crushed tibialis anterior muscle (TA) section illustrating 
non-homogeneity of the damage 
Dashed black box – undamaged fibers. Sections of the same muscle separated by several hundreds of μm apart 
additionally illustrate longitudinal non-homogeneity of the damage: black box – necrotic/regenerating area. Notice 
that the black box on one section contains only necrotic fibers, while on other necrotic parts are reduced.  
#
Note: for protocol, see Histology in Materials and Methods section of Project 1 
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We assumed that this type of injury might therefore have less damaging effect, and result 
mainly in regeneration of the damaged fibers rather than complete fiber necrosis and formation 
of new fibers as in the case of cardiotoxin. Nevertheless, crushing led to severe damage 
evaluated by contractility measurements at 10 days post injury (Figure 2). Results were similar to 
the ones obtained for cardiotoxin injection at the same time point after the infliction of a wound.  
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#Figure 2 Muscle contractility measurements on injured and uninjured TA muscles 10 days after the crush of 
muscle creatine kinase muscle-specific PGC-1α transgenic (MCK-mTG) mice  
Values for crushed muscles are normalized to the values of uncrushed ones and plotted as % of recovery. (A) 
Maximal force measurement; (B) Fatigue resistance measurement (repetitive measurements), (C) weight of TA 
muscles; (D) Specific force calculation  
#
Note: for protocol, see Muscle contractility measurements in situ in Materials and Methods section of Project 1; 
here, fatigue protocol consisted of 50 repeated contractions (100Hz for 500ms, evoked once every 2 seconds). The 
time to reach 70% of the initial force was measured. 
 
Furthermore, data obtained from crush injuries were difficult to analyze due to 
heterogeneous destruction of the muscle tissue, which complicated quantification and 
normalization (Figure 3). Since our results did not indicate considerably lower impact of crush 
injury compared to cardiotoxin, we decided not to focus on this injury model. 
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Figure 3 Immunohistochemistry (IHC) and quantification of regenerative area on same muscle sample as in 
Figure 1 
(A) laminin-green, dapi-blue, embryonic myosin heavy chain (eMyHC)-red. Undamaged, regenerating and necrotic 
parts of tissue section are in white boxes and magnified above. (B) Quantification results of regeneration based on 
eMyHC staining 7 days after the crush injury in TA of myogenic factor 5 muscle-specific knock-out (Myf5- mKO) 
mice 
#
Note: for protocol, see Histology in Materials and Methods section of Project 1 (primary antibody against eMyHC: 
F1.652 DSHB; secondary antibody: goat-anti-mouse IgG1 Alexa568 A21124 Invitrogen) 
 
Likewise, we also tested downhill running as a strenuous exercise model, which through 
eccentric contractions inflicts damage to the muscle (22). After extensive optimization of the 
running protocol, time points analyzed and choice of affected muscles, we were not able to 
achieve measurable injury relevant to the process of regeneration. More specifically, we could 
not detect necrosis and regeneration of fibers on the histological level. Consequently, this injury 
model was also excluded from the study.  
However, there are other means of inducing injury in muscle tissue based on lengthening  
contractions, and in a more pronounced and controllable way compared to forced eccentric 
exercise. The exercise based, and therefore physiologically relevant model, employs in situ 
contractions of the muscle of choice in anesthetized mice (23). It would be important to 
complement the data that we obtained with this model of injury before excluding the contribution 
of PGC-1α in the regeneration outcome in terms of pace of reaching full recovery. In our 
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experiments, cardiotoxin induced complete necrosis of myotubes and PGC-1α levels dropped 
drastically in both transgenic and wild-type mice. We demonstrated that PGC-1α expression 
slowly increased and reached basal levels regardless of the transgene’s presence. Therefore, if 
we make use of an injury method that will preserve the existing difference in PGC-1α levels 
between genotypes by not inducing thorough destruction of myotubes, which is something that is 
observed in most human muscle injuries, we might expect to see more relevant alterations in the 
recovery process.    
Regarding in vitro experiments, it would be useful to expand the current data by closely 
analyzing differentiation of transgenic vs. wild-type myoblasts, especially after prolonged 
differentiation, which should result in pronounced differences in PGC-1α expression compared 
to our results. Alternatively, one can induce PGC-1α expression virally in the myoblast stage at 
the initiation of differentiation, and determine if PGC-1α controls the differentiation process. 
Based on the in vitro data from the toxicity studies of the viruses we generated (increased 
creatine kinase expression after 2 days of transduction with PGC multiplicity of infection (MOI) 
1000 compared to GFP MOI 1000), it is possible to expect an increase in differentiation with 
higher levels of PGC-1α (24).      
In addition to affecting regeneration, PGC-1α seems to make a direct contribution to 
sarcolemma resealing capabilities as well. We demonstrated a reduced propensity for resealing in 
C2C12 myoblasts upon knock-down (KD) of PGC-1α. This was accompanied by differential 
expression of several important genes, the most promising being synaptotagmin VII (Syt7) (25). 
Namely, we were able to detect massive upregulation of Syt7 with viral overexpression of PGC-
1α in C2C12 myoblasts and myotubes, but also increased protein levels in PGC-1α transgenic 
mice. In addition, previously published Chip-seq data from our laboratory indicate direct 
regulation of Syt7 by PGC-1α (26). Furthermore, we found that increase in integrin 7α (Itga7) 
upon exercise is dependent on PGC-1α expression, and could be responsible for modestly 
reduced membrane stability in PGC-1α mKO mice observed after downhill running (DHR). 
Having in mind the difference in membrane stability and resealing (27), it would be interesting to 
further explore the role of PGC-1α in these processes.   
Based on our results, Syt7 would give a clear target gene to follow in order to 
demonstrate that its expression is the reason for the observed phenotype in the resealing (25), 
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given that the protein levels are reduced in PGC-1α mKO mice. It would be also worth looking 
at the protein levels of mitsugumin 53 (MG53) in mouse models with gain and loss of function 
of PGC-1α. We detected an increase MG53 on the mRNA level only in the transgenic mice, and 
MG53 is one of the few proteins for which a direct role in skeletal muscle membrane resealing 
has been demonstrated (28). In addition, it would be significant to supplement the experimental 
proof for reduced membrane repair with PGC-1α knock-out by looking at the primary myoblasts 
and fibers isolated from the mKO mice, and also to test for resealing in the contexts of injury 
induced by various factors. This would strengthen the findings and prove that the observed effect 
is also present in the physiologically closer model (ex vivo vs. in vitro).  However, one needs to 
be careful in order to be able to distinguish between membrane leakiness caused by damage or 
the stretching effect (27). Therefore, membrane damage ex vivo can be induced by exposure to 
detergent solution, microelectrode penetration or bead rolling (28, 29), whereas membrane 
stability can be evaluated with milder protocols for stretching (e.g. FlexCell Tension system) or 
contraction by electrical stimulation (30-33).   
With regard to the difference between membrane stability and resealing, we demonstrated 
that Itga7 levels are increased in wild type (WT) but not PGC-1α mKO after exercise. Itga7 is 
known to provide membrane stabilization and protection in cases of subsequent injury (34, 35). 
Therefore, it would be interesting to repeat the downhill running experiment but with two bouts 
of running separated by one week, and then assess sarcolemma damage in mice. Exercise is 
known to make muscles resistant to damage (36), and one reason for this is possibly the increase 
in Itga7 (35). However, PGC-1α also increases with exercise and plays a role in muscle 
adaptation to exercise (37). In that respect, it would be useful to complement the existing data 
with DHR in PGC-1α transgenic mice and see whether increased levels of PGC-1α without the 
exercise provide augmented stability to the membrane, or whether the protective effect of 
exercise can be exacerbated by overexpression of PGC-1α.    
Finally, the potentially direct role of PGC-1α in membrane resealing could be supported 
by overexpressing PGC-1α in dysferlin knock-out (Dysf-/-) mice (38). We should expect the 
overall dystrophic phenotype to be alleviated, and membrane resealing, specifically, improved. 
In addition, if Syt7 (25) is indeed the main factor in PGC-1α-dependent resealing, reduction and 
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induction of Syt7 in the muscle of genetically modified mice would result in decreased and 
increased capability to repair sarcolemma, respectively. 
Next, we were able to delineate the influence of PGC-1α expression in the satellite cell 
(SC) niche, on SC activation and proliferation. SCs with higher levels of PGC-1α in the niche 
(muscle fiber) were able to respond to activation stimuli in a faster manner. The proliferative 
output of these cells was also increased compared to control mice. In Myf5-mKO mice, SC 
activation seemed reduced and with slower progression towards differentiated myoblast stage, 
although this difference was not significant. By using primary fibers from PGC-1α mouse 
models, we found that at least partially, increased SC proliferation with PGC-1α overexpression 
was due to differential expression of fibronectin in the basal lamina of muscle fibers. More 
specifically, we detected reduced levels of fibronectin in PGC-1α transgenic mice, and increased 
in Myf5-mKO mice. In addition, in the proof-of-concept experiment, we confirmed that extrinsic 
fibronectin reduces the proliferative output of SCs. Contrary to the results in Myf5-mKO, SC 
proliferative output and fibronectin levels were unchanged in human α-skeletal actin (HSA)-
mKO mice.    
Apart from SC activation and proliferation, another possible role of PGC-1α in the 
context of SCs is quiescence. In that respect, there are previous studies indicating the potential 
implication of PGC-1α in quiescence of stem cells, primarily hematopoietic stem cells (HSCs). It 
has been reported that knock-out of liver kinase B1 (LKB1
-/-
) leads to depletion of HSCs, but 
surprisingly, this effect is not dependent on 5' AMP-activated protein kinase (AMPK) or 
mammalian target of rapamycin complex 1 (mTORC1) signaling. Metabolic profiling 
experiments determined changes in peroxisome proliferator-activated receptor (PPAR) 
pathways, such as downregulation in PGCs (39-41). In addition, knock-out of promyelocytic 
leukemia protein (PML
-/-) results in HSC depletion as well. PML together with PPARδ is 
responsible for HSC asymmetric division and therefore self-renewal through increased 
mitochondrial fatty acid oxidation (FAO) (42). In breast cancer, PML-dependent cell survival 
was reliant on PGC-1α deacetylation favoring PPAR signaling (43). Additionally, limited ROS 
production is another factor contributing to stem cell quiescence (44, 45), and PGC-1α is a 
known regulator of ROS metabolism through induced production of ROS-detoxifying enzymes 
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(10). Therefore, it would be important to investigate more closely the role of PGC-1α in SCs, 
both in terms of SC maintenance and activation. 
Another potentially interesting finding in MCK-mTG mice is related to SC senescence. 
Specifically, we measured lower expression of fibroblast growth factor 2 (FGF-2) in 
combination with increased levels of sprouty 1 (Spry1). Myf5-mKO mice on the other hand 
exhibited an increase in both FGF-2 and Spry1. These measurements were carried out in 2-3 
month-old mice. Spry1 is a significant regulator of SC senescence. In SCs, Spry1 is important for 
self-renewal and reversible quiescence, and is an inhibitor of FGF signaling (46). FGF-2 
expression in the SC niche increases with age and provokes SC activation. Prolonged FGF 
signaling has the same effect as loss of Spry1 and results in SC depletion (47). Therefore, it 
would be worthwhile to study SCs in aged MCK-mTG and Myf5-mKO mice in regard to FGF 
signaling.  
PGC-1α expression increases with exercise and leads to muscle adaptation to exercise 
(37). One outcome of regular endurance exercise is a fiber type switch towards the oxidative 
phenotype (48). Oxidative fibers are known to have more SCs than glycolytic ones (49). At the 
same time, acute as well as long-term exercise increases SC numbers (50-52). Although PGC-1α 
overexpression mimics the trained phenotype of muscles in some aspects (11), this does not 
extend, for example, to SC numbers. Consequently, it would be interesting to explore the effects 
of long-term exercise on SC numbers and behavior in PGC-1α loss and gain of function mice.  
The finding that PGC-1α overexpression in fibers does not result in increased SC 
numbers came as a surprise to us. However, this discrepancy could be partially explained by the 
detected differences in fibronectin (FN) expression. We compared expression levels of several 
ECM/basal lamina components between oxidative and glycolytic muscles, with or without PGC-
1α overexpression (Figure 4).  
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#Figure 4. Relative mRNA expression levels of genes in oxidative soleus (SOL) vs. glycolytic (TA) muscles and 
in oxidative muscle (SOL) from WT vs. MCK-mTG mice 
 
#Note: for qPCR protocol, see RNA extraction and relative quantitative PCR (qPCR) in Materials and Methods 
section of Project 2 
 
We noticed that oxidative SOL muscle has double the expression levels of PGC-1α compared to 
glycolytic TA, as expected, and that this is accompanied by increased FN expression levels. On 
the other hand, when we compared relative expression levels of the same genes in SOL muscle 
of WT and MCK-mTG mice, we detected even higher expression of PGC-1α in MCK-mTG, 
followed by a reduction in FN expression. Given the phenotype documented for LARGE
myd
 mice 
(53), which describes co-occurrence of increased SC numbers and elevated FN levels, we can 
speculate that overexpression of PGC-1α does not follow the oxidative muscle characteristics in 
terms of SC numbers due to the reduced FN expression.  
Another exciting research direction would be to assess the outcomes of conditional PGC-
1α loss and overexpression in SCs, and in that context short- and long-term effects of PGC-1α on 
adult SC quiescence, activation and self-renewal. There might still be some surprises for us 
regarding PGC-1α function in SCs. For example, we could expect that overexpression of PGC-
1α in SCs might lead to increased SC cycling, activation and therefore potential SC depletion 
over time due to an increase in oxidative phosphorylation (OXPHOS). On the other hand, one 
can speculate that increased PGC-1α signaling would primarily boost FAO, which would expand 
SC self-renewal capacity. 
Although we have only scratched the surface of PGC-1α’s role in SC biology, we have 
demonstrated some interesting and surprising features, especially in relation to PGC-1α 
overexpression in fibers. Nevertheless, these indirect effects of PGC-1α might also affect SCs 
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themselves. Hence, it would also be essential to screen for intrinsic differences of SCs upon 
PGC-1α overexpression or loss in fibers. For this reason, crossing MCK-mTG mice with Pax7-
GFP mice would provide easy access to the pure SC population that can be isolated by 
fluorescence-activated cell sorting (FACS) and analyzed in vitro. Our finding regarding 
modulation of SC behavior via PGC-1α in the niche is particularly interesting from a therapeutic 
point of view.  
In terms of therapeutic applications, we were also interested in exploring what the effects 
PGC-1α overexpression in myoblasts, prior to their usage in cell transplantations, might have on 
muscle regeneration. In our proof-of-concept study, we aimed to induce PGC-1α expression in 
isolated human myoblasts, and then inject them into mice in order to monitor their behavior over 
time. Non-invasive observation of their survival, vascularity, migration and metabolic activity is 
possible with positron emission tomography (PET), which is already used in the clinic (54-56). 
One of the main obstacles in cell transplantation techniques is compromised cell survival due to 
reduced innervation and blood vessel formation (57). As PGC-1α controls both of these 
processes (2, 15) and has additionally been demonstrated to alleviate dystrophic conditions (2-5), 
improve muscle endurance (11) and diminish age-related deterioration (16), we hypothesized 
that the application of PGC-1α in skeletal muscle regeneration as a gene therapy treatment would 
prove beneficial. This project is an interdisciplinary enterprise involving three laboratories 
specializing in molecular biology, transplantational medicine and medical imaging.   
We have reached the stage where all the optimizations have been made and standards for 
inducing injury and delivering treatments (cell transplantation) as well as assessing muscle 
functionality, have been established. We are awaiting the final results which should demonstrate 
if PGC-1α overexpression in myoblasts can provide a benefit in skeletal muscle regenerative 
medicine. We hope we will be able to answer this question by looking at muscle tissue formation 
and survival, as well as vascularization and innervation, both in vivo using PET, and ex vivo 
using isolated tissue.  
Based on the results presented in this thesis, we could speculate that PGC-1α might prove 
to be of greater use in muscle regenerative medicine than initially thought. Fusion of transduced 
myoblasts with recipient myotubes would increase PGC-1α levels in the fiber, which could 
replicate to a certain extent the conditions seen in PGC-1α overexpressing (MCK-mTG) mice. 
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Therefore, we could expect to observe the positive effect on SCs and possibly stability and repair 
of the sarcolemma. In addition, in cases of minor injuries leading to partial myofiber necrosis, we 
could detect improved regeneration due to altered immune response and SC behavior. This 
outcome would be limited not only in size (as complete necrosis of myofibers would result in 
loss of PGC-1α expression from the transgene), but also in time, due to the limited duration of 
the transgene expression from the adenovirus (58).     
If the results concerning combined gene and cell therapy (PGC-1α overexpression in 
human myoblasts) in mice are positive, the next step would be to translate this into humans, and 
therefore the first task would be to establish a safe way of PGC-1α induction in myoblasts. For 
this, another vehicle, with a reduced propensity to induce immune response would be optimal. 
Possible solutions include adeno-associated viruses (AAV) and naked DNA (59) . While AAVs 
have low immunogenicity and are able to transduce muscles after intramuscular (60) and 
systemic administration (61) and are therefore very good candidates for gene delivery in vivo, 
their propensity to transduce myoblasts in vitro is much reduced (62). In addition, AVVs have 
lower insert size capacity compared to adnoviruses, which can be a limiting factor (63). On the 
other hand, naked DNA transfer has long been significantly less potent delivery tool compared to 
viral vectors. However, this is improved using chemical (e.g. liposome) or physical (e.g. 
electroporation) approaches, which considerably reduce the differences in efficiency compared 
to viral vectors (64). 
In addition, our gene therapy approach would be combined with autologous stem cell 
therapy in patients, again, in order to prevent immune reaction. This approach would be 
potentially applicable for intramuscular injections and therefore treating selected muscles, as lack 
of homing ability in intravenously injected myoblasts is the limiting factor in skeletal muscle 
regenerative medicine (65). 
Our findings are overall in line with the existing body of literature on the therapeutic 
potential of PGC-1α in the context of muscular dystrophies. The results presented here further 
contribute to the understanding of the multifaceted role of PGC-1α overexpression in the mouse 
model of Duchenne muscular dystrophy (DMD). More specifically, our data indicate 
improvement of regenerative potential in addition to muscle protection. Moreover, there seems to 
Discussion and Outlook 
200 
be a direct link between sarcolemma resealing and stability with PGC-1α expression levels, 
although this requires further investigation.  
Exercise is not a therapeutic option in many cases of muscular disease, while in others, it 
is very difficult to define an exercise regimen that could improve the condition without causing 
more harm (66, 67). Therefore, raising PGC-1α levels might be an interesting alternative to 
exercise. Although PGC-1α is a nodal factor in skeletal muscle adaptation to endurance exercise, 
its induction does not fully mimic the effects of exercise. For example, we detected reduced SC 
numbers in PGC-1α transgenic mice, while endurance exercise increases their number. However, 
more important than numbers might be the myogenic capacity of SCs, which increases with 
endurance exercise (51), while PGC-1α overexpression in muscle seems to improve SC 
activation and proliferation.    
We should emphasize that although we have discovered several important roles of PGC-
1α in skeletal muscle regeneration and repair, many more questions have emerged as a 
consequence. Therefore, future research could provide a more complete and clear picture of the 
ways in which we can exploit PGC-1α for therapeutic purposes in muscle regenerative medicine 
and muscular dystrophies, by answering some of these newly posed questions.  
 
 
 
 
 
  
Discussion and Outlook 
201 
9.1 References 
1. Murray, J., and Huss, J. M. (2011) Estrogen-related receptor alpha regulates skeletal 
myocyte differentiation via modulation of the ERK MAP kinase pathway. Am J Physiol 
Cell Physiol 301, C630-645 
2. Handschin, C., Kobayashi, Y. M., Chin, S., Seale, P., Campbell, K. P., and Spiegelman, 
B. M. (2007) PGC-1alpha regulates the neuromuscular junction program and ameliorates 
Duchenne muscular dystrophy. Genes & development 21, 770-783 
3. Selsby, J. T., Morine, K. J., Pendrak, K., Barton, E. R., and Sweeney, H. L. (2012) 
Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in 
the mdx mouse. PloS one 7, e30063-e30063 
4. Hollinger, K., Gardan-Salmon, D., Santana, C., Rice, D., Snella, E., and Selsby, J. T. 
(2013) Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of 
dystrophin-associated protein complex components and satellite cell signaling. American 
journal of physiology. Regulatory, integrative and comparative physiology 305, R13-23 
5. Chan, M. C., Rowe, G. C., Raghuram, S., Patten, I. S., Farrell, C., and Arany, Z. (2014) 
Post-natal induction of PGC-1alpha protects against severe muscle dystrophy 
independently of utrophin. Skeletal Muscle 4, 2-2 
6. Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. 
L., and Spiegelman, B. M. (2006) PGC-1alpha protects skeletal muscle from atrophy by 
suppressing FoxO3 action and atrophy-specific gene transcription. Proceedings of the 
National Academy of Sciences of the United States of America 103, 16260-16265 
7. Handschin, C., and Spiegelman, B. M. (2008) The role of exercise and PGC1alpha in 
inflammation and chronic disease. Nature 454, 463-469 
8. Handschin, C., Chin, S., Li, P., Liu, F., Maratos-Flier, E., Lebrasseur, N. K., Yan, Z., and 
Spiegelman, B. M. (2007) Skeletal muscle fiber-type switching, exercise intolerance, and 
myopathy in PGC-1alpha muscle-specific knock-out animals. The Journal of biological 
chemistry 282, 30014-30021 
9. Eisele, P. S., Salatino, S., Sobek, J., Hottiger, M. O., and Handschin, C. (2013) The 
peroxisome proliferator-activated receptor γ coactivator 1α/β (PGC-1) coactivators 
repress the transcriptional activity of NF-κB in skeletal muscle cells. The Journal of 
biological chemistry 288, 2246-2260 
10. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jager, S., Handschin, C., 
Zheng, K., Lin, J., Yang, W., Simon, D. K., Bachoo, R., and Spiegelman, B. M. (2006) 
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 
transcriptional coactivators. Cell 127, 397-408 
11. Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, 
P., Isotani, E., Olson, E. N., Lowell, B. B., Bassel-Duby, R., and Spiegelman, B. M. 
(2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch 
muscle fibres. Nature 418, 797-801 
12. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., 
Cinti, S., Lowell, B., Scarpulla, R. C., and Spiegelman, B. M. (1999) Mechanisms 
controlling mitochondrial biogenesis and respiration through the thermogenic coactivator 
PGC-1. Cell 98, 115-124 
Discussion and Outlook 
202 
13. Vega, R. B., Huss, J. M., and Kelly, D. P. (2000) The coactivator PGC-1 cooperates with 
peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear 
genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20, 1868-1876 
14. Wende, A. R., Huss, J. M., Schaeffer, P. J., Giguere, V., and Kelly, D. P. (2005) PGC-
1alpha coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a 
mechanism for transcriptional control of muscle glucose metabolism. Mol Cell Biol 25, 
10684-10694 
15. Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., 
Laznik, D., Chinsomboon, J., Rangwala, S. M., Baek, K. H., Rosenzweig, A., and 
Spiegelman, B. M. (2008) HIF-independent regulation of VEGF and angiogenesis by the 
transcriptional coactivator PGC-1alpha. Nature 451, 1008-1012 
16. Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., and Moraes, C. T. (2009) 
Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease 
during aging. Proc Natl Acad Sci U S A 106, 20405-20410 
17. McCroskery, S., Thomas, M., Platt, L., Hennebry, A., Nishimura, T., McLeay, L., 
Sharma, M., and Kambadur, R. (2005) Improved muscle healing through enhanced 
regeneration and reduced fibrosis in myostatin-null mice. Journal of cell science 118, 
3531-3541 
18. Pelosi, L., Giacinti, C., Nardis, C., Borsellino, G., Rizzuto, E., Nicoletti, C., Wannenes, 
F., Battistini, L., Rosenthal, N., Molinaro, M., and Musarò, A. (2007) Local expression of 
IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines 
and chemokines. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 21, 1393-1402 
19. Tidball, J. G. (2005) Inflammatory processes in muscle injury and repair. 345-353 
20. Ceafalan, L. C., Popescu, B. O., and Hinescu, M. E. (2014) Cellular Players in Skeletal 
Muscle Regeneration. BioMed research international 2014, 957014-957014 
21. Chargé, S. B. P., and Rudnicki, M. a. (2004) Cellular and molecular regulation of muscle 
regeneration. Physiological reviews 84, 209-238 
22. Armstrong, R. B., Warren, G. L., and Warren, J. A. (1991) Mechanisms of exercise-
induced muscle fibre injury. Sports Med 12, 184-207 
23. McCully, K. K., and Faulkner, J. A. (1985) Injury to skeletal muscle fibers of mice 
following lengthening contractions. J Appl Physiol (1985) 59, 119-126 
24. Chamberlain, J. S., Jaynes, J. B., and Hauschka, S. D. (1985) Regulation of creatine 
kinase induction in differentiating mouse myoblasts. Mol Cell Biol 5, 484-492 
25. Chakrabarti, S., Kobayashi, K. S., Flavell, R. a., Marks, C. B., Miyake, K., Liston, D. R., 
Fowler, K. T., Gorelick, F. S., and Andrews, N. W. (2003) Impaired membrane resealing 
and autoimmune myositis in synaptotagmin VII-deficient mice. The Journal of cell 
biology 162, 543-549 
26. Baresic, M., Salatino, S., Kupr, B., van Nimwegen, E., and Handschin, C. (2014) 
Transcriptional network analysis in muscle reveals AP-1 as a partner of PGC-1alpha in 
the regulation of the hypoxic gene program. Mol Cell Biol 34, 2996-3012 
27. Allen, D. G., and Whitehead, N. P. (2011) Duchenne muscular dystrophy - What causes 
the increased membrane permeability in skeletal muscle? The international journal of 
biochemistry & cell biology 43, 290-294 
28. Cai, C., Masumiya, H., Weisleder, N., Matsuda, N., Nishi, M., Hwang, M., Ko, J.-K., 
Lin, P., Thornton, A., Zhao, X., Pan, Z., Komazaki, S., Brotto, M., Takeshima, H., and 
Discussion and Outlook 
203 
Ma, J. (2009) MG53 nucleates assembly of cell membrane repair machinery. Nature cell 
biology 11, 56-64 
29. Reddy, A., Caler, E. V., and Andrews, N. W. (2001) Plasma membrane repair is mediated 
by Ca(2+)-regulated exocytosis of lysosomes. Cell 106, 157-169 
30. Passey, S., Martin, N., Player, D., and Lewis, M. P. (2011) Stretching skeletal muscle in 
vitro: does it replicate in vivo physiology? Biotechnology letters 33, 1513-1521 
31. Tsivitse, S. K., Mylona, E., Peterson, J. M., Gunning, W. T., Pizza, F. X., Susan, K., and 
Gunning, T. (2005) Mechanical loading and injury induce human myotubes to release 
neutrophil chemoattractants. 43606, 721-729 
32. Manabe, Y., Miyatake, S., Takagi, M., Nakamura, M., Okeda, A., Nakano, T., Hirshman, 
M. F., Goodyear, L. J., and Fujii, N. L. (2012) Characterization of an acute muscle 
contraction model using cultured C2C12 myotubes. PLoS One 7, e52592 
33. Ito, A., Yamamoto, Y., Sato, M., Ikeda, K., Yamamoto, M., Fujita, H., Nagamori, E., 
Kawabe, Y., and Kamihira, M. (2014) Induction of functional tissue-engineered skeletal 
muscle constructs by defined electrical stimulation. Sci Rep 4, 4781 
34. Boppart, M. D., Burkin, D. J., and Kaufman, S. J. (2006) Alpha7beta1-integrin regulates 
mechanotransduction and prevents skeletal muscle injury. Am J Physiol Cell Physiol 290, 
C1660-1665 
35. Boppart, M. D., Volker, S. E., Alexander, N., Burkin, D. J., and Kaufman, S. J. (2008) 
Exercise promotes alpha7 integrin gene transcription and protection of skeletal muscle. 
Am J Physiol Regul Integr Comp Physiol 295, R1623-1630 
36. Proske, U., and Morgan, D. L. (2001) Muscle damage from eccentric exercise: 
mechanism, mechanical signs, adaptation and clinical applications. J Physiol 537, 333-
345 
37. Baar, K., Wende, A. R., Jones, T. E., Marison, M., Nolte, L. a., Chen, M., Kelly, D. P., 
and Holloszy, J. O. (2002) Adaptations of skeletal muscle to exercise: rapid increase in 
the transcriptional coactivator PGC-1. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology 16, 1879-1886 
38. Bansal, D., Miyake, K., Vogel, S. S., Groh, S., Chen, C. C., Williamson, R., McNeil, P. 
L., and Campbell, K. P. (2003) Defective membrane repair in dysferlin-deficient 
muscular dystrophy. Nature 423, 168-172 
39. Gan, B., Hu, J., Jiang, S., Liu, Y., Sahin, E., Zhuang, L., Fletcher-Sananikone, E., Colla, 
S., Wang, Y. A., Chin, L., and Depinho, R. A. (2010) Lkb1 regulates quiescence and 
metabolic homeostasis of haematopoietic stem cells. Nature 468, 701-704 
40. Nakada, D., Saunders, T. L., and Morrison, S. J. (2010) Lkb1 regulates cell cycle and 
energy metabolism in haematopoietic stem cells. Nature 468, 653-658 
41. Gurumurthy, S., Xie, S. Z., Alagesan, B., Kim, J., Yusuf, R. Z., Saez, B., Tzatsos, A., 
Ozsolak, F., Milos, P., Ferrari, F., Park, P. J., Shirihai, O. S., Scadden, D. T., and 
Bardeesy, N. (2010) The Lkb1 metabolic sensor maintains haematopoietic stem cell 
survival. Nature 468, 659-663 
42. Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., Schafer, Z. T., Evans, 
R. M., Suda, T., Lee, C. H., and Pandolfi, P. P. (2012) A PML-PPAR-delta pathway for 
fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 18, 1350-
1358 
43. Carracedo, A., Weiss, D., Leliaert, A. K., Bhasin, M., de Boer, V. C., Laurent, G., 
Adams, A. C., Sundvall, M., Song, S. J., Ito, K., Finley, L. S., Egia, A., Libermann, T., 
Discussion and Outlook 
204 
Gerhart-Hines, Z., Puigserver, P., Haigis, M. C., Maratos-Flier, E., Richardson, A. L., 
Schafer, Z. T., and Pandolfi, P. P. (2012) A metabolic prosurvival role for PML in breast 
cancer. J Clin Invest 122, 3088-3100 
44. Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., 
Hosokawa, K., Sakurada, K., Nakagata, N., Ikeda, Y., Mak, T. W., and Suda, T. (2004) 
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic 
stem cells. Nature 431, 997-1002 
45. Ito, K., Hirao, A., Arai, F., Takubo, K., Matsuoka, S., Miyamoto, K., Ohmura, M., Naka, 
K., Hosokawa, K., Ikeda, Y., and Suda, T. (2006) Reactive oxygen species act through 
p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12, 446-451 
46. Shea, K. L., Xiang, W., LaPorta, V. S., Licht, J. D., Keller, C., Basson, M. A., and Brack, 
A. S. (2010) Sprouty1 regulates reversible quiescence of a self-renewing adult muscle 
stem cell pool during regeneration. Cell Stem Cell 6, 117-129 
47. Chakkalakal, J. V., Jones, K. M., Basson, M. A., and Brack, A. S. (2012) The aged niche 
disrupts muscle stem cell quiescence. Nature 490, 355-360 
48. Schiaffino, S., and Reggiani, C. (2011) Fiber types in mammalian skeletal muscles. 
Physiological reviews 91, 1447-1531 
49. Gibson, M. C., and Schultz, E. (1982) The distribution of satellite cells and their 
relationship to specific fiber types in soleus and extensor digitorum longus muscles. Anat 
Rec 202, 329-337 
50. Parise, G., McKinnell, I. W., and Rudnicki, M. a. (2008) Muscle satellite cell and atypical 
myogenic progenitor response following exercise. Muscle & Nerve 37, 611-619 
51. Shefer, G., Rauner, G., Yablonka-Reuveni, Z., and Benayahu, D. (2010) Reduced 
satellite cell numbers and myogenic capacity in aging can be alleviated by endurance 
exercise. PLoS One 5, e13307 
52. Dreyer, H. C., Blanco, C. E., Sattler, F. R., Schroeder, E. T., and Wiswell, R. a. (2006) 
Satellite cell numbers in young and older men 24 hours after eccentric exercise. Muscle 
& nerve 33, 242-253 
53. Ross, J., Benn, A., Jonuschies, J., Boldrin, L., Muntoni, F., Hewitt, J. E., Brown, S. C., 
and Morgan, J. E. (2012) Defects in glycosylation impair satellite stem cell function and 
niche composition in the muscles of the dystrophic Large(myd) mouse. Stem cells 
(Dayton, Ohio) 30, 2330-2341 
54. Facey, K., Bradbury, I., Laking, G., and Payne, E. (2007) Overview of the clinical 
effectiveness of positron emission tomography imaging in selected cancers. Health 
Technol Assess 11, iii-iv, xi-267 
55. Tulving, E., Kapur, S., Craik, F. I., Moscovitch, M., and Houle, S. (1994) Hemispheric 
encoding/retrieval asymmetry in episodic memory: positron emission tomography 
findings. Proc Natl Acad Sci U S A 91, 2016-2020 
56. Tillisch, J., Brunken, R., Marshall, R., Schwaiger, M., Mandelkern, M., Phelps, M., and 
Schelbert, H. (1986) Reversibility of cardiac wall-motion abnormalities predicted by 
positron tomography. N Engl J Med 314, 884-888 
57. Koning, M., Harmsen, M. C., van Luyn, M. J., and Werker, P. M. (2009) Current 
opportunities and challenges in skeletal muscle tissue engineering. J Tissue Eng Regen 
Med 3, 407-415 
58. Quantin, B., Perricaudet, L. D., Tajbakhsh, S., and Mandel, J. L. (1992) Adenovirus as an 
expression vector in muscle cells in vivo. Proc Natl Acad Sci U S A 89, 2581-2584 
Discussion and Outlook 
205 
59. Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Felgner, 
P. L. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 
60. Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. 
A., Kurtzman, G. J., and Byrne, B. J. (1996) Gene delivery to skeletal muscle results in 
sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U 
S A 93, 14082-14087 
61. Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. 
G., Russell, D. W., and Chamberlain, J. S. (2004) Systemic delivery of genes to striated 
muscles using adeno-associated viral vectors. Nat Med 10, 828-834 
62. Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., 3rd, and 
Porteus, M. H. (2013) A survey of ex vivo/in vitro transduction efficiency of mammalian 
primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one 
engineered adeno-associated virus serotype. Virol J 10, 74 
63. Lai, C. M., Lai, Y. K., and Rakoczy, P. E. (2002) Adenovirus and adeno-associated virus 
vectors. DNA Cell Biol 21, 895-913 
64. Lu, Q. L., Bou-Gharios, G., and Partridge, T. A. (2003) Non-viral gene delivery in 
skeletal muscle: a protein factory. Gene Ther 10, 131-142 
65. Tedesco, F. S., Dellavalle, A., Diaz-Manera, J., Messina, G., and Cossu, G. (2010) 
Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin 
Invest 120, 11-19 
66. Lovering, R. M., Porter, N. C., and Bloch, R. J. (2005) The muscular dystrophies: from 
genes to therapies. Phys Ther 85, 1372-1388 
67. Rowe, G. C., Safdar, A., and Arany, Z. (2014) Running forward: new frontiers in 
endurance exercise biology. Circulation 129, 798-810 
 
 
Acknowledgments 
206 
10 Acknowledgments 
I would like to thank my supervisor Christoph Handschin for giving me the opportunity 
to work on these exciting projects and for his constructive suggestions, continuous support and 
optimism. I would also like to express my gratitude to the Werner Siemens Foundation, which 
enabled me to pursue my PhD at the Biozentrum. My PhD Committee Members, Markus Rüegg 
and Michael Sinnreich I would like to thank for following the development of my projects, as 
well as Florian Bentzinger for his valuable input and suggestions. 
The conclusion of the experimental part of my PhD was accelerated by the efforts of 
Markus Beer, who assisted by pipetting countless qPCR plates and helped with various other bits 
and pieces of experimental work, also contributing a healthy dose of humor.  
My start in the lab was much easier thanks to Mario Barešić and Joaquin Perez Schindler, 
who were always there to jump in and help. Petra Eisele was my go-to person for project-related 
questions and was very open to discussion. In addition, I would like to thank all of the previous 
and current members of the Handschin lab for contributing to a friendly atmosphere. 
Thanks to the unselfish assistance of Didier Montarras and Perrine Castets, I was able to 
learn methods concerning myofiber and satellite cell isolation and staining, which I heavily 
applied during my PhD work. Without Arnaud Ferry and Bilal Azakir, and their expertise that 
they readily shared, this thesis would lack important data on the functional recovery of muscle 
after injury and membrane resealing upon laser injury.  
Microscopy-related questions and appropriate approaches for analyzing images, I always 
addressed to Oliver Biehlmaier, Alexia Loynton-Ferrand and Niko Ehrenfeuchter. Daniel 
Fröhlich provided support with various IT problems. 
Last but not least, I would like to thank my family and friends for being there for me and 
especially my husband Danilo Selić for his extensive help with various computer-related matters 
and encouragement.  
